CA2405557C - Albumin fusion proteins - Google Patents

Albumin fusion proteins Download PDF

Info

Publication number
CA2405557C
CA2405557C CA2405557A CA2405557A CA2405557C CA 2405557 C CA2405557 C CA 2405557C CA 2405557 A CA2405557 A CA 2405557A CA 2405557 A CA2405557 A CA 2405557A CA 2405557 C CA2405557 C CA 2405557C
Authority
CA
Canada
Prior art keywords
cells
lymphocytes
geneseq
protein
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2405557A
Other languages
French (fr)
Other versions
CA2405557A1 (en
Inventor
Craig A. Rosen
William A. Haseltine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2405557(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of CA2405557A1 publication Critical patent/CA2405557A1/en
Application granted granted Critical
Publication of CA2405557C publication Critical patent/CA2405557C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormones [GH] (Somatotropin)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

ALBUMIN FUSION PROTEINS
BACKGROUND OF THE INVENTION
The invention relates generally to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin. The invention further relates to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin, that exhibit extended shelf-life and/or extended or therapeutic activity in solution. These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention." The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells.
The invention is also directed to methods of in vitro stabilizing a Therapeutic protein via fusion or conjugation of the Therapeutic protein to albumin or fragments or variants of albumin.
Human serum albumin (HSA, or HA), a protein of 585 amino acids in its mature form (as shown in Figure 15 or in SEQ ID NO:18), is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HA for clinical use is produced by extraction from human blood. The production of recombinant HA (rHA) in microorganisms has been disclosed in EP

and EP 361 991.
The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a carrier and transporter of polypeptides in vivo. The use of albumin as a component of an albumin fusion protein as a carrier for various proteins has been suggested in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HA
for fusions to polypeptides has also been proposed (EP 399 666). Fusion of albumin to the Therapeutic protein may be achieved by genetic manipulation, such that the DNA
coding for HA, or a fragment thereof, is joined to the DNA coding for the Therapeutic protein. A
suitable host is then transformed or transfected with the fused nucleotide sequences, so arranged on a suitable plasmid as to express a fusion polypeptide. The expression may be effected in vitro from, for example, prokaryotic or eukaryotic cells, or in vivo e.g. from a trans genic organism.
Therapeutic proteins in their native state or when recombinantly produced, such as interferons and growth hormones, are typically labile molecules exhibiting short shelf-lives, particularly when formulated in aqueous solutions. The instability in these molecules when formulated for administration dictates that many of the molecules must be lyophilized and refrigerated at all times during storage, thereby rendering the molecules difficult to transport and/or store. Storage problems are particularly acute when pharmaceutical formulations must be stored and dispensed outside of the hospital environment. Many protein and peptide drugs also require the addition of high concentrations of other protein such as albumin to reduce or prevent loss of protein due to binding to the container. This is a major concern with respect to proteins such as IFN. For this reason, many Therapeutic proteins are formulated in combination with large proportion of albumin carrier molecule (100-1000 fold excess), though this is an undesirable and expensive feature of the formulation.
Few practical solutions to the storage problems of labile protein molecules have been proposed. Accordingly, there is a need for stabilized, long lasting formulations of proteinaceous therapeutic molecules that are easily dispensed, preferably with a simple formulation requiring minimal post-storage manipulation.
SUMMARY OF THE INVENTION
The present invention is based, in part, on the discovery that Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the Therapeutic protein's activity for extended periods of time in solution, in vitro and/or in vivo, by genetically or chemically fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to stabilize the protein and/or its activity. In addition it has been determined that the use of albumin-fusion proteins or albumin conjugated proteins may reduce the need to formulate protein solutions with large excesses of carrier proteins (such as albumin, unfused) to prevent loss of Therapeutic proteins due to factors such as binding to the container.
The present invention encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin. The present invention also encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin, that is sufficient to prolong the shelf life of the Therapeutic protein, and/or stabilize the Therapeutic protein and/or its activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells.
The invention also encompasses pharmaceutical formulations comprising an albumin fusion protein of the invention and a pharmaceutically acceptable diluent or carrier. Such formulations may be in a kit or container. Such kit or container may be packaged with instructions pertaining to the extended shelf life of the Therapeutic protein.
Such formulations may be used in methods of treating, preventing, ameliorating, or diagnosing a disease or disease symptom in a patient, preferably a mammal, most preferably a human, comprising the step of administering the pharmaceutical formulation to the patient.
In other embodiments, the present invention encompasses methods of preventing treating, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the "Preferred Indication Y" column of Table 1 comprising administering to a patient in which such treatment, prevention or amelioration is desired an albumin fusion protein of the invention that comprises a Therapeutic protein portion corresponding to a Therapeutic protein (or fragment or variant thereof) disclosed in the "Therapeutic Protein X" column of Table 1 (in the same row as the disease or disorder to be treated is listed in the "Preferred Indication Y" column of Table 1) in an amount effective to treat prevent or ameliorate the disease or disorder.
In another embodiment, the invention includes a method of extending the shelf life of a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to extend the shelf-life of the Therapeutic protein. In a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.
In another embodiment, the invention includes a method of stabilizing a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) in solution, comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to stabilize the Therapeutic protein.
In .a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.
The present invention further includes transgenic organisms modified to contain the nucleic acid molecules of the invention, preferably modified to express the albumin fusion proteins encoded by the nucleic acid molecules.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts the extended shelf-life of an HA fusion protein in terms of the biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 5 weeks at 37 C. Under these conditions, hGH has no observed activity by week 2.
Figure 2 depicts the extended shelf-life of an HA fusion protein in terms of the stable biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 3 weeks at 4, 37, or 50 C. Data is normalized to the biological activity of hGH at time zero.
Figures 3A and 3B compare the biological activity of HA-hGH with hGH in the Nb2 cell proliferation assay. Figure 3A shows proliferation after 24 hours of incubation with various concentrations of hGH or the albumin fusion protein, and Figure 3B
shows proliferation after 48 hours of incubation with various concentrations of hGH
or the albumin fusion protein.
Figure 4 shows a map of a plasmid (pPPC0005) that can be used as the base vector into which polynucleotides encoding the Therapeutic proteins (including polypeptide and fragments and variants thereof) may be cloned to form HA-fusions. Plasmid Map key:
PRB lp: PRBI S. cerevisiae promoter; FL: Fusion leader sequence; rHA: cDNA
encoding HA; ADHlt: ADHI S. cerevisiae terminator; T3: T3 sequencing primer site; T7:

sequencing primer site; Amp R: 13-lactamase gene; on: origin of replication.
Please note that in the provisional applications to which this application claims priority, the plasmid in Figure 4 was labeled pPPC0006, instead of pPPC0005. In addition the drawing of this plasmid did not show certain pertinent restriction sites in this vector. Thus in the present application, the drawing is labeled pPPC0005 and more restriction sites of the same vector are shown.
Figure 5 compares the recovery of vial-stored HA-IFN solutions of various concentrations with a stock solution after 48 or 72 hours of storage.
Figure 6 compares the activity of an HA-a-IFN fusion protein after administration to monkeys via IV or SC.

Figure 7 describes the bioavailability and stability of an HA-a-IFN fusion protein.
Figure 8 is a map of an expression vector for the production of HA-_-IFN.
Figure 9 shows the location of loops in HA.
Figure 10 is an example of the modification of an HA loop.
Figure 11 is a representation of the HA loops.
Figure 12 shows the HA loop IV.
Figure 13 shows the tertiary structure of HA.
Figure 14 shows an example of a scFv-HA fusion Figure 15 shows the amino acid sequence of the mature form of human albumin (SEQ
ID NO:18) and a polynucleotide encoding it (SEQ ID NO:17).
DETAILED DESCRIPTION
As described above, the present invention is based, in part, on the discovery that a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) may be stabilized to extend the shelf-life and/or retain the Therapeutic protein's activity for extended periods of time in solution (or in a pharmaceutical composition) in vitro and/or in vivo, by genetically fusing or chemically conjugating the Therapeutic protein, polypeptide or peptide to all or a portion of albumin sufficient to stabilize the protein and its activity.
The present invention relates generally to albumin fusion proteins and methods of treating, preventing, or ameliorating diseases or disorders. As used herein, "albumin fusion protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a fragment or variant thereof) to at least one molecule of a Therapeutic protein (or fragment or variant thereof). An albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion (i.e., the albumin fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or a portion of a Therapeutic protein is joined in-frame with a polynucleotide encoding all or a portion of albumin) or chemical conjugation to one another. The Therapeutic protein and albumin protein, once part of the albumin fusion protein, may be referred to as a "portion", "region" or "moiety" of the albumin fusion protein (e.g., a "Therapeutic protein portion" or an "albumin protein portion").
In one embodiment, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein (e.g., as described in Table 1) and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment of a Therapeutic protein and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Therapeutic protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the albumin fusion protein is the mature portion of serum albumin.
In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Therapeutic protein portion of the albumin fusion protein is the mature portion of the Therapeutic protein. In a further preferred embodiment, the Therapeutic protein portion of the albumin fusion protein is the extracellular soluble domain of the Therapeutic protein. In an alternative embodiment, the Therapeutic protein portion of the albumin fusion protein is the active form of the Therapeutic protien.
In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment or variant of a Therapeutic protein and a biologically active and/or therapeutically active fragment or variant of serum albumin. In preferred embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, the mature portion of a Therapeutic protein and the mature portion of serum albumin.
Therapeutic proteins As stated above, an albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.
As used herein, "Therapeutic protein" refers to proteins, polypeptides, antibodies, peptides or fragments or variants thereof, having one or more therapeutic and/or biological activities. Therapeutic proteins encompassed by the invention include but are not limited to, proteins, polypeptides, peptides, antibodies, and biologics. (The terms peptides, proteins, and polypeptides are used interchangeably herein.) It is specifically contemplated that the term "Therapeutic protein" encompasses antibodies and fragments and variants thereof. Thus an albumin fusion protein of the invention may contain at least a fragment or variant of a Therapeutic protein, and/or at least a fragment or variant of an antibody.
Additionally, the term "Therapeutic protein" may refer to the endogenous or naturally occurring correlate of a Therapeutic protein.
By a polypeptide displaying a "therapeutic activity" or a protein that is "therapeutically active" is meant a polypeptide that possesses one or more known biological and/or therapeutic activities associated with a Therapeutic protein such as one or more of the Therapeutic proteins described herein or otherwise known in the art. As a non-limiting example, a "Therapeutic protein" is a protein that is useful to treat, prevent or ameliorate a disease, condition or disorder. As a non-limiting example, a "Therapeutic protein" may be one that binds specifically to a particular cell type (normal (e.g., lymphocytes) or abnormal e.g., (cancer cells)) and therefore may be used to target a compound (drug, or cytotoxic agent) to that cell type specifically.
In another non-limiting example, a "Therapeutic protein" is a protein that has a biological activity, and in particular, a biological activity that is useful for treating preventing or ameliorating a disease. A non-inclusive list of biological activities that may be possessed by a Therapeutic protein includes, enhancing the immune response, promoting angiogenesis, inhibiting angiogenesis, regulating hematopoietic functions, stimulating nerve growth, enhancing an immune response, inhibiting an immune response, or any one or more of the biological activities described in the "Biological Activities" section below.
As used herein, "therapeutic activity" or "activity" may refer to an activity whose effect is consistent with a desirable therapeutic outcome in humans, or to desired effects in non-human mammals or in other species or organisms. Therapeutic activity may be measured in vivo or in vitro. For example, a desirable effect may be assayed in cell culture. As an example, when hGH is the Therapeutic protein, the effects of hGH on cell proliferation as described in Example 1 may be used as the endpoint for which therapeutic activity is measured. Such in vitro or cell culture assays are commonly available for many Therapeutic proteins as described in the art. Examples of assays include, but are not limited to those described herein in the Examples section or in the "Exemplary Activity Assay"
column of Table 1.
Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, such as cell surface and secretory proteins, are often modified by the attachment of one or more oligosaccharide groups. The modification, referred to as glycosylation, can dramatically affect the physical properties of proteins and can be important in protein stability, secretion, and localization. Glycosylation occurs at specific locations along the polypeptide backbone. There are usually two major types of glycosylation:
glycosylation characterized by 0-linked oligosaccharides, which are attached to serine or threonine residues; and glycosylation characterized by N-linked oligdsaccharides, which are attached to asparagine residues in an Asn-X-Ser/Thr sequence, where X can be any amino acid except proline. N-acetylneuramic acid (also known as sialic acid) is usually the terminal residue of both N-linked and 0-linked oligosaccharides. Variables such as protein structure and cell type influence the number and nature of the carbohydrate units within the chains at different glycosylation sites. Glycosylation isomers are also common at the same site within a given cell type.
For example, several types of human interferon are glycosylated. Natural human interferon-a2 is 0-glycosylated at threonine 106, and N-glycosylation occurs at asparagine 72 in interferon-a14 (Adolf et al., J. Biochem 276:511 (1991); Nyman TA et al., J. Biochem 329:295 (1998)). The oligosaccharides at asparagine 80 in natural interferon-3 la may play an important factor in the solubility and stability of the protein, but may not be essential for its biological activity. This permits the production of an unglycosylated analog (interferon-I3lb) engineered with sequence modifications to enhance stability (Hosoi et al., J.
Interferon Res.
8:375 (1988; Karpusas et al., Cell Mol Life Sci 54:1203 (1998); Knight, J.
Interferon Res.
2:421 (1982); Runkel et al., Pharm Res 15:641 (1998); Lin, Dev. Biol. Stand.
96:97 (1998))1. Interferon-y contains two N-linked oligosaccharide chains at positions 25 and 97, both important for the efficient formation of the bioactive recombinant protein, and having an influence on the pharmacokinetic properties of the protein (Sareneva et al., Eur. J. Biochem 242:191 (1996); Sareneva et al,. Biochem J. 303:831 (1994); Sareneva et al., J. Interferon Res. 13:267 (1993)). Mixed 0-linked and N-linked glycosylation also occurs, for example in human erythropoietin, N-linked glycosylation occurs at asparagine residues located at positions 24, 38 and 83 while 0-linked glycosylation occurs at a serine residue located at position 126 (Lai et al., J. Biol. Chem. 261:3116 (1986); Broudy .et al., Arch. Biochem.
Biophys. 265:329 (1988)).
Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin = 25 fusion protein of the invention, as well as analogs and variants thereof, may be modified so that glycosylation at one or more sites is altered as a result of manipulation(s) of their nucleic acid sequence, by the host cell in which they are expressed, or due to other conditions of their expression. For example, glycosylation isomers may be produced by abolishing or introducing glycosylation sites, e.g., by substitution or deletion of amino acid residues, such as substitution of glutamine for asparagine, or unglycosylated recombinant proteins may be produced by expressing the proteins in host cells that will not glycosylate them, e.g. in E. coli or glycosylation-deficient yeast. These approaches are described in more detail below and are known in the art.

Therapeutic proteins (particularly those disclosed in Table 1) and their nucleic acid sequences are well known in the art and available in public databases such as Chemical Abstracts Services Databases (e.g., the CAS Registry), GenBank, and GenSeq as shown in Table 1.
Additional Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, one or more of the Therapeutic proteins or peptides disclosed in the "Therapeutic Protein X"
column of Table 1, or fragment or variable thereof.
Table 1 provides a non-exhaustive list of Therapeutic proteins that correspond to a Therapeutic protein portion of an albumin fusion protein of the invention. The "Therapeutic Protein X" column discloses Therapeutic protein molecules followed by parentheses containing scientific and brand names that comprise, or alternatively consist of, that Therapeutic protein molecule or a fragment or variant thereof. "Therapeutic protein X" as used herein may refer either to an individual Therapeutic protein molecule (as defined by the amino acid sequence obtainable from the CAS and Genbank accession numbers), or to the entire group of Therapeutic proteins associated with a given Therapeutic protein molecule disclosed in this column. The "Exemplary Identifier" column provides Chemical Abstracts Services (CAS) Registry Numbers (published by the American Chemical Society) and/or Genbank Accession Numbers ((e.g., Locus ID, NP_XXXXX (Reference Sequence Protein), and XP_XXXXX (Model Protein) identifiers available through the national Center for Biotechnology Information (NCBI)) that correspond to entries in the CAS
Registry or Genbank database which contain an amino acid sequence of the Therapeutic Protein Molecule or of a fragment or variant of the Therapeutic Protein Molecule. In addition GenSeq Accession numbers and/or journal publication citations are given to identify the exemplary amino acid sequence for some polypeptides. The "PCT/Patent Reference"
column provides U.S. Patent numbers, or PCT International Publication Numbers corresponding to patents and/or published patent applications that describe the Therapeutic protein molecule. The "Biological activity" column describes Biological activities associated with the Therapeutic protein molecule. The "Exemplary Activity Assay"
column provides references that describe assays which may be used to test the therapeutic and/or biological activity of a Therapeutic protein or an albumin fusion protein of the invention comprising a Therapeutic protein X portion.
. .
The "Preferred Indication Y" column describes disease, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by Therapeutic protein X
or an albumin fusion protein of the invention comprising a Therapeutic protein X
portion.
Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1-, Protein X Identifier ---I
BMP-1 GeneSeq W08800205 BMP1 belongs to the BMP-1 activity can be determined Induction of Cartilage, Tissue o .6.
.6.
Accession P80618 transforming growth factor-beta using the following assays known in and Bone Growth, and .6.
(TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes morphogenic proteins induce Jan;27(1):84-8; Eur J Biochem 1996 cartilage and bone formation, Apr 1;237(1):295-302; J Biol Chem, play an important role in Vol. 274, Issue 16, 10897-10902, nephrogenesis, and play an April 16, 1999; and Hogan, B. L. M.
important role in the (1996) Genes Dev. 10, 1580-1594.
development of many organs, including lung, heart, teeth, gut, skin, and particularly the kidney.
n _ BMP-2 GeneSeq W08800205 BMP-2 belongs to the BMP-2 activity can be determined Induction of Cartilage, Tissue Accession P80619 transforming growth factor-beta using the following assays known in and Bone Growth, and iv a, (TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes 0 co morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 co co --, bone formation. Apr 1;237(1):295-302; J Biol Chem, 1---, Vol. 274, Issue 16, 10897-10902, iv April 16, 1999; and Hogan, B. L. M.

iv (1996) Genes Dev. 10, 1580-1594.
H
BMP-2B GeneSeq US5631142 BMP-2b belongs to the BMP-2b activity can be determined Induction of Cartilage, Tissue 0 Accession transforming growth factor-beta using the following assays known in and Bone Growth, and 0 co W24850 (TGFB) superfamily. Bone the art: Nat Genet. 2001 Diabetes morphogenic protein induces Jan;27(I):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
BMP-4 GeneSeq W00020591 BMP-4 belongs to the BMP-4 activity can be determined Induction of Cartilage, Tissue Accession B02796 transforming growth factor-beta using the following assays known in and Bone Growth, and IV
n (TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes 1-3 morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 cp bone formation. Apr 1;237(1):295-302; J Biol Chem, o 1--, Vol. 274, Issue 16, 10897-10902, --..
1--, April 16, 1999; and Hogan, B. L. M.
t-.) o (1996) Genes Dev. 10, 1580-1594.
1--, Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier BMP-5 GeneSeq = W00020591 BMP-5 belongs to the BMP-5 activity can be determined Induction of Cartilage, Tissue Accession B02797 transforming growth factor-beta using the following assays known in and Bone Growth, and (TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes -morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
BMP-6 GeneSeq US5187076 BMP-6 belongs to the BMP-6 activity can be determined Induction of Cartilage, Tissue Accession R32904 transforming growth factor-beta using the following assays known in and Bone Growth, and (TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, 0 Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
IsJ
Osteogenic GeneSeq W09'734626 OP-1 belongs to the transforming OP-1 activity can be determined Induction of Cartilage, Tissue Protein-1; OP-1; Accession growth factor-beta (TGFB) using the following assays known in and Bone Growth, and 0 BMP-7 W34783 superfamily. Bone morphogenic the art: Nat Genet. 2001 Diabetes protein induces bone formation. Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, co Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
Osteogenic GeneSeq W09406399 OP-2 belongs to the transforming OP-2 activity can be determined Induction of Cartilage, Tissue Protein-2 Accession R57973 growth factor-beta (TGFB) using the following assays known in and Bone Growth, and superfamily. Bone morphogenic the art: Nat Genet. 2001 Diabetes protein induces bone formation. Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier GDF-1 GeneSeq W09406449 Members of the TGF-beta family The effect of GDF-1 on signaling Developmental disorders, Accession R60961 of proteins initiate cell signaling can be assayed by treating Primary Induction of Cartilage, Tissue by binding to heteromeric BAECs transfected with a construct and Bone Growth, and receptor complexes of type I called p3TP-Lux, containing a TGF- Diabetes (TbetaRI) and type II (TbetaRII) beta responsive promoter fused to a serine/threonine kinase receptors reporter gene, and measuring (reviewed by Massague, J. et al. luciferase gene expression (Wrana (1994) Trends Cell Biol. 4:172- et al., 1994, Nature 370: 341-347).
178; Miyazono, K. et al. (1994) Adv. Immunol. 55:181-220).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaR1I, which then recruits and phosphotylates TbetaRI.
Activated TbetaRI then propagates the signal to downstream targets (Chen, F.

and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).
BMP-9 GeneSeq W09533830 BMP-9 belongs to the BMP-9 activity can be determined Induction of Cartilage, Tissue Accession R86903 transforming growth factor-beta using the following assays known in and Bone Growth, and (TGFB) superfamily. Bone the art: Nat Genet. 2001 Diabetes mOrphogenic protein induces Jan;27(1):84-8;
Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
BMP-10 GeneSeq W09426893 BMP-10 belongs to the BMP-10 activity can be determined Induction of Cartilage, Tissue o .6.
Accession R66202 transforming growth factor-beta using the following assays known in and Bone Growth, and .6.
.6.
(TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
BMP-12 GeneSeq W09516035 BMP-12 belongs to the BMP-12 activity can be determined Induction of Cartilage, Tissue Accession R78734 transforming growth factor-beta using the following assays known in and Bone Growth, and (TGFB) superfamily. Bone the art:
Nat Genet. 2001 Diabetes n morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, 0 iv Vol. 274, Issue 16, 10897-10902, a, Ala 16, 1999; and Hogan, B. L. M.
co co LP (1996) Genes Dev. 10, 1580-1594. co -.3 BMP-15 GeneSeq W09636710 BMP-15 belongs to the BMP-15 activity can be determined Induction of Cartilage, Tissue iv Accession transforming growth factor-beta using the following assays known in and Bone Growth, and 0 iv W11261 (TGFB) superfamily. Bone the art: Nat Genet. 2001 Diabetes H
morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 0 bone formation. Apr 1;237(1):295-302; J Biol Chem, 0 co Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
BMP-17 GeneSeq W09929718 BMP-17 belongs to the BMP-17 activity can be determined Induction of Cartilage, Tissue Accession transforming growth factor-beta using the following assays known in and Bone Growth, and Y17870 (TGFB) superfamily. Bone the art: Nat Genet. 2001 Diabetes morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, IV
Vol. 274, Issue 16, 10897-10902, n ,-i April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
cp o 1--, --..
1--, o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier BMP-18 GeneSeq W09929718 BMP-18 belongs to the BMP-18 activity can be determined Induction of Cartilage, Tissue Accession transforming growth factor-beta using the following assays known in and Bone Growth, and Y17871 (TGFB) superfamily. Bone the art: Nat Genet. 2001 Diabetes morphogenic protein induces Jan;27(1):84-8; Eur J Biochem 1996 bone formation. Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.
Inhibin alpha GeneSeq W00020591 The inhibin beta A subunit joins Tumor suppressor activity of inhibin Tumor suppression.
Accession B02806 the alpha subunit to form a can be determined using assays pituitary FSH secretion inhibitor, known in the art: Matzuk et al., Inhibin has been shown to Nature 1992 Nov 26;360(6402):313-regulate gonadal stromal cell 9.

proliferation negatively and to have tumour-suppressor activity.
)¨t In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease.

co Inhibin beta GeneSeq W00020591 The inhibin beta A subunit joins Tumor suppressor activity of inhibin Tumor suppression.
Accession B02808 the alpha subunit to form a can be determined using assays pituitary FSH secretion inhibitor, known in the art: Matzuk et al., Inhibin has been shown to Nature 1992 Nov 26;360(6402):313-regulate gonadal stromal cell 9.
proliferation negatively and to have tumour-suppressor activity.
In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Cerebus Protein GeneSeq W09849296 Cerebus is believed to be BMP
activity, in the presence of the BMP Antagonist useful for Accession involved in the inhibition of antagonist Cerebus, can be Osteosarcoma, abnormal bone W86032 BMP activity determined using the following growth assays known in the art: Nat Genet.
2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.
Soluble BMP GeneSeq W09614579 Soluble BMP receptor kinase BMP activity, in the presence of the BMP Antagonist useful for Receptor Kinase Accession R95227 protein-3 is involved in the soluble antagonist BMP receptor Osteosarcoma, abnormal bone Protein-3 binding of BMPs. Soluble BMP
kinase protein-3, can be determined growth receptor kinase protein-3 is using the following assays known in 0 useful as an antagonist for the the art:
Nat Genet. 2001 inhibition of BMP activity Jan;27(1):84-8; Eur J Biochem 1996 ON
Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999; and Hogan, B. L. M.
(1996) Genes Dev. 10, 1580-1594.

BMP GeneSeq W09741250 BMPs belong to the transforming BMP activity, in the presence of the Bone formation or 0 co Processing Accession growth factor-beta (TGFB) Furin, can be determined using the Regeneration Abnormalities Enzyme Furin W36099 superfamily. Bone morphogenic following assays known in the art:
protein induces bone formation. Nat Genet. 2001 Jan;27(1):84-8; Eur J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999;
and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier TGF-beta 1 GeneSeq W09216228 Members of the TGF-beta family The effect of TGF betas on useful for treating cancer and Accession R29657 of proteins initiate cell signaling signaling can be assayed by treating to promote wound by binding to heteromeric Primary BAECs transfected with a healing receptor complexes of type I construct called p3TP-Lux, (TbetaRI) and type II (TbetaRII) containing a TGF-beta responsive serine/threonine kinase receptors promoter fused to a reporter gene, (reviewed by Massague, J. et al. and measuring luciferase gene (1994) Trends Cell Biol. 4:172- expression (Wrana et al., 1994, 178; Miyazono, K. et al. (1994) Nature 370: 341-347).
Adv. Immunol. 55:181-220).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI.
Activated TbetaRI then propagates the signal to downstream targets (Chen, F.

and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier TGE-beta 2 GeneSeq EP542679 Members of the TGF-beta family The effect of TGF betas on useful for treating cancer and Accession R39659 of proteins initiate cell signaling signaling can be assayed by treating to promote wound by binding to heteromeric Primary BAECs transfected with a healing receptor complexes of type I construct called p3TP-Lux, (TbetaRI) and type El (TbetaRII) containing a TGF-beta responsive serine/threonine kinase receptors promoter fused to a reporter gene, (reviewed by Massague, J. et al. and measuring luciferase gene (1994) Trends Cell Biol. 4:172- expression (Wrana et al., 1994, 178; Miyazono, K. et al. (1994) Nature 370: 341-347).
Adv. Immunol. 55:181-220).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, co 1.) which then recruits and co phosphorylates TbetaRI.
Activated TbetaRI then oo propagates the signal to 1.) co downstream targets (Chen, F.
co 1.) and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.
co L. et al. (1994) Nature 370:341-co co 347).

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier ZTGF-beta 9 GeneSeq W00015798 Members of the TGF-beta family The effect of TGF betas on useful for treating cancer and Accession of proteins initiate cell signaling signaling can be assayed by treating to promote wound Y70654 by binding to heteromeric Primary BAECs transfected with a healing receptor complexes of type I construct called p3TP-Lux, (TbetaRI) and type II (TbetaR11) containing a TGF-beta responsive serine/threonine kinase receptors promoter fused to a reporter gene, (reviewed by Massague, J. et al. and measuring luciferase gene (1994) Trends Cell Biol. 4:172- expression (Wrana et al., 1994, 178; Miyazono, K. et al. (1994) Nature 370: 341-347).
Adv. Immunol. 55:181-220).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI.
L-E; Activated TbetaRI then propagates the signal to downstream targets (Chen, F.

and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Anti-TGF beta GB2305921 Members of the TGF-beta family The effect of TGF betas on Useful for control of fibrosis, family of proteins initiate cell signaling signaling, in the presence of an anti- immune, and inflammatory antibodies by binding to heteromeric TGF beta antibody, can be assayed disease receptor complexes of type I by treating Primary BAECs (TbetaRI) and type II (TbetaRII) transfected with a construct called serine/threonine kinase receptors p3TP-Lux, containing a TGF-beta (reviewed by Massague, J. et al. responsive promoter fused to a (1994) Trends Cell Biol. 4:172- reporter gene, and measuring 178; Miyazono, K. et al. (1994) luciferase gene expression (Wrana Adv. Immunol. 55:181-220). et at., 1994, Nature 370: 341-347).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI.
Activated TbetaRI then propagates the signal to downstream targets (Chen, F.

and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Latent TGF- GeneSeq W00012551 Members of the TGF-beta family The effect of TGF betas on Useful for inhibiting tissue or beta binding Accession of proteins initiate cell signaling signaling, in the presence of a TGF- tumor growth protein II Y70552 by binding to heteromeric beta binding protein, can be assayed receptor complexes of type I by treating Primary BAECs (TbetaRI) and type II (TbetaRII) transfected with a construct called serine/threonine kinase receptors p3TP-Lux, containing a TGF-beta (reviewed by Massague, J. et al. responsive promoter fused to a (1994) Trends Cell Biol. 4:172- reporter gene, and measuring 178; Miyazono, K. et al. (1994) luciferase gene expression (Wrana Adv. Immunol. 55:181-220). et al., 1994, Nature 370: 341-347).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, 1.) which then recruits and phosphotylates TbetaRI.
Activated TbetaRI then propagates the signal to 1.) downstream targets (Chen, F.

1.) and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MP52 GeneSeq W09741250 Members of the TGF-beta family The effect of TGF betas on Bone formation or Accession of proteins initiate cell signaling signaling can be assayed by treating Regeneration Abnormalities W36100 by binding to heteromeric Primary BAECs transfected with a receptor complexes of type I construct called p3TP-Lux, (TbetaRI) and type II (TbetaRII) containing a TGF-beta responsive serine/threonine kinase receptors promoter fused to a reporter gene, (reviewed by Massague, J. et al. and measuring luciferase gene (1994) Trends Cell Biol. 4:172- expression (Wrana et al., 1994, 178; Miyazono, K. et al. (1994) Nature 370: 341-347).
Adv. Immunol. 55:181-220).
Activation of this heteromeric receptor complex occurs when TGF-beta. binds to TbetaRII, which then recruits and phosphorylates TbetaRI.
Activated TbetaRI then propagates the signal to downstream targets (Chen, P.

and Weinberg, R. A. (1995) PNAS92:1565-1569; Wrana, J.

L. et al. (1994) Nature 370:341-co 347).
b57 Protein GeneSeq W09837195 BMPs are involved in the BMP
activity, in the presence of b57 BMP Antagonist useful for Accession induction of bone formation. protein, can be determined using the Osteosarcoma, abnormal bone W69293 Specific antagonists are useful is following assays known in the art: growth preventing this activity from Nat Genet. 2001 Jan;27(1):84-8; Eur occurring. J Biochem 1996 Apr 1;237(1):295-302; J Biol Chem, Vol. 274, Issue 16, 10897-10902, April 16, 1999;
and Hogan, B. L. M. (1996) Genes Dev. 10, 1580-1594.

, Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
Resistin GeneSeq W00064920 This gene belongs to the family Ability of resistin to influence type Type II diabetes and vD
.6.
Accession defined by mouse F1ZZI and II diabetes can be determined using Syndrome X .6.
.6.
W69293 FIZZ3/Resistin genes. The assays known in the art: Pontoglio et characteristic feature of this al., J Clin Invest 1998 May family is the C-terminal stretch 15;101(10):2215-22.
of 10 cys residues with identical spacing. The mouse homolog of this protein is secreted by adipocytes, and may be the hormone potentially linking obesity to type II diabetes.
n Galectin-4 GeneSeq W09703190 Galectins are a family of Ability of Galectin-4 polypeptides Lactose intolerance Accession carbohydrate-binding proteins to bind lactose can be determined iv W11841 characterized by an affinity for using assays known in the art: Wada co beta- galactoside containing et al., J
Biol Chem 1997 Feb co co ..) glycoconjugates.
28;272(9):6078-86.
APM-1; ACRP- GeneSeq W00026363 ACPR30 gene is exclusively Ability of ACRP30 polypeptides to Obesity, Metabolic disorders, iv 30; Famoxin Accession expressed in adipose tissue.
influence obesity and fat oxidation Lipid Metabolism; Hormone iv ' fatty acid oxidation by muscle known in the art: Fruebis et al., Proc 0 tissue. Natl Acad Sci U S A 2001 Feb 0 co 13;98(4):2005-10.
ACRP-30 GeneSeq W00063376 ACPR30 gene is exclusively Ability of ACRP30 homologue Obesity, Metabolic disorders, Homologue; Accession B30234 expressed in adipose tissue.
polypeptides to influence obesity Lipid Metabolism; Hormone Complement ACRP30 is thought to increase and fat oxidation can be determined Secretion Component Clq fatty acid oxidation by muscle using assays known in the art:
C tissue. Fruebis et al., Proc Natl Acad Sci U
S A 2001 Feb 13;98(4):2005-10.
Calpain-I0a GeneSeq W00023603 Calpain is believed to play a role Ability of Calpain-10 to influence Diabetes mellitus; Regulation IV
n Y79567 activity, and therefore may be using assays known in the art: Insulin mediated glucose tp useful in the treatment of type II Pontoglio et al., J Clin Invest 1998 transport disorders o 1--, diabetes. May 15;101(10):2215-22. --..
1--, n.) o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
Calpain-10b GeneSeq W00023603 Calpain is believed to play a role Ability of Calpain-10 to influence Diabetes mellitus; Regulation vD
.6.
.6.
Accession in insulin secretion and insulin type II diabetes can be determined of Insulin secretory response; .6.
Y79568 activity, and therefore may be using assays known in the art: Insulin mediated glucose useful in the treatment of type II Pontoglio et al., J Clin Invest 1998 transport disorders diabetes. May 15;101(10):2215-22.
Calpain-10c GeneSeq W00023603 Calpain is believed to play a role Ability of Calpain-10 to influence Diabetes mellitus; Regulation Accession in insulin secretion and insulin type II diabetes can be determined of Insulin secretory response;
Y79569 activity, and therefore may be using assays known in the art: Insulin mediated glucose useful in the treatment of type II Pontoglio et al., J Clin Invest 1998 transport disorders diabetes. May 15;101(10):2215-22.
PDGF-D GeneSeq W00027879 Vascular Endothelial Growth Proliferation assay using NR6R- Wound Healing; n Accession Factor 3T3 cells (Rizzino 1988 Cancer Atherosclerosis Y71130 Res. 4-8:
4266) iv a, FasL GeneSeq W09936079 Activities associated with Activity can be determined using Apoptosis-related disorders; 0 co Accession apoptosis and immune system Apoptosis assays known in the art: Autoimmune disorders; Graft- co co ts.) Y28594 functions. Walczak et al. (1996) EMBOJ 16: v-Host disorders =-.3 ==I
5386-5397.
N) Chondromoduli GeneSeq W00029579 Chondromodulin proteins are Ability of Chondromodulin-like Antiangiogenic agent; 0 iv n-like protein Accession cartilage proteins thought to protein to inhibit vascularization can Osteoblast proliferation H1 Y71262 confer resistance to be determined using assays known stimulator; prevents 0 angiogenesis, and thus are useful in the art: Hiraki et al., J Biol Chem vascularization of cartilage co as anti-angiogenic agents that 1997 Dec I9;272(51):32419-26. tissue; Useful to treat cancer.
may have utility in combating cancer.
Patched GeneSeq US5837538 Patched is a tumour-suppressor Ability of soluble Patched to bind to Receptor for Hedgehog Accession receptor for Sonic hedgehog and inhibit the activities of shh can cellular proliferation signaling W72969 (shh), which is a protein that be determined using assays known molecule. This receptor is controls developmental in the art:
Stone etal., Nature 1996 useful as a means of patterning and growth. Nov 14;384(6605):129-34. preventing cellular IV
n proliferation via the shh signaling pathway, thus useful cp for cancers.
o 1--, =---...
1--, n.) o 1--, =

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ----I
Patched-2 GeneSeq W09953058 Patched is a tumour-suppressor Ability of soluble Patched to bind to Receptor for Hedgehog o .6.
.6.
Accession receptor for Sonic hedgehog and inhibit the activities of shh can cellular proliferation signaling .6.
controls developmental in the art:
Stone et al., Nature 1996 useful as a means of patterning and growth. Nov 14;384(6605):129-34. preventing cellular proliferation via the shh signaling pathway, thus useful for cancers.
Maspin; GeneSeq W09405804 Maspin is a member of the serpin The inhibitory effects of Maspin and Tumor suppressor which is Protease Accession R50938 family of serine protease other protease inhibitors can be down-regulated in breast suppress tumor metastasis. art such as a labeled protease has tumour substrate, for example, Universal suppressing and invasion iv a,.
Protease Substrate (casein, suppressing activity 0 co resorufin-labeled): Roche Molecular co co ts.) Biochemicals, Cat. No. 1080733.
lit iv cell proliferation, disclosed by Cao et al (1996) J. treatment of cancers. H
Biol. Chem. 271 29461-29467 aFGF; FGF-1 GeneSeq EP298723 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and 0 co Accession P94037 313 cells (Rizzino 1988 Cancer proliferation of cells, such as Res. 48: 4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer agents , bFGF; FGF2 GeneSeq FR2642086 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and Accession R06685 313 cells (Rizzino 1988 Cancer proliferation of cells, such as Res. 48: 4266); Examples 23 and 39 epithelial cells and IV
n disclosed herein.
keratinocytes. Antagonists 1-3 may be useful as anti-cancer cp agents o 1--, -....
1--, o 1--, c,.) .

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
FGF-3; INT-2 GeneSeq W09503831 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and o .6.
Accession R07824 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as .6.
.6.
Res. 48: 4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer agents FGF-4; HST-1; GeneSeq W09503831 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and HBGF-4 Accession R07825 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as Res. 48: 4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer n agents FGF-5 GeneSeq W09730155 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and c) iv a, Accession 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as c) el W22600 Res. 48:
4266); Examples 23 and 39 epithelial cells and el el ts.) disclosed herein. keratinocytes. Antagonists a\
may be useful as anti-cancer iv c) agents c) iv FGF-6; Heparin GeneSeq EP613946 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and ' H
binding secreted Accession R58555 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as c) transforming Res. 48:
4266); Examples 23 and 39 epithelial cells and c) co factor-2 disclosed herein. keratinocytes. Antagonists may be useful as anti-cancer agents FGF-8 GeneSeq W09524928 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and Accession R80783 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as Res. 48: 4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer IV
n agents cp o 1--, --, 1--, o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ---.I
FGF-9; Glia GeneSeq W09503831 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and .tD
.6.
.6.
activating factor Accession R70822 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as .6.
Res. 48: 4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer agents FGF-12; GeneSeq W09635708 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and Fibroblast Accession 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as growth factor W06309 Res. 48:
4266); Examples 23 and 39 epithelial cells and homologous disclosed herein. keratinocytes. Antagonists factor-1 may be useful as anti-cancer n agents .

FGF-15 GeneSeq W09927100 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and iv a, Accession 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as co Y08582 Res. 48:
4266); Examples 23 and 39 epithelial cells and co co t.) disclosed herein. keratinocytes. Antagonists ..]
--) may be useful as anti-cancer N) agents iv FGF-16 GeneSeq W09918128 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and H
Accession 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as Y05474 Res. 48:
4266); Examples 23 and 39 epithelial cells and 0 co disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer agents , FGF-18 GeneSeq W09927100 Fibroblast Growth Factor Proliferation assay using NR6R- Promotion of growth and Accession 3T3 cells (Rizzino 1988 Cancer proliferation of cells, such as Y08590 Res. 48:
4266); Examples 23 and 39 epithelial cells and disclosed herein.
keratinocytes. Antagonists may be useful as anti-cancer IV
n agents cp o 1¨, , 1¨, n.) o 1¨, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier -----I
flt-3 ligand GeneSeq EP627487 Stem Cell Progenitor Chemokine activities can be Promotion of immune cell .6.
Accession R67541 determined using assays known in growth and/or differentiation .6.
.6.
the art: Methods in Molecular Biology, 2000, vol. 138: Chemoldne Protocols. Edited by: A.E.I.
Proudfoot, T.N.C. Wells, and C.A.
Power. 0 Humana Press Inc., Totowa, NJ
VEGF-110 GeneSeq W00013702 Promotes the growth and/or VEGF activity can be determined Promotion of growth and Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y69417 as those disclosed in International vascular endothelial cells.
n Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and iv a, may be applicable for cancer VEGF-121 GeneSeq W00071713 Promotes the and/or Growth activity can be determined Promotion of growth and co co Accession B50432 proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as co -.3 oo as those disclosed in International vascular endothelial cells. iv Publication No. W00045835, for Antagonists may be useful as 0 iv example.
anti-angiogenic agents, and H
may be applicable for cancer .

VEGF-138 GeneSeq W09940197 Promotes the growth and/or VEGF activity can be determined Promotion of growth and 0 co Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y43483 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenie agents, and may be applicable for cancer VEGF-145 GeneSeq W00013702 Promotes the growth and/or VEGF activity can be determined Promotion of growth and Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y69413 as those disclosed in International vascular endothelial cells. IV
Publication No. W00045835, for Antagonists may be useful as n example.
anti-angiogenic agents, and cp may be applicable for cancer o , 1--, --..
1--, o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
VEGF-162 GeneSeq W09940197 Promotes the growth and/or VEGF activity can be determined Promotion of growth and o .6.
.6.
Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as .6.
Y43484 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and may be applicable for cancer VEGF-165 GeneSeq W00013702 Promotes the growth and/or VEGF activity can be determined Promotion of growth and Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y69414 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and n may be applicable for cancer VEGF-182 GeneSeq W09940197 Promotes the growth and/or VEGF activity can be determined Promotion of growth and 0 iv a, Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as 0 Y43483 as those disclosed in International vascular endothelial cells.
co in N) Publication No. W00045835, for Antagonists may be useful as co -.3 v;) example.
anti-angiogenic agents, and iv may be applicable for cancer iv VEGF-189 GeneSeq W00013702 Promotes the growth and/or VEGF activity can be determined Promotion of growth and H
Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as 0 Y69415 as those disclosed in International vascular endothelial cells. 0 co Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and may be applicable for cancer VEGF-206 GeneSeq W00013702 Promotes the growth and/or VEGF activity can be determined Promotion of growth and Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y69416 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and IV
n may be applicable for cancer cp o 1¨, --., 1¨, o 1¨, c,.) .

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ----I
VEGF-D GeneSeq W09807832 Promotes the growth and/or VEGF activity can be determined Promotion of growth and o .6.
.6.
Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as .6.
W53240 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and may be applicable for cancer VEGF-E; GeneSeq W09947677 Promotes the growth and/or VEGF activity can be determined Promotion of growth and VEGF-X Accession proliferation of endothelial cells using assays known in the art, such proliferation of cells, such as Y33679 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and n may be applicable for cancer VEGF GeneSeq W09831794 Receptor for VEGF polypeptides VEGF activity, in the presence of VEGF Receptor. Fusion iv a, Receptor; KDR; Accession flk-1 polypeptides, can be protein with the extracellular 0 flk-1 W69679 determined using assays known in domain is useful as an anti-coin co La the art, such as those disclosed in angiogenic agent. Agonists o International Publication No.
may be useful in the N) W00045835, for example.
promotion of angiogenesis 0 .
iv Soluble VEGF GeneSeq US5712380 Receptor for VEGF polypeptides VEGF activity, in the presence of VEGF Receptor. Fusion1 H

Receptor Accession VEGF
Receptor polypeptides, can protein with the extracellular 1 W47037 be determined using assays known domain is useful as an anti- 0 co in the art, such as those disclosed in angiogenic agent. Agonists International Publication No.
may be useful in the W00045835, for example.
promotion of angiogenesis fit-1 GeneSeq W00021560 Receptor for VEGF polypeptides VEGF activity, in the presence of VEGF Receptor. Fusion Accession fit-1 polypeptides, can be protein with the extracellular Y70751 determined using assays known in domain is useful as an anti-the art, such as those disclosed in angiogenic agent. Agonists International Publication No.
may be useful in the IV
n W00045835, for example.
promotion of angiogenesis 1-3 cp o 1--, -...
1--, o 1--, c,.) , Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ---I
VEGF R-3; flt-4 GeneSeq W00058511 Receptor for VEGF polypeptides VEGF activity, in the presence of VEGF Receptor. Fusion vD
.6.
.6.
Accession B29047 flt-4 polypeptides, can be protein with the extracellular .6.
determined using assays known in domain is useful as an anti-the art, such as those disclosed in angiogenic agent. Agonists International Publication No.
may be useful in the W00045835, for example.
promotion of angiogenesis Neuropilin-1 GeneSeq W09929858 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and Accession Factor using assays known in the art, such proliferation of cells, such as Y06319 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and 0 may be applicable for cancer .

Neuropilin-2 GeneSeq W09929858 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and iv a, Accession Factor using assays known in the art, such proliferation of cells, such as 0 co Y03618 as those disclosed in International vascular endothelial cells.
co co t..,J Publication No. W00045835, for Antagonists may be useful as I-, example.
anti-angiogenic agents, and iv may be applicable for cancer iv Human fast GeneSeq W09730085 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis , twitch skeletal Accession proteins that are thought to inhibit angiogenesis can be 1 muscle troponin W22597 inhibit angiogenesis. High levels determined using assays known in 0 co C may contibute to the difficulty the art:. Proc Natl Acad Sci U S A
encountered in revascularizing 1999 Mar 16;96(6):2645-50.
the ischemic myocardium after cardiovascular injury.
Human fast GeneSeq W09730085 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis twitch skeletal Accession proteins that are thought to inhibit angiogenesis can be muscle troponin W22598 inhibit angiogenesis. High levels determined using assays known in I. may contibute to the difficulty the art:. Proc Natl Acad Sci U S A IV
n encountered in revascularizing 1999 Mar 16;96(6):2645-50.

the ischemic myocardium cp after cardiovascular injury.
o 1¨, --..
1¨, tµ.) o 1¨, c,.) .

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---.I
Human fast GeneSeq W09730085 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis vD
.6.
.6.
twitch skeletal Accession proteins that are thought to inhibit angiogenesis can be .6.
muscle troponin W22599 inhibit angiogenesis. High levels determined using assays known in T may contibute to the difficulty the art:. Proc Natl Acad Sci U S A
encountered in revascularizing 1999 Mar 16;96(6):2645-50.
the ischemic myocardium after cardiovascular injury.
fragment. GeneSeq W09719955 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis myofibrillar Accession proteins that are thought to inhibit angiogenesis can be protein W18053 inhibit angiogenesis. High levels determined using assays known in Troponin I may contibute to the difficulty the art:. Proc Natl Acad Sci U S A n encountered in revascularizing 1999 Mar 16;96(6):2645-50.

the ischemic myocardium 1.) a, after cardiovascular injury.

in myofibrillar GeneSeq W09719955 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis in in t..,..) contractile Accession proteins that are thought to inhibit angiogenesis can be rs.) protein W18054 inhibit angiogenesis. High levels determined using assays known in 1.) Troponin I may contibute to the difficulty the art:. Proc Natl Acad Sci U S A 0 1.) I
encountered in revascularizing 1999 Mar 16;96(6):2645-50.
H
the ischemic myocardium after cardiovascular injury.

co Troponin GeneSeq W09933874 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis peptides Accessions proteins that are thought to inhibit angiogenesis can be Y29581, Y29582, inhibit angiogenesis. High levels determined using assays known in Y29583, Y29584, may contibute to the difficulty the art:. Proc Natl Acad Sci U S A .
Y29585, and encountered in revascularizing 1999 Mar 16;96(6):2645-50.
Y29586 the ischemic myocardium after cardiovascular injury.
Human fast GeneSeq W00054770 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis IV
n twitch skeletal Accession B00134 proteins that are thought to inhibit angiogenesis can be 1-3 muscle inhibit angiogenesis. High levels determined using assays known in cp Troponin may contibute to the difficulty the art:. Proc Nati Acad Sci U S A o 1--, subunit C. encountered in revascularizing 1999 Mar 16;96(6):2645-50. -....
1--, n.) the ischemic myocardium o 1--, after cardiovascular injury.
c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human fast GeneSeq W00054770 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis twitch skeletal Accession B00135 proteins that are thought to inhibit angiogenesis can be muscle inhibit angiogenesis. High levels determined using assays known in Troponin may contibute to the difficulty the art:. Proc Nat! Acad Sci U S A
subunit I encountered in revascularizing 1999 Mar 16;96(6):2645-50.
Protein the ischemic myocardium after cardiovascular injury.
Human fast GeneSeq W00054770 Troponins are contractile Ability of soluble Troponins to Anti-angiogenesis twitch skeletal Accession B00136 proteins that are thought to inhibit angiogenesis can be muscle inhibit angiogenesis. High levels determined using assays known in Troponin may contibute to the difficulty the art:. Proc Nat! Acad Sci U S A
subunit T encountered in revascularizing 1999 Mar 16;96(6):2645-50.

the ischemic myocardium after cardiovascular injury.

Plasminogen GeneSeq W09013648 PAIs are believed to play a role Methods that measure plasminogen Anti-angiogenesis; blood-Activator Accession R08411 in cancer, and cardiovascular activator inhibitor (PAI) activity are clotting disorders.
Inhibitor-1; disease and blood-clotting known in the art, for example, assay PAT-1 disorders, the ability of PAT
to inhibit tissue 0 plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep co 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A
1999 Mar 16;96(6):2645-50.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Plasminogen GeneSeq DE3722673 PAIs are believed to play a role Methods that measure plasminogen Anti-angiogenesis; blood-Activator Accession P94160 in cancer, and cardiovascular activator inhibitor (PAL) activity are clotting disorders.
Inhibitor-2; disease and blood-clotting known in the art, for example, assay PAI-2 disorders. the ability of PAI
to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A
1999 Mar 16;96(6):2645-50.

Plasminogen GeneSeq W09102057 PAIs are believed to play a role Methods that measure plasminogen Anti-angiogenesis; blood-Activator Accession R10921 in cancer, and cardiovascular activator inhibitor (PAL) activity are clotting disorders.
Inhibitor-2; disease and blood-clotting known in the art, for example, assay PAI-2 disorders. the ability of PAI
to inhibit tissue plasminogen activator (tPA) or urokinase (uPA): J Biochem Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res co Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A
1999 Mar 16;96(6):2645-50.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human PAI-1 GeneSeq W09105048 PAIs are believed to play a role Methods that measure plasminogen Anti-angiogenesis; blood-mutants Accessions in cancer, and cardiovascular activator inhibitor (PAL) activity are clotting disorders.
R11755, R11756, disease and blood-clotting known in the art, for example, assay R11757, R11758, disorders, the ability of PAI to inhibit tissue R11759, R11760, plasminogen activator (tPA) or R11761, R11762, urokinase (uPA): J Biochem = and R11763 Biophys Methods 2000 Sep 11;45(2):127-40, Breast Cancer Res Treat 1996;41(2):141-6. Methods that measure anti-angiogenesis activity are known in the art, for example, Proc Natl Acad Sci U S A
1999 Mar 16;96(6):2645-50.

CXCR3; CXC GeneSeq W00018431 Chemokines are a family of Chemokine activities can be Soluble CXCR3 polypeptides chemokine Accession related small, secreted proteins determined using assays known in may be useful for inhibiting receptor 3 Y79372 involved in biological processes the art: Methods in Molecular chemokine activities and viral ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine infection.

angiogenesis, and leukocyte Protocols. Edited by: A.E.I.

trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ

co including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Modified GeneSeq W09737005 Chemokines are a family of Chemokine activities can be Immune disorders Rantes Accession related small, secreted proteins determined using assays known in W38129 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power.
Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 La human chemokines have been described, which bind to ¨17 1.) receptors thus far identified.

1.) CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier RANTES GeneSeq EP905240 Chemokines are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in Y05299 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. C) Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MCP-la GeneSeq W09509232 Chemokines are a family of Chemokine activities can be Immune disorders Accession R73914 related small, secreted proteins determined using assays known in involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 LA) human chemokines have been co described, which bind to ¨17 receptors thus far identified.

= 0 CO

=
Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MCP-lb GeneSeq W09929728 Chemokines are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in Y26176 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been v:) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MCP-1 receptor GeneSeq W09519436 Chemokines are a family of Chemokine activities can be Soluble MCP-1 Receptor Accession R79165 related small, secreted proteins determined using assays known in polypeptides may be useful for involved in biological processes the art: Methods in Molecular inhibiting chemokine activities ranging from hematopoiesis, Biology, 2000, vol. 138: Chemolcine and viral infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 1.) receptors thus far identified.

1.) CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MCP-3 GeneSeq W09509232 Chemokines are a family of Chemokine activities can be Immune disorders Accession R73915 related small, secreted proteins determined using assays known in involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemoldne angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. @ Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MCP-4 receptor GeneSeq W09809171 Chemokines are a family of Chemokine activities can be Soluble MCP-4 Receptor Accession related small, secreted proteins determined using assays known in polypeptides may be useful for W56689 involved in biological processes the art: Methods in Molecular inhibiting chemokine activities ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine and viral infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier RANTES GeneSeq US5652133 Chemokines are a family of Chemokine activities can be Soluble RANTES Receptor receptor Accession related small, secreted proteins determined using assays known in polypeptides may be useful for W26588 involved in biological processes the art:
Methods in Molecular inhibiting chemokine activities ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine and viral infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CCR5 variant GeneSeq W09854317 Chemokines are a family of Chemokine activities can be Soluble CCR5 polypeptides Accession related small, secreted proteins determined using assays known in may be useful for inhibiting W88238 involved in biological processes the art:
Methods in Molecular chemokine activities and viral ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine infection.
angiOgenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CCR7 GeneSeq US6153441 Chemokines are a family of Chemokine activities can be Soluble CCR7 polypeptides Accession B50859 related small, secreted proteins determined using assays known in may be useful for inhibiting involved in biological processes the art: Methods in Molecular chemokine activities and viral ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. CD Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CXC3 GeneSeq W09727299 Chemokines are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in W23345 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Eotaxin GeneSeq W09700960 Chemokines are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in W10099 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

Neurotactin GeneSeq US6013257 Neurotactin may play a role in Chemotactic leukocyte migration Immune disorders Accessions W09742224 chemotactic leukocyte migration assays are known in the art, for 0 Y77537, W34307, and brain inflammation example: J.
Immunol. Methods 33, 0 co Y53259, and processes. ((1980)); Nature 1997 Jun Y77539 5;387(6633):611-7.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CKbeta- GeneSeq US6153444 Chemokines are a family of Chemokine activities can be Immune disorders 9 Accession B50860 related small, secreted proteins determined using assays known in involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨47 receptors thus far identified.

Lymphotactin GeneSeq W00073320 Chemokines are a family of Chemokine activities can be Immune disorders Accession B50052 related small, secreted proteins determined using assays known in involved in biological processes the art: Methods in Molecular co ranging from hernatopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, =
and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MIP-3 alpha GeneSeq W09801557 Chemokines are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in W44398 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemolcines exert their effects by acting on a family of seven transmembrane G

MIP-3 beta GeneSeq W09801557 Chemoldnes are a family of Chemokine activities can be Immune disorders Accession related small, secreted proteins determined using assays known in W44399 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine 0 angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. 0 family are involved in a similarly Power. Humana Press Inc., co diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier MIP-Gamma GeneSeq W09504158 Chemokines are a family of Chemokine activities can be Immune disorders Accession R70798 related small, secreted proteins determined using assays known in involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power.
Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven 1.) transmembrane G

Stem Cell GeneSeq W09104274 Chemokines are a family of Chemokine activities can be Hematopoietic growth factors Inhibitory Accession R11553 related small, secreted proteins determined using assays known in Factor involved in biological processes the art: Methods in Molecular 1.) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine 1.) angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.

family are involved in a similarly Power.
Humana Press Inc., 0 co diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G
thrombopoietin GeneSeq W09521920 Thrombopoietin is involved in Thrombopoietin (TPO) can be Hematopoietic growth factors Accession R79905 the regulation of the growth and assayed to determine regulation of 1-3 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol thereof.
2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.

, Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier -----I
c-kit ligand; GeneSeq EP992579 and c-kit ligand is thought to Chemokine activities can be Hematopoietic growth factors o .6.
SCF; Mast cell Accession EP676470 stimulate the proliferation of determined using assays known in .6.
.6.
growth factor; Y53284, R83978 mast cells, and is able to the art: Methods in Molecular MGF; and R83977 augment the proliferation of both Biology, 2000, vol. 138: Chemokine Fibrosarcoma- myeloid and lymphoid Protocols. Edited by: A.E.I.
derived stem hematopoietic progenitors in Proudfoot, T.N.C. Wells, and C.A.
cell factor bone marrow culture. C-kit Power.
Humana Press Inc., ligand is also thought to act Totowa, NJ
synergistically with other cytokines.
Platelet derived GeneSeq W00066736 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and n growth factor Accession B48653 ,=. Factor using assays known in the art, such proliferation of cells, such as as those disclosed in International vascular endothelial cells. 1.) Publication No. W00045835, for Antagonists may be useful as a, co example.
anti-angiogenic agents, and co ui may be applicable for cancer co -.]
).¨

Melanoma GeneSeq W09503328 Melanoma inhibiting protein has Tumor suppressor activity of Cancer; melenoma 1.) inhibiting Accession R69811 melanoma-inhibiting activity and melanoma inhibiting protein can be 0 1.) protein can be used to treat cancer determined using assays known in H
(melanoma, glioblastoma, the art:
Matzuk et al., Nature 1992 0 neuroblastoma, small cell lung Nov 26;360(6402):313-9. 0 co cancer, neuroectodermal tumours) or as an inimunosuppressant (it inhibits 11,-2 or phytohaemagglutinin induced proliferation of peripheral blood lymphocytes.
.
Glioma-derived GeneSeq EP399816 _ Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and IV
growth factor Accession R08120 Factor using assays known in the art, such proliferation of cells, such as n as those disclosed in International vascular endothelial cells. 1-3 Publication No. W00045835, for Antagonists may be useful as cp example.
anti-angiogenic agents, and 1--, --, may be applicable for cancer 1--, n.) o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---.I
Platelet derived GeneSeq EP682110 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and o .6.
growth factor Accession R84759 Factor using assays known in the art, such proliferation of cells, such as .6.
.6.
-precursor A as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and may be applicable for cancer Platelet derived GeneSeq EP682110 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and growth factor Accession R84760 Factor using assays known in the art, such proliferation of cells, such as precursor B as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and n may be applicable for cancer Platelet derived GeneSeq EP282317 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and 0 iv a, co -.3 N.) example.
anti-angiogenic agents, and iv may be applicable for cancer , iv Placental GeneSeq W09206194 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and H

R23059 and as those disclosed in International vascular endothelial cells. 0 co R23060 Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and may be applicable for cancer Placental GeneSeq DE19748734 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and Growth Factor- Accession Factor using assays known in the art, such proliferation of cells, such as 2 Y08289 as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Antagonists may be useful as example.
anti-angiogenic agents, and IV
n may be applicable for cancer cp o 1-, --..
1-, o 1-, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ----I
Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer vD
.6.
.6.
derivativel Accession the regulation of the growth and assayed to determine regulation of .6.
Y77244 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol thereof.
2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.
Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer derivative2 Accession the regulation of the growth and assayed to determine regulation of Y77255 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol n thereof.
2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and 0 1.) a, within.

in Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer in in LA derivative3 Accession the regulation of the growth and assayed to determine regulation of La Y77262 differentiation of growth and differentiation of 1.) megakaryocytes and precursors megakaryocytes. Mol Cell Biol 1.) thereof.
2001 Apr;21(8):2659-70; Exp H
Hematol 2001 Jan;29(1):51-8 and 0 within.

co Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer derivative4 Accession the regulation of the growth and assayed to determine regulation of Y77267 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol thereof.
2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.
, Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer IV
n derivative5 Accession the regulation of the growth and assayed to determine regulation of 1-3 Y77246 differentiation of growth and differentiation of cp megakaryocytes and precursors megakaryocytes. Mol Cell Biol o thereof.
2001 Apr;21(8):2659-70; Exp 1--, --..
1--, Hematol 2001 Jan;29(1):51-8 and tµ.) o within.
1--, Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer derivative6 Accession the regulation of the growth and assayed to determine regulation of Y77253 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol thereof. 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.
Thrombopoietin GeneSeq W00000612 Thrombopoietin is involved in Thrombopoietin (TPO) can be Thrombocytopenia, cancer derivative7 Accession the regulation of the growth and assayed to determine regulation of Y77256 differentiation of growth and differentiation of megakaryocytes and precursors megakaryocytes. Mol Cell Biol (-) thereof. 2001 Apr;21(8):2659-70; Exp Hematol 2001 Jan;29(1):51-8 and within.

Fractalkine GeneSeq US6043086 Fractalkine is believed to play a Fractalkine activity can be Immune disorders (J1 Accession role in chemotactic leukocyte determined using Chemotactic Y53255 migration and neurological leukocyte migration assays known disorders. in the art, for example: J. Immunol. 0 Methods 33, ((1980)); Nature 1997 EL
Jun 5;387(6633):611-7.

co Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CXC3 GeneSeq W09727299 Chemokines are a family of Chemokine activities can be Immune disorders Accession - related small, secreted proteins determined using assays known in W23345 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been (.11 described, which bind to ¨17 receptors thus far identified.

co , Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ---I
CCR7 GeneSeq US6153441 Chemokines are a family of Chemokine activities can be Soluble CCR7 polypeptides o .6.
.6.
Accession B50859 related small, secreted proteins determined using assays known in may be useful for inhibiting .6.
involved in biological processes the art: Methods in Molecular chemokine activities and viral ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The n chemokines exert their effects by acting on a family of seven iv a, transmembrane G-protein-co coupled receptors. Over 40 co co t.n. human chemokines have been described, which bind to ¨17 iv receptors thus far identified.

iv Nerve Growth GeneSeq EP414151 Nerve Growth Factor = Proliferation assay using NR6R- Neurological disorders, cancer H
Factor-beta Accession R11474 3T3 cells (Rizzino 1988 Cancer 0 Res. 48: 4266) co Nerve Growth GeneSeq EP859056 Nerve Growth Factor Proliferation assay using NR6R- Neurological disorders, cancer Factor-beta2 Accession 3T3 cells (Rizzino 1988 Cancer W69725 Res. 48:
4266) Neurotrophin-3 GeneSeq W09821234 Neurotrophins regulate neuronal Trk tyrosine kinase activation assays Neurological disorders, cancer Accession cell survival and synaptic known in the art can be used to W48889 plasticity. assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A
2001 Mar 13;98(6):3555-3560.
IV
n Accession R47100 cell survival and synaptic known in the art can be used to cp plasticity. assay for neurotrophin activity, for o 1--, example, Proc Natl Acad Sci U S A
--, 1--, 2001 Mar 13;98(6):3555-3560.
t-.) o c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Neurotrophin- GeneSeq W09325684 Neurotrophins regulate neuronal Trk tyrosine kinase activation assays Neurological disorders, cancer 4a Accession R47101 cell survival and synaptic known in the art can be used to plasticity. assay for neurotrophin activity, for example, Proc Natl Acad Sci U S A
2001 Mar 13;98(6):3555-3560.
13;98(6):3555-3560 Neurotrophin- GeneSeq W09325684 Neurotrophins regulate neuronal Trk tyrosine kinase activation assays Neurological disorders, cancer 4b Accession R47102 cell survival and synaptic known in the art can be used to plasticity. assay for neurotrophin activity, for tyrosine ldnases. example, Proc Natl Acad Sci U S A
2001 Mar 13;98(6):3555-3560.
Neurotrophin- GeneSeq W09325684 Neurotrophins regulate neuronal Trk tyrosine kinase activation assays Neurological disorders, cancer 4c Accession R47103 cell survival and synaptic known in the art can be used to plasticity. assay for neurotrophin activity, for 0 example, Proc Natl Acad Sci U S A
2001 Mar 13;98(6):3555-3560.
Neurotrophin- GeneSeq W09325684 Neurotrophins regulate neuronal Trk tyrosine kinase activation assays Neurological disorders, cancer 4d Accession R47104 cell survival and synaptic known in the art can be used to 0 plasticity. assay for neurotrophin activity, for EL

example, Proc Natl Acad Sci U S A

2001 Mar 13;98(6):3555-3560.
co Platelet-Derived GeneSeq US5219739 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and Growth Factor Accession R38918 Factor using assays known in the art, such proliferation of cells, such as A chain as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Hematopoietic and immune example.
disorders. Antagonists may be useful as anti-angiogenic agents, and may be applicable for cancer Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---I
Platelet-Derived GeneSeq US5219739 Vascular Endothelial Growth VEGF activity can be determined Promotion of growth and o .6.
.6.
Growth Factor Accession R38919 Factor using assays known in the art, such proliferation of cells, such as .6.
B chain as those disclosed in International vascular endothelial cells.
Publication No. W00045835, for Hematopoietic and immune example.
disorders. Antagonists may be - useful as anti-angiogenic agents, and may be applicable for cancer Stromal Derived GeneSeq W09948528 Stromal Growth Factor Proliferation assay using NR6R- Hematopoietic, immune Factor-1 alpha Accession 3T3 cells (Rizzino 1988 Cancer disorders, cancer Y39995 Res. 48:
4266) n Stromal Derived GeneSeq CA2117953 Stromal Growth Factor Proliferation assay using NR6R- Hematopoietic, immune Factor-1 beta Accession R75420 3T3 cells (Rizzino 1988 Cancer disorders, cancer iv Res. 48: 4266) a, ol Tarc GeneSeq W09711969 Chemotactic for T lymphocytes.
Chemotactic leukocyte migration Antiinflammatory. Immune ol ol oo Accession May play a role in T-cell assays are known in the art, for disorders, cancer W14917 development. Thought to bind example: J. Immunol. Methods 33, iv CCR8 and CCR4 ((1980)) iv Prolactin GeneSeq W09521625 Prolactin is involved in immune Immune cell proliferation and Reproductive system H1 Accession R78691 cell proliferation and apoptosis.
suppression of apoptosis by disorders, cancer. 0 prolactin can be assayed by methods co well-known in the art, for example, Buckley, AR and Buckley DJ, Ann N Y Acad Sci 2000; 917:522-33, and within.
Prolactin2 GeneSeq US5955346 Prolactin is involved in immune Immune cell proliferation and Reproductive system Accession cell proliferation and apoptosis.
suppression of apoptosis by disorders, cancer.
Y31764 prolactin can be assayed by methods well-known in the art, for example, IV
n Buckley, AR and Buckley DJ, Ann N Y Acad Sci 2000; 917:522-33, cp and within.
o 1--, --..
1--, o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier -----I
Follicle GeneSeq EP974359 FSH stimulates secretion of FSH
activities can be determined Reproductive system o .6.
.6.
stimulating Accession interleukin-1 by cells isolated using assays known in the art: J disorders, cancer .6.
hormone Alpha Y54160 from women in the follicular Gend Specif Med 1999 Nov-subunit phase Dec;2(6):30-4 ; Mol Cell Endocrinol.
1997 Nov 15;134(2):109-18.
stimulating Accession interleukin-1 by cells isolated using assays known in the art: J disorders, cancer hormone Beta Y54161 from women in the follicular Gend Specif Med 1999 Nov-subunit phase Dec;2(6):30-4 ; Mol Cell Endocrinol.
1997 Nov n 15;134(2):109-18.

Substance P GeneSeq W00054053 Substance P is associated with Immunoregulation and bone marrow di a b e t e s mellitus, iv a,.
(tachykinin) Accession B23027 immunoregulation. cell proliferation by substance P can hypertension, cancer 0 co be assayed by methods well-known co co ul in the art, for example, Lai et al. -..3 1/4.0 Proc Natl Acad Sci USA 2001 Mar N) 27; 98(7):3970-5; JaIlat-Daloz et al. 0 iv Allergy Asthma Proc 2001 Jan-Feb; ' H
22(1):17-23; Kahler et al. Exp Lung 0 Res 2001 Jan-Feb; 27(1):25-46; and 0 co Adamus MA and Dabrowski ZJ. J
Cell Biochem 2001; 81(3)499-506.
Oxytocin GeneSeq W00053755 Oxytocin is involved in the Oxytocin and prostaglandin E(2) inflammatory disorders, (Neurophysin I) Accessions induction of prostaglandin (E2) release and Oxytocin (Ca2+) immunologic disorders, cancer B24085 and release, as well as an increased increase can be assayed by methods amount of calcium release by well-known in the art, for example, smooth muscle cells.
Pavan et al., AM J Obset Gynecol 2000 Jul; 183(1):76-82 and Holda et IV
n al., Cell Calcium 1996 Jul;20(1):43- 1-3 51.
cp o 1--, --..
1--, n.) o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Vasopressin GeneSeq W00053755 Vasopressin is believed to have a Vasopressin activity can be inflammatory disorders, (Neurophysin Accessions direct antidiuretic action on the determined using assays known in immunologic disorders, cancer II) B24085 and kidney, and it is thought to cause the art, for example, Endocr Regul B24086 vasoconstriction of the 1996 Mar;30(1):13-17.
peripheral vessels.
IL-1 GeneSeq EP165654 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession P60326 multifunctional cyto k in es determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &

cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, ct\ and/or inhibition of interferons.
IL-1 mature GeneSeq EP456332 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R14855 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 synthesized by lymphocytes, the art: Matthews et al., in EL

monocytes, and macrophages. Lymphokines and Interferons: A

Known functions include Practical Approach, Clemens et al., co stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-1 beta GeneSeq W09922763 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer Y08322 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, ,and/or inhibition of interferons.
IL-3 variants GeneSeq W08806161 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer P80382, P80383, synthesized by lymphocytes, the art: Matthews et al., in 0 P80384, and monocytes, and macrophages. Lymph okines and Interferons:
crµ P80381 Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-4 GeneSeq W08702990 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession P70615 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and interferons:
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &

cells, B cells, eosinophils, and Mostowski (1990) I Immunol lymphocytes), chemotaxis of Methods 132,287-295.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-4 muteins GeneSeq W09747744 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer W52151, synthesized by lymphocytes, the art:
Matthews et al., in W52152, monocytes, and macrophages. Lymph okines and Interferons: A
W52153, Known functions include Practical Approach, Clemens et al., W52154, stimulating proliferation of eds, IRL
Press, Washington, D.C.
W52155, immune cells (e.g., T helper 1987, pp.
221-225; and Siegel &
W52156, cells, B cells, eosinophils, and Mostowski (1990) J Immunol W52157, lymphocytes), chemotaxis of Methods 132,287-295.
W52158, neutrophils and T lymphocytes, W52159, and/or inhibition of interferons.
W52160, W52161, 1.) W52162, W52163, W52164, and 1.) IL-1 alpha GeneSeq EP324447 Interleukins are a group of Interleukin activity can be inflammatory disorders, 0 1.) Accession P90108 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A

co Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ----I
_ IL-3 variants GeneSeq W09307171 Interleukins are a group of Interleukin activity can be inflammatory disorders, o .6.
.6.
Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer .6.
R38561, R38562, synthesized by lymphocytes, the art: Matthews et al., in R38563, R38564, monocytes, and macrophages.
Lymphokines and interferons: A
R38565, R38566, Known functions include Practical Approach, Clemens et al., R38567, R38568, stimulating proliferation of eds, IRL Press, Washington, D.C.
R38569, R38570, immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et R38571, and cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140 323-R38572 lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.
n _ IL-6 GeneSeq W09402512 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 iv R45717 and synthesized by lymphocytes, the art: Matthews et al., in a, R45718 monocytes, and macrophages.
Lymphokines and Interferons: A in in in cs, Known functions include Practical Approach, Clemens et al., 3..a stimulating proliferation of eds, IRL Press, Washington, D.C.
iv immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al iv . cells, B cells, eosinophils, and (1987) Bur. J. Immunol 17, 1411- 1 H
lymphocytes), chemotaxis of 16.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
.
, IL43 GeneSeq W09404680 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R48624 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation, of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Boutelier et IV
n cells, B cells, eosinophils, and al (1995) J. Immunol. Methods lymphocytes), chemotaxis of 181,29.
cp neutrophils and T lymphocytes, o 1--, and/or inhibition of interferons.
--..
1--, n.) o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-4 mutein GeneSeq DE4137333 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R47182 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &
cells, B cells, eosinophils, and Mostowski (1990) J Immunol lymphocytes), chemotaxis of Methods 132,287-295.
neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-4 mutein GeneSeq DE4137333 Interleukins are a group of Interleukin activity can be inflammatory disorders, Y124X Accession R47183 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &

cells, B cells, eosinophils, and Mostowski (1990) J Immunol lymphocytes), chemotaxis of Methods 132,287-295.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-4 mutein GeneSeq DE4137333 Interleukins are a group of Interleukin activity can be inflammatory disorders, Y124G Accession R47184 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
= immune cells (e.g., T helper 198'7, pp. 221-225; and Siegel &
cells, B cells, eosinophils, and Mostowski (1990) J Immunol lymphocytes), chemotaxis of Methods 132,287-295.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09317698 Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin-10 Accession R41664 multifunctional cytokines determined using assays known in immunologic disorders, cancer (precursor) synthesized by lymphocytes, the art: Matthews et at., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Thompson-cells, B cells, eosinophils, and Snipes et al (1991) J. Exp. Med.
lymphocytes), chemotaxis of 173, 507-510.
neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09318783-A Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin 10 Accession R42642 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
ui 0\ Known functions include Practical Approach, Clemens et at., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Thompson-cells, B cells, eosinophils, and Snipes et al (1991) J. Exp. Med.
lymphocytes), chemotaxis of 173, 507-510.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq EP569042 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-1 Accession R42947 multifunctional cytokines determined using assays known in immunologic disorders, cancer beta precursor. synthesized by lymphocytes, the art: Matthews et al,, in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et at., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Interleukin- GeneSeq EP578278 Interleukins are a group of Interleukin activity can be inflammatory disorders, lalpha Accession R45364 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, TEL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
MIRAP GeneSeq W09117184 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R14400 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq JP04063595 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-3 Accession R22813 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) 3 Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq JP04063595 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-3 Accession R22814 multifunctional cytokines determined using assays known in immunologic disorders, cancer variant synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-li fragments GeneSeq EP541920 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 R35484 and synthesized by lymphocytes, the art: Matthews et al., in R35485 monocytes, and macrophages. Lymphokines and Interferons: A
c:s) Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &

cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-1 inhibitor GeneSeq EP541920 1nterleukins are a group of Interleukin activity can be inflammatory disorders, (IL-li). Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer R35486 and synthesized by lymphocytes, the art: Matthews et al., in R35484 monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier ICE 22 kD GeneSeq EP533350 Interleukins are a group of Interleukin activity can be inflammatory disorders, subunit. Accession R33780 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
(-) ICE 20 IcD GeneSeq EP533350- Interleukins are a group of Interleukin activity can be inflammatory disorders, subunit. Accession R33781 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 synthesized by lymphocytes, the art: Matthews at al., in monocytes, and macrophages. Lymphokines and interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225.

cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
ICE 10 kr) GeneSeq EP533350 Interleukins are a group of Interleukin activity can be inflammatory disorders, subunit. Accession R33782 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews at al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09317698 Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin-10 Accession R41664 multifunctional cytokines determined using assays known in immunologic disorders, cancer (precursor) synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Thompson-cells, B cells, eosinophils, and Snipes et al (1991) J. Exp. Med.
lymphocytes), chemotaxis of 173,507-510.
neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09318783 Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin 10. Accession R42642 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens at al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Thompson-cells, B cells, eosinophils, and Snipes et al (1991) J. Exp. Med.
lymphocytes), chemotaxis of 173, 507-510.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq EP569042- Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-1 Accession R42447 multifunctional cytokines determined using assays known in immunologic disorders, cancer beta precursor synthesized by lymphocytes, the art:
Matthews et at., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) .1 Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09403492 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-6 Accession R49041 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al cells, B cells, eosinophils, and (1987) Eur. J. Immunol 17, 1411-lymphocytes), chemotaxis of 16.
neutrophils and T lymphocytes, and/or inhibition of interferons.
Mutant GeneSeq W09411402- Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin 6 Accession R54990 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 S176R synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., c:3 stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al cells, B cells, eosinophils, and (1987) Eur. J. Immunol 17, 1411-lymphocytes), chemotaxis of 16.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
Interleukin 6 GeneSeq JP06145063 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R55256 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al cells, B cells, eosinophils, and (1987) Eur. J. Immunol 17, 1411-lymphocytes), chemotaxis of 16.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Interleukin 8 GeneSeq JP06100595 Interleukins are a group of Interleukin activity can be Soluble IL-8 receptor (IL-8) receptor Accession R53932 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Holmes et al cells, B cells, eosinophils, and (1991)Science 253, 1278-80.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq US5328988 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-7. Accession R59919 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Park et al cells, B cells, eosinophils, and (1990) J .Exp. Med. 171, 1073-79.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co = and/or inhibition of interferons.
IL-3 containing GeneSeq W09521254 Interleukins are a group of Interleukin activity can be inflammatory disorders, fusion protein. Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer R79342 and synthesized by lymphocytes, the art: Matthews et al., in R79344 monocytes, and macrophages.
Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-3 mutant GeneSeq W09521254 Interleukins are a group of Interleukin activity can be inflammatory disorders, proteins Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer R79254, R79255, synthesized by lymphocytes, the art: Matthews et al., in R79256, R79257, monocytes, and macrophages.
Lymphokines and Interferons: A
R79258, R79259, Known functions include Practical Approach, Clemens et al., R79260, R79261, stimulating proliferation of eds, IRL Press, Washington, D.C.
R79262, R79263, immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et R79264, R79265, cells, B cells, eosinophils, and al (1989) .1 Cell Physiol. 140 323-R79266, R79267, lymphocytes), chemotaxis of 334.
R79268, R79269, neutrophils and T lymphocytes, R79270, R79271, and/or inhibition of interferons.
R79272, R79273, R79274, R79275, R79276, R79277, R79278, R79279, R79280, R79281, ts.) R79282, R79283, R79284, and IL-15 GeneSeq ZA9402636 Interleukins are a group of Interleukin activity can be inflammatory disorders, 0 Accession R66927 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 co synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Gin i et al cells, B cells, eosinophils, and (1994) EMBO J. 13 2822-2830.
= lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-12p40 GeneSeq AU9466072 Interleukins are a group of Interleukin activity can be inflammatory disorders, subunit. Accession R63018 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
AGF GeneSeq W09429344 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R64240 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225.

cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq W09519786 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-12 Accession R79187 multifunctional cytokines determined using assays known in immunologic disorders, cancer 40 kD subunit synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09530695 Interleukins are a group of Interleukin activity can be Soluble IL-15 receptor interleukin-15 Accession R90843 multifunctional cytokines determined using assays known in polypeptides may be useful for receptor from synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin clone P1 monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., 1' helper 1987, pp. 221-225; and Gin i et al cells, B cells, eosinophils, and (1994) EMBO J. 13 2822-2830.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09604306- Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-7 Accession R92796 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Park et al cells, B cells, eosinophils, and (1990) J .Exp. Med. 171, 1073-79.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
interleukin-9 GeneSeq W09604306 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R92797 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier interleukin-3 GeneSeq W09604306 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R92801 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09604306 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-5 Accession R92802 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140, 323-lymphocytes), chemotaxis of 334.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
Recombinant GeneSeq DE19617202 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-16 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W33373 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Lim et al cells, B cells, eosinophils, and (1996) J. Irnmunol. 156, 2566-70.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IL-16 GeneSeq DE19617202 Interleukins are a group of Interleukin activity can be inflammatory disorders, protein Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W33234 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Lim et al cells, B cells, eosinophils, and (1996) J. Immunol. 156, 2566-70.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Thr117 human GeneSeq W09708321 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin 9 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 W27521 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., ON
stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225.

cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Met117 human GeneSeq W09708321 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin 9 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W27522 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymph okines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq US5817306 Interleukins are a group of Interleukin activity can be inflammatory disorders, intracellular IL- Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 1 receptor W80777 synthesized by lymphocytes, the art:
Matthews et al., in antagonist. monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq EP864585 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-18 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 protein (IL-18) W77158 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons:
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Ushio et al cells, B cells, eosinophils, and (1996) J. Immunol. 156, 4274-79.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq EP861663 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin 18 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W77077 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Ushio et al cells, B cells, eosinophils, and (1996) J. Iinmunol. 156, 4274-79.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

, Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X Identifier ---.I
Human GeneSeq EP861663 Interleukins are a group of Interleukin activity can be inflammatory disorders, o .6.
.6.
interleukin 18 Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer .6.
derivatives W77083, synthesized by lymphocytes, the art: Matthews et al., in W77084, monocytes, and macrophages.
Lymphokines and Interferons: A
W77085, Known functions include Practical Approach, Clemens et al., W77086, stimulating proliferation of eds, IRL Press, Washington, D.C.
W77087, immune cells (e.g., T helper 1987, pp. 221-225; and Ushio et al W77088, and cells, B cells, eosinophils, and (1996) J. Immunol. 156, 4274-79.
W77089 lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
, n Interleukin-9 GeneSeq W09827997 Interleukins are a group of Interleukin activity can be inflammatory disorders, (IL-9) mature Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 iv protein (Thr117 W68158 synthesized by lymphocytes, the art: Matthews et al., in a, co version). monocytes, and macrophages.
Lymphokines and Interferons: A in in --.1 Known functions include Practical Approach, Clemens et al., -..3 eo stimulating proliferation of eds, IRL Press, Washington, D.C.
iv immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al iv cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.

H
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-9 mature GeneSeq W09827997 Interleukins are a group of Interleukin activity can be inflammatory disorders, protein variant Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer (Met117 W68157 synthesized by lymphocytes, the art: Matthews et al., in version). monocytes, and macrophages.
Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al IV
- cells, B cells, eosinophils, and (1989) Blood 74, 1880-84. n lymphocytes), chemotaxis of neutrophils and T lymphocytes, cp o and/or inhibition of interferons.
1--, --..
1--, n.) o 1--, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IL-9 GeneSeq W09824904 Interleukins are a group of Interleukin activity can be inflammatory disorders, receptor protein Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer variant #3. W64058 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human IL-9 GeneSeq W09824904 Interleukins are a group of Interleukin activity can be Soluble IL-9 receptor receptor protein Accession multifunctional cytokines determined using assays known in polypeptides may be useful for variant fragment W64060 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74,1880-84.
EL
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human IL-9 GeneSeq W09824904 Interleukins are a group of Interleukin activity can be Soluble IL-9 receptor receptor protein Accession multifunctional cytokines determined using assays known in polypeptides may be useful for variant W64061 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin fragment#3. monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09817689 Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin-12 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer p40 protein W51311 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et at, stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Hon et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09817689 Interleukins are a group of Interleukin activity can be inflammatory disorders, Interleukin-12 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer p35 protein W51312 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
co Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70,1069-1078.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human protein GeneSeq DE19649233- Interleukins are a group of Interleukin activity can be inflammatory disorders, with IL-16 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer activity W63753 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Lim et al cells, B cells, eosinophils, and (1996) J. Immunol. 156, 2566-70.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human protein GeneSeq DE19649233- Interleukins are a group of Interleukin activity can be inflammatory disorders, with IL-16 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer activity W59425 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., 1' helper 1987, pp. 221-225; and Lim et al cells, B cells, eosinophils, and (1996) J. Immunol. 156, 2566-70.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq US5747024 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-15 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 W53878 synthesized by lymphocytes, the art:
Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons:
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Gin i et al cells, B cells, eosinophils, and (1994) EMBO J. 13 2822-2830.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human wild- GeneSeq W09747744 Interleukins are a group of Interleukin activity can be inflammatory disorders, type interleukin- Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 4 (hIL-4) W52149 synthesized by lymphocytes, the art:
Matthews et al., in protein monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &
cells, B cells, eosinophils, and Mostowski (1990) J Immunol lymphocytes), chemotaxis of Methods 132,287-295.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier interleukin-4 GeneSeq W09747744 Interleukins are a group of Interleukin activity can be inflammatory disorders, muteins Accessions multifunctional cytokines determined using assays known in immunologic disorders, cancer W52150, synthesized by lymphocytes, the art: Matthews et al., in W52151, monocytes, and macrophages.
Lymphokines and Interferons: A
W52153, Known functions include Practical Approach, Clemens et al., W52154, stimulating proliferation of eds, IRL Press, Washington, D.C.
W52155, immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &
W52156, cells, B cells, eosinophils, and Mostowski (1990) J Immunol W52157, lymphocytes), chemotaxis of Methods 132,287-295.
W52158, neutrophils and T lymphocytes, W52159, and/or inhibition of interferons.
W52160, W52161, co W52162, co W52163, oo W52164, W52165, co -W52166, and co Human GeneSeq W09935268 Interleukins are a group of Interleukin activity can be inflammatory disorders, co interleukin 1 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer co co delta Y28408 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
=
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09935268 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-1 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer receptor Y24395 synthesized by lymphocytes, the art: Matthews et al., in antagonist beta monocytes, and macrophages.
Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IFtL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
.cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human EDIRF GeneSeq W09932632 Interleukins are a group of Interleukin activity can be inflammatory disorders, II protein Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer sequence Y22199 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
co Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225.

cells, 13 cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human EDIRF GeneSeq W09932632 Interleukins are a group of Interleukin activity can be inflammatory disorders, I protein Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer sequence Y22197 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IL- GeneSeq W09919480 Interleukins are a group of Interleukin activity can be Soluble IL-1RD10 receptor IRD10 protein Accession multifunctional cytokines determined using assays known in polypeptides may be useful for sequence Y14131 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human IL- GeneSeq W09919480 Interleukins are a group of Interleukin activity can be Soluble IL-1RD9 receptor 1RD9 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for Y14122 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
oo Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human DNAX GeneSeq WO9919491 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-40 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer Y09196 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier (DIL-40) GeneSeq W09919491 Interleukins are a group of Interleukin activity can be inflammatory disorders, alternative Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer sequence Y09197 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-11 GeneSeq W09405318 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R50176 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
oo Known functions include Practical Approach, Clemens et al., (../1 stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Lu et al cells, B cells, eosinophils, and (1994) I immunol. Methods 173, 19.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq EP566410 Interleukins are a group of Interleukin activity can be inflammatory disorders, adipogenesis Accession R43260 multifunctional cytokines determined using assays known in immunologic disorders, cancer inhibitory factor synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons:
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-11 GeneSeq JP08127539 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W02202 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
=
immune cells (e.g., T helper 1987, pp. 221-225; and Lu et al cells, B cells, eosinophils, and (1994) J immunol. Methods 173, 19.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-14 GeneSeq W09416074 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R55800 multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
oo Known functions include Practical Approach, Clemens et al., co stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Ambrus et al cells, B cells, eosinophils, and (1993) PNAS 90, 63330-34.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-17 receptor GeneSeq US6072033 Interleukins are a group of Interleukin activity can be Soluble IL-17 receptor Accession B03807 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yao et al cells, B cells, eosinophils, and (1995) J. Immunol. 155, 5483-86.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-17 GeneSeq W09518826 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R76573 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons:
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yao et al cells, B cells, eosinophils, and (1995) J. Immunol. 155, 5483-86.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
CTLA-8 GeneSeq W09704097 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer 0 W13651 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
oo Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225.

cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
IL-19 GeneSeq W09808870 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer W37935 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Gallagher et cells, B cells, eosinophils, and al (2000) Genes Irnmun. 1, 442-50.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier IL-21 (TIF) GeneSeq W00024758 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer Y92879 synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Parrish-cells, B cells, eosinophils, and Novak et al (2000) Nature 408, 57-lymphocytes), chemotaxis of 63.
neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-8 receptor GeneSeq W09306229 Interleukins are a group of Interleukin activity can be Soluble IL-8 receptor Accession R33420 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting inter! eukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
oo Known functions include Practical Approach, Clemens et al., co stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Holmes et al cells, B cells, eosinophils, and (1991)Science 253, 1278-80.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human type II GeneSeq US5464937 Interleukins are a group of Interleukin activity can be Soluble type II interleukin-1 interleulcin-1 Accession R85480 multifunctional cytokines determined using assays known in receptor polypeptides may be receptor synthesized by lymphocytes, the art: Matthews et al., in useful for inhibiting monocytes, and macrophages. Lymphokines and Interferons: A interleukin activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq EP638644 Interleukins are a group of Interleukin activity can be Soluble 1L-12 receptor interleukin-12 Accession R69632 multifunctional cytokines determined using assays known in polypeptides may be useful for receptor synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Interleukin 8 GeneSeq US5440021 Interleukins are a group of Interleukin activity can be Soluble IL-8 receptor B

receptor B Accession R80758 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin 0 monocytes, and macrophages. Lymphokines and Interferons: A activities.
oo Known - functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Holmes et al cells, B cells, eosinophils, and (1991)Science 253, 1278-80.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human IL-8 GeneSeq JP08103276 Interleukins are a group of Interleukin activity can be Soluble IL-8 receptor A
receptor protein Accession B09989 multifunctional cytokines determined using assays known in polypeptides may be useful for hIL8RA synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Holmes et al cells, B cells, eosinophils, and (1991)Science 253, 1278-80.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IL-8 GeneSeq JP08103276 Interleukins are a group of Interleukin activity can be Soluble IL-8 receptor receptor protein Accession B09990 multifunctional cytokines determined using assays known in polypeptides may be useful for hIL8RB synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Holmes et al cells, B cells, eosinophils, and (1991)Science 253, 1278-80.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Interleukin-2 GeneSeq W09621732- Interleukins are a group of Interleukin activity can be Soluble IL-2 receptor receptor Accession R97569 multifunctional cytokines determined using assays known in polypeptides may be useful for associated synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin 0 protein p43 monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Gillis et al cells, = B cells, eosinophils, and (1978) J. Immunol. 120, 2027.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq W09629408 Interleukins are a group of Interleukin activity can be Soluble IL-17 receptor interleukin-17 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for receptor W04185 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yao et al cells, B cells, eosinophils, and (1995) J. Immunol. 155, 5483-86.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09619574 Interleukins are a group of Interleukin activity can be Soluble IL-11 receptor interleukin-11 Accession R99090 multifunctional cytokines determined using assays known in polypeptides may be useful for receptor synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Lu et al cells, B cells, eosinophils, and (1994) J immunol. Methods 173, 19.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09623067 Interleukins are a group of Interleukin activity can be inflammatory disorders, interleukin-1 Accession multifunctional cytokines determined using assays known in immunologic disorders, cancer receptor W01911 synthesized by lymphocytes, the art: Matthews et al., in accessory monocytes, and macrophages.
Lymphokines and Interferons: A
v.) protein Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
EL
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
AGF Protein GeneSeq US5488032 Interleukins are a group of Interleukin activity can be inflammatory disorders, Accession R92749 multifunctional cytokines determined using assays known in immunologic disorders, cancer synthesized by lymphocytes, the art: Matthews et al., in monocytes, and macrophages. Lymphokines and Interferons: A
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Protein X Identifier Human GeneSeq W09607739 Interleukins are a group of Interleukin activity can be Soluble IL- type-3 receptor interleukin-1 Accession R91064 multifunctional cytokines determined using assays known in polypeptides may be useful for type-3 receptor synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Orencole &
cells, B cells, eosinophils, and Dinarello (1989) Cytokine 1, 14-20.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq W09720926 Interleukins are a group of Interleukin activity can be Soluble IL-13 beta receptor interleukin-13 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for beta receptor W24972 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Boutelier et cells, B cells, eosinophils, and al (1995) J. Immunol. Methods lymphocytes), chemotaxis of 181,29.
neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq W09720926 Interleukins are a group of Interleukin activity can be Soluble IL-13 alpha receptor interleukin-13 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for alpha receptor W24973 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Boutelier et - cells, B cells, eosinophils, and al (1995) J. Immunol. Methods lymphocytes), chemotaxis of 181,29.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq US5599905 Interleukins are a group of Interleukin activity can be Soluble IL-4 receptor interleukin-4 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for receptor W13499 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Siegel &
cells, B cells, eosinophils, and Mostowski (1990) J Immunol lymphocytes), chemotaxis of Methods 132,287-295.
neutrophils and T lymphocytes, and/or inhibition of interferons.
Human GeneSeq EP759466 Interleukins are a group of Interleukin activity can be Soluble IL-12 beta-2 receptor interleukin-12 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for 0 beta-2 receptor W12771 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
v;)0 Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human GeneSeq EP759466 Interleukins are a group of Interleukin activity can be Soluble IL-12 beta-1 receptor interleukin-12 Accession multifunctional cytokines determined using assays known in polypeptides may be useful for beta-1 receptor. W12772 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Hon i et al cells, B cells, eosinophils, and (1987), Blood 70, 1069-1078.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IL-9 GeneSeq W09824904 Interleukins are a group of Interleukin activity can be Soluble IL-9 receptor receptor protein Accessions multifunctional cytokines determined using assays known in polypeptides may be useful for W64055, synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin W64056, and monocytes, and macrophages. Lymphokines and Interferons: A activities.
W64057 Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yang et al cells, B cells, eosinophils, and (1989) Blood 74, 1880-84.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
IL-10 receptor GeneSeq US5716804 Interleukins are a group of Interleukin activity can be Soluble IL-10 receptor Accession multifunctional cytokines determined using assays known in polypeptides may be useful for W41804 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Thompson-cells, B cells, eosinophils, and Snipes et al (1991) J. Exp. Med.
lymphocytes), chemotaxis of 173, 507-510.
neutrophils and T lymphocytes, co and/or inhibition of interferons.
Human IL-6 GeneSeq JP11196867 Interleukins are a group of Interleukin activity can be Soluble IL-6 receptor receptor Accession multifunctional cytokines determined using assays known in polypeptides may be useful for Y30938 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lyrnphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al cells, B cells, eosinophils, and (1987) Eur. J. Immunol 17, 1411-lymphocytes), chemotaxis of 16.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier 11-17 receptor GeneSeq US6096305 Interleukins are a group of Interleukin activity can be Soluble IL-17 receptor Accession multifunctional cytokines determined using assays known in polypeptides may be useful for Y97181 synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Yao et al cells, B cells, eosinophils, and (1995) J. Immunol. 155, 5483-86.
lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
=
11-17 receptor GeneSeq US6100235 Interleukins are a group of Interleukin activity can be Soluble IL-17 receptor Accession multifunctional cytokines determined using assays known in polypeptides may be useful for Y97131 synthesized by lymphocytes, the art: Matthews et al., in inhibiting i n terl eukin 0 monocytes, and macrophages. Lymphokines and Interferons: A activities.
1/4.0 Known functions include Practical Approach, Clemens et al., LAI
stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Yao et al cells, B cells, eosinophils, and (1995) J. Immunol. 155, 5483-86.
EL
lymphocytes), chemotaxis of neutrophils and T lymphocytes, co and/or inhibition of interferons.
human GeneSeq EP509826 Interleukins are a group of Interleukin activity can be Soluble IL-3 receptor interleukin-3 Accession R25300 multifunctional cytokines determined using assays known in polypeptides may be useful for receptor synthesized by lymphocytes, the art: Matthews et al., in inhibiting i n te rleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J. Cell Physiol. 140 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GM- GeneSeq W09102063 Interleukins are a group of Interleukin activity can be Soluble GM-CSF receptor CSF receptor Accession R10919 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225.
cells, B cells, eosinophils, and lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
Human IL-5 GeneSeq EP492214 Interleukins are a group of Interleukin activity can be Soluble IL-5 receptor alpha receptor alpha Accession R25064 multifunctional cytokines determined using assays known in polypeptides may be useful for chain synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin 0 monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140, 323-lymphocytes), chemotaxis of 334.

neutrophils and T lymphocytes, co and/or inhibition of interferons.
11-5 receptor GeneSeq W09847923 Interleukins are a group of Interleukin activity can be Soluble IL-5 receptor Accession multifunctional cytokines determined using assays known in polypeptides may be useful for W82842 synthesized by lymphocytes, the art:
Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Kitamura et cells, B cells, eosinophils, and al (1989) J Cell Physiol. 140, 323-lymphocytes), chemotaxis of 334.
neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier 11-6 receptor GeneSeq JP05091892 Interleukins are a group of Interleukin activity can be Soluble IL-6 receptor Accession R37215 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, 1RL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Aarden et al cells, 13 cells, eosinophils, and (1987) Eur. J. Immunol 17, 1411-lymphocytes), chemotaxis of 16.
neutrophils and T lymphocytes, and/or inhibition of interferons.
human B cell GeneSeq AU8928720 Interleukins are a group of Interleukin activity can be Soluble B cell stimulating stimulating Accession P90525 multifunctional cytokines determined using assays known in factor-2 receptor polypeptides 0 factor-2 synthesized by lymphocytes, the art:
Matthews et al., in may be useful for inhibiting receptor monocytes, and macrophages. Lymphokines and Interferons: A interleukin activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp.221-225.

cells, B cells, eosinophils, and lymphocytes), chemotaxis of =
neutrophils and T lymphocytes, co and/or inhibition of interferons.
1L-7 receptor GeneSeq EP403114 Interleukins are a group of Interleukin activity can be Soluble IL-7 receptor clone Accession R08330 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.
immune cells (e.g., T helper 1987, pp. 221-225; and Park et al cells, 13 cells, eosinophils, and (1990) J .Exp. Med. 171,1073-79.

lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier EPO receptor; GeneSeq W09008822 EPO Receptor is involved in the EPO
Receptor activity can be inflammatory disorders, EPOR Accession R06512 proliferation and differentiation determined using assays known in immunologic disorders, of erythroblasts. the art, such as, J Biol Chem 2001 cancer, erythroblast Mar 23;276(12):8995-9002; JAK2 proliferation and protein tyrosine kinase activity: differentiation Blood 1994 Sep 1;84(5):1501-7 and Mol Cell Biol. 1994 Oct;14(10):6506-14.
IL-15 receptor GeneSeq W09530695 Interleukins are a group of Interleukin activity can be Soluble IL-15 receptor Accession R90843 multifunctional cytokines determined using assays known in polypeptides may be useful for synthesized by lymphocytes, the art: Matthews et al., in inhibiting interleukin monocytes, and macrophages. Lymphokines and Interferons: A activities.
Known functions include Practical Approach, Clemens et al., stimulating proliferation of eds, IRL Press, Washington, D.C.

immune cells (e.g., T helper 1987, pp. 221-225; and Girl et al cells, B cells, eosinophils, and (1994) EMBO J. 13 2822-2830.
co lymphocytes), chemotaxis of neutrophils and T lymphocytes, and/or inhibition of interferons.
CD137; 4-1BB GeneSeq W09507984 Activities associated with Apoptosis activity, NF-kB Soluble 4-1BB receptor 0 Receptor Accession R70977 apoptosis, NF-kB activation, activation, and B and T cell co- polypeptides may be useful for 0 co Protein and co-stimulation of immune stimulation can be determined using inhibiting apoptosis, NF-kB
cells such as T and B cells, assays known in the art: Moore et activation, and/or co-al., 1999, Science, 285(5425):260-3; stimulation of immune cells Song HY etal., 1997 Proc Natl Acad such as B and T cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier BCMA GeneSeq W00068378 Activities associated with Apoptosis activity, NF-kB Soluble BCMA receptor Accession apoptosis, NF-kB activation, activation, and B and T cell co- polypeptides may be useful for Y71979 and co-stimulation of immune stimulation can be determined using inhibiting apoptosis, NF-kB
cells such as T and B cells, assays known in the art: Moore et activation, and/or co-al., 1999, Science, 285(5425):260-3; stimulation of immune cells Song HY etal., 1997 Proc Natl Acad such as B and T cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
CD27 GeneSeq W09201049 Activities associated with Apoptosis activity, NF-kB Soluble CD27 polypeptides Accession R20814 apoptosis, NF-kB activation, activation, and B and T cell co- may be useful for inhibiting and co-stimulation of immune stimulation can be determined using apoptosis, NF-kB activation, cells such as T and B cells, assays known in the art: Moore et and/or co-stimulation of al., 1999, Science, 285(5425):260-3; immune cells such as B and T

Song HY etal., 1997 Proc Natl Acad cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

CD30 GeneSeq DE4200043 Activities associated with Apoptosis activity, NF-kB Soluble CD30 polypeptides Accession R35478 apoptosis, NF-kB activation, activation, and B and T cell co- may be useful for inhibiting 0 and co-stimulation of immune stimulation can be determined using apoptosis, NF-kB activation, 0 co cells such as T and B cells, assays known in the art: Moore et and/or co-stimulation of al., 1999, Science, 285(5425):260-3; immune cells such as B and T
Song HY etal., 1997 Proc Natl Acad cells.
=
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CD40 GeneSeq W09945944 Activities associated with Apoptosis activity, NF-kB Soluble CD40 polypeptides Accession apoptosis, NF-kB activation, activation, and B and T cell co- may be useful for inhibiting Y33499 and co-stimulation of immune stimulation can be determined using apoptosis, NF-kB activation, cells such as T and B cells, assays known in the art: Moore et and/or co-stimulation of al., 1999, Science, 285(5425):260-3; immune cells such as B and T
Song HY etal., 1997 Proc Natl Acad cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
EDAR Genbank Activities associated with Apoptosis activity, NF-kB Immune Disorders, Accession apoptosis, NF-kB activation, activation, and B and T cell co- Lymphomas, X-I inked AAD50077 and co-stimulation of immune stimulation can be determined using hypohidrotic ectodermal cells such as T and B cells, assays known in the art: Moore et dysplasia al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

0X40; ACT-4 GeneSeq W09512673 Activities associated with Apoptosis activity, NF-kB Immune Disorders, Accession R74737 apoptosis, NF-kB activation, activation, and B and T cell co- Lymphomas, T cell disorders 0 and co-stimulation of immune stimulation can be determined using co cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier TACI GeneSeq W09839361 Activities associated with Apoptosis activity, NF-kB Soluble TACI receptor Accession apoptosis, NF-kB activation, activation, and B and T cell co- polypeptides may be useful for W75783 and co-stimulation of immune stimulation can be determined using inhibiting apoptosis, NF-kB
cells such as T and B cells, assays known in the art: Moore et activation, and/or co-al., 1999, Science, 285(5425):260-3; stimulation of immune cells Song HY etal., 1997 Proc Nat! Acad such as B and T cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
TNF-R GeneSeq AU9058976 Activities associated with Apoptosis activity, NF-kB Soluble TNF-R receptor Accession R10986 apoptosis, NF-kB activation, activation, and B and T cell co- polypeptides may be useful for and co-stimulation of immune stimulation can be determined using inhibiting apoptosis, NF-kB
cells such as T and B cells. assays known in the art: Moore et activation, and/or co- 0 al., 1999, Science, 285(5425):260-3; stimulation of immune cells Song HY etal., 1997 Proc Natl Acad such as B and T cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

TNF-RII; TNF GeneSeq EP418014 Activities associated with Apoptosis activity, NF-kB Soluble TNFR-II receptor p75 Receptor; Accession R11141 apoptosis, NF-kB activation, activation, and B and T cell co- polypeptides may be useful for 0 Death Receptor and co-stimulation of immune stimulation can be determined using inhibiting apoptosis, NF-kB 0 co cells such as T and B cells, assays known in the art: Moore et activation, and/or co-al., 1999, Science, 285(5425):260-3; stimulation of immune cells Song HY etal., 1997 Proc Natl Acad such as B and T cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier hAP0-4; TROY GeneSeq W09911791 Activities associated with Apoptosis activity, NF-kB Immune Disorders, Cancers Accession apoptosis, NF-kB activation, activation, and B and T cell co-W93581 and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
TNF-alpha GeneSeq EP205038 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, precursor Accession P60074 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

Human TNF- GeneSeq EP619372 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, alpha Accession R62463 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer 0 and co-stimulation of immune stimulation can be determined using co cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human TNF- GeneSeq EP563714 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, alpha Accession R42679 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
Human TNF- GeneSeq W00064479 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, beta (LT-alpha) Accession B37799 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

LT-alpha GeneSeq EP250000 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession P70107 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer 0 and co-stimulation of immune stimulation can be determined using co cells such as T and B cells. assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier LT-beta GeneSeq W09413808 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession R56869 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song NY etal., 1997 Proc Nati Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
OPGL GeneSeq W09846751 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, W83195 and co-stimulation of immune stimulation can be determined using cancer, loss of bone mass, cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik 41= and Nissen-Meyer, 1986, J.

Immunol. Methods.

FasL GeneSeq W09903999 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer 0 W98071 and co-stimulation of immune stimulation can be determined using 0 co cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song MY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Fasl, GeneSeq W09903998 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer W95041 and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Nati Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
CD27L GeneSeq W09405691 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession R50121 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Nati Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.

Immunol. Methods.

CD30 ligand GeneSeq W09324135 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession R45007 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer 0 and co-stimulation of immune stimulation can be determined using co cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Nati Acad Sd U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier CD4OL GeneSeq W09529935 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession 1285486 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and J cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
4-1BB ligand GeneSeq US5674704 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer W26657 and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;

Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik C31 and Nissen-Meyer, 1986, J.

Immunol. Methods.

FAS Ligand GeneSeq W00058465 Activities associated with Apoptosis activity, NF-kB Soluble DcR3 polypeptides Fa Inhibitory Accession B19335 apoptosis, NF-kB activation, activation, and B and T cell co- may be useful for inhibiting Protein (DcR3) and co-stimulation of immune stimulation can be determined using apoptosis, NF-kB activation, co cells such as T and B cells. assays known in the art: Moore et and/or co-stimulation of al., 1999, Science, 285(5425):260-3; immune cells such as B and T
Song HY etal., 1997 Proc Natl Acad cells.
Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier OX4OL GeneSeq W09521915 Activities associated with Apoptosis activity, NF-kB inflammatory disorders, Accession R79903 apoptosis, NF-kB activation, activation, and B and T cell co- immunologic disorders, cancer and co-stimulation of immune stimulation can be determined using cells such as T and B cells, assays known in the art: Moore et al., 1999, Science, 285(5425):260-3;
Song HY etal., 1997 Proc Natl Acad Sci U S A 94(18):9792-6; Epsevik and Nissen-Meyer, 1986, J.
Immunol. Methods.
Protease GeneSeq W09106561 Peptides that inhibit the HIV
protease activities are known in HIV, inflammatory disorders, inhibitor Accessions function/binding of HIV the art: HIV
protease assays: immunologic disorders, peptides R12435, R12436, EP0387231. One can modify the cancer, viral infections R12437, R12438, assay to look for inhibition using 0 R12439, R12440, any of the disclosed protease and R1244 inhibitor polypeptides.
Retroviral GeneSeq EP387231 Peptides that inhibit the HIV
protease activities are known in HIV, inflammatory disorders, protease Accessions function/binding of HIV the art: HIV
protease assays: immunologic disorders, inhibitors R06660, R06661, EP0387231. One can modify the cancer, viral infections 0 R06662, R06663, assay to look for inhibition using R06664, R06665, any of the disclosed protease 0 R06666, R06667, inhibitor polypeptides. 0 co R06668, R06669, R06670, R06671, R06672, R06673, R06674, R06675, and R06676 Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier HIV protease GeneSeq W09301828 Peptides that inhibit the HIV
protease activities are known in IIW, inflammatory disorders, inhibiting Accessions function/binding of HW the art: HIV protease assays: immunologic disorders, peptides 1159293, 1159294, EP0387231.
One can modify the cancer, viral infections R59295 , R59296 assay to look for inhibition using , R59297, any of the disclosed protease R59298, 1159299, inhibitor polypeptides.
R59300, R59301, R59302, 1159301, R59302, 1159303, R59304, 1159305, R59306, R59307, R59308, 1159309, R59310, R59311, R59312, R59313, R59314, R59315, P5 R59316, R59317, c.:
cc R59318, R59319, R59320, R59321, R59322, 1159323, R59324, 1159325, R59326, R59327, co R59328, 1159329, 1159330, R59331, 1159332, 1159333, R59334, 1159335, R59336, 1159337, R59338, 1159339, 1159340, 1159341, R59342, 1159343, R59344, 1159345, R59346, 1159347, R59348, 1159349, and 1159350 Therapeutic Exemplary PCT/Patent Number Biological Activity I Exemplary Activity Assay Preferred Indication Y
Protein X Identifier HIV-1 protease GeneSeq 1)&1412174 Peptides that inhibit the HIV protease activities are known in HIV, inflammatory disorders, inhibitors Accessions function/binding of HIV
the art: HIV protease assays: immunologic disorders, R86326, R86327, EP0387231.
One can modify the cancer, viral infections R86328, R86329, assay to look for inhibition using R86330, R86331, any of the disclosed protease R86332, R86333, inhibitor polypeptides.
R86334, R86335, R86336, R86337, R86338, R86339, R86340, R86341, R86342, R86343, R86344, R86345 R86346, R86347, R86348, R86349, R86350, R86351, u, R86352, R86353, µ.c) R86354, R86355 R86356, R86357, R86358, R86359, R86360, R86361, R86362, R86363, co R86364, R86365 R86366, R86367, R86368, R86369, R86370, and HIV Inhibitor GeneSeq W09959615 Peptides that inhibit the HIV
protease activities are known in IIW, inflammatory disorders, Peptide Accession function/binding of HIV
the art: HIV protease assays: immunologic disorders, Y89687 EP0387231.
One can modify the cancer, viral infections assay to look for inhibition using any of the disclosed protease inhibitor polypeptides.

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o 1¨, Protein X Identifier ---I
HIV Inhibitor GeneSeq W09948513 Peptides that inhibit the HIV protease activities are known in HIV, inflammatory disorders, o .6.
.6.
Peptide Accession function/binding of HIV
the art: HIV protease assays: immunologic disorders, .6.
Y31955 EP0387231.
One can modify the cancer, viral infections assay to look for inhibition using any of the disclosed protease inhibitor polypeptides.
HIV Inhibitor vvww.sciencex Peptides that inhibit the HIV
protease activities are known in HIV, inflammatory disorders, Peptide press.or function/binding of HIV
the art: HIV protease assays: immunologic disorders, g;
EP0387231. One can modify the cancer, viral infections Published assay to look for inhibition using Online 12 any of the disclosed protease n January 2001; inhibitor polypeptides.

10.1126/seienc N) .1, e.1057453 in in Human GeneSeq W09509232 Chemokines are a family of Chemokine activities can be Immune disorders, particularly co 1--., -.3 . monocyte Accession R73915 related small, secreted proteins determined using assays known in useful for treating bacterial o iv chemoattractant involved in biological processes the art: Methods in Molecular and/or viral menigitis 0 factor hMCP-3 ranging from hematopoiesis, Biology, 2000, vol. 138:
Chemokine iv angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. H

trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. 0 family are involved in a similarly Power. Humana Press Inc., co diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-IV
coupled receptors. Over 40 n human chemokines have been described, which bind to ¨17 cp o receptors thus far identified.
--..
1¨, o 1¨, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09509232 Chemokines are a family of Chemokine activities can be Immune disorders, particularly monocyte Accession 103914 related small, secreted proteins determined using assays known in useful for treating bacterial chemoattractant involved in biological processes the art: Methods in Molecular and/or viral menigitis factor hMCP-1 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemoldne angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO
.10 Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human gro-beta GeneSeq W09429341 Chemokines are a family of Chemokine activities can be Immune disorders, chemokine Accessions related small, secreted proteins determined using assays known in inflammatory disorders, blood-R66699 and involved in biological processes the art: Methods in Molecular related disorders, stern cell W17671 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplantation, cancer angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemolcines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been t\.) described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human gro- GeneSeq W09429341 Chemokines are a family of Chemokine activities can be Immune disorders, gamma Accessions related small, secreted proteins determined using assays known in inflammatory disorders, blood-chemokine R66700 and involved in biological processes the art:
Methods in Molecular related disorders, stem cell W17672 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplantation, cancer angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemOkines exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO
- -Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human gro- GeneSeq W09429341 Chemokines are a family of Chemoldne activities can be Immune disorders, alpha Accessions related small, secreted proteins determined using assays known in inflammatory disorders, blood-chemokine R66698 and involved in biological processes the art: Methods in Molecular related disorders, stem cell W18024 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplantation, cancer angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., = diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W0963248I Chemokines are a family of Chemokine activities can be Immune disorders, partcularly eosinophil- Accession related small, secreted proteins determined using assays known in treatment of eosinophilia, expressed W05186 involved in biological processes the art:
Methods in Molecular inflammation, allergies, chemokine ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine asthma, leukaemia and (EEC) angiogenesis, and leukocyte Protocols. Edited by: A.E.I. lymphoma trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemokines are a family of Chemokine activities can be Cancer and blood-related protein PF4-414 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R92318 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99809 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been 0\
described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemoldnes are a family of Chemokine activities can be Cancer and blood-related protein IL-8M3 Accession R99812 related small, secreted proteins determined using assays known in disorders, particularly involved in biological processes the art: Methods in Molecular myelosuppression ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ; and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09613587 Chemokines are a family of Chemokine activities can be Cancer and blood-related interleukin-8 Accession R99814 related small, secreted proteins determined using assays known in disorders, particularly (IL-8) involved in biological processes the art: Methods in Molecular myelosuppression ranging from hematopoiesis, Biology, 2000, vol. 138: Chemoldne angiogenesis, and leukocyte Protocols, Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ;
and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemokines are a family of Chemokine activities can be Cancer and blood-related protein IL-8M1 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R998I5 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99803 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ;
and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been %.0 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemoldnes are a family of Chemoldne activities can be Cancer and blood-related protein IL-8M8 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R99816 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99805 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot;
T.N.C. Wells, and C.A.
family are involved in a similarly Power. C, Humana Press Inc., diverse range of pathologies Totowa, NJ;
and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been ts.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemokines are a family of Chemokine activities can be Cancer and blood-related protein 1L-8M9 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R99817 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99806 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ; and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemoldnes are a family of Chemokine activities can be Cancer and blood-related protein IL- Accessions related small, secreted proteins determined using assays known in disorders, particularly 8M10 Full- R99818 and involved in biological processes the art: Methods in Molecular myelosuppression Length and R99804 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine Mature angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. C) Humana Press Inc., diverse range of pathologies Totowa, NJ; and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine-like GeneSeq W09613587 Chemokines are a family of Chemokine activities can be Cancer and blood-related protein PF4-M2 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R99819 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99807 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemoldne-like GeneSeq W09613587 Chemoldnes are a family of Chemokine activities can be Cancer and blood-related protein PF4-426 Accessions related small, secreted proteins determined using assays known in disorders, particularly Full-Length and R99822 and involved in biological processes the art: Methods in Molecular myelosuppression Mature R99811 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human foetal GeneSeq W09622374 Chemokines are a family of Chemokine activities can be Immune disorders spleen Accession R98499 related small, secreted proteins determined using assays known in expressed involved in biological processes the art:
Methods in Molecular chemokine, ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine FSEC angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Prom:Ifoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Liver expressed GeneSeq W09616979 Chemokines are a family of Chemokine activities- can be Inflammation of the liver chemokine-1 Accession R95689 related small, secreted proteins determined using assays known in (LVEC-1) involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Prouclfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Liver expressed GeneSeq W09616979 Chemokines are a family of Chemokine activities can be Inflammation of the liver chemokine-2 Accession R95690 related small, secreted proteins determined using assays known in (LVEC-2) involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Pituitary GeneSeq W09616979 Chemokines are a family of Chemo'due activities can be Inflammation, particularly of expressed Accession R95691 related small, secreted proteins determined using assays known in the liver chemokine involved in biological processes the art: Methods in Molecular (PGEC) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. C.) Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been co described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Adenoid- GeneSeq W09617868 Chemokines are a family of Chemokine activities can be Inflammation, angiogenesis, expressed Accession R97664 related small, secreted proteins determined using assays known in tumorigenesis, chemokine involved in biological processes the art: Methods in Molecular musculoskeletal disorders (ADEC) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The (-) chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been %.0 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09741230 Chemokines are a family of Chemokine activities can be Immune disorders, cell chemokine CC- Accession related small, secreted proteins determined using assays known in migration, proliferation, and 2 W38170 involved in biological processes the art: Methods in Molecular differentiation disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09741230 Chemokines are a family of Chemokine activities can be Immune disorders, cell chemokine Accession related small, secreted proteins determined using assays known in migration, proliferation, and HCC-1 W38171 involved in biological processes the art:
Methods in Molecular differentiation disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeel W09741230 Chemokines are a family of Chemokine activities can be Immune disorders, cell chemokine CC- Accession related small, secreted proteins determined using assays known in migration, proliferation, and 3 W38172 involved in biological processes the art: Methods in Molecular differentiation disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. C:) Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Novel beta- GeneSeq W09739126 Chemokines are a family of Chemokine activities can be Immune disorders, vascular chemokine Accession related small, secreted proteins determined using assays known in disorders, cancer designated W27271 involved in biological processes the art:
Methods in Molecular PTEC ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CX3C GeneSeq W09727299 Chemokines are a family of Chemokine activities can be Immune disorders, 111 amino acid Accession related small, secreted proteins determined using assays known in inflammatory diseases, chemokine W23344 involved in biological processes the art: Methods in Molecular abnormal proliferation, ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine regeneration, degeneration, angiogenesis, and leukocyte Protocols. Edited by: A.E.I. and atrophy trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc, diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CCF18 GeneSeq W09721812 Chemokines are a family of Chemokine activities can be Abnormal physiology and chemokine Accession related small, secreted proteins determined using assays known in development disorders, can W25942 involved in biological processes the art: Methods in Molecular also be used as an anti-viral ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine agent angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human beta- GeneSeq W09725427 Chemokines are a family of Chemokine activities can be Chemotaxis, blood-related chemokine Accession related small, secreted proteins determined using assays known in disorders, viral infection, HIV, H1305 (MCP-2) W26655 involved in biological processes the art: Methods in Molecular wound healing, cancer ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been 04% described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09712914 Chemokines are a family of Chemokine activities can be Inflammatory and immune eosinocyte CC Accession related small, secreted proteins determined using assays known in disorders type chemokine W14990 involved in biological processes the art: Methods in Molecular eotaxin ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human thymus GeneSeq W09711969 Chemokines are a family of Chemokine activities can be Inflammatory and immune and activation Accession related small, secreted proteins determined using assays known in disorders regulated W14917 involved in biological processes the art: Methods in Molecular cytokine ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (TARC) angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
= including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been 00 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09712041 Chemokines are a family of Chemokine activities can be Cancer, wound healing, chemokine beta- Accession related small, secreted proteins determined using assays known in immune disorders 8 short forms W16315 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and-leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemolcines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to -17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Macrophage GeneSeq W09640923 Chemokines are a family of Chemokine activities can be Inflammatory diseases, wound derived Accession related small, secreted proteins determined using assays known in healing, angiogenesis chemokine, W20058 involved in biological processes the art: Methods in Molecular MDC ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been C described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09844117 Chemokines are a family of Chemokine activities can be Inflammatory and immune chemokine Accession related small, secreted proteins determined using assays known in diseases ZSIG-35 W30565 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

=
Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Primate CC GeneSeq W09832858 Chemokines are a family of Chemokine activities can be Immune and inflammatory chemokine Accession related small, secreted proteins determined using assays known in disorders, abnormal "ILINCK" W69990 involved in biological processes the art:
Methods in Molecular proliferation, regeneration, ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine generation and atrophy angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by , acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Primate CXC GeneSeq W09832858 Chemokines are a family of Chemokine activities can be Immune and inflammatory chemokine Accession related small, secreted proteins determined using assays known in disorders, abnormal "IBICK" W69989 involved in biological processes the art:
Methods in Molecular proliferation, regeneration, ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine generation and atrophy angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

co Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CC-type GeneSeq W09831809 Chemokines are a family of Chemokine activities can be Immune, inflammatory, and chemokine Accession related small, secreted proteins determined using assays known in infectious disorders, cancer protein W69163 involved in biological processes the art: Methods in Molecular designated SLC ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (secondary angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
lymphoid trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
chemokine) family are involved in a similarly Power. CD Humana Press Inc., diverse range of pathologies TotOwa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to -17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CC GeneSeq W09826071 Chemokines are a family of Chemokine activities can be Cancer and infectious diseases, chemokine ELC Accession related small, secreted proteins determined using assays known in particularly herpes virus protein W62542 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been - described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human DVic-1 GeneSeq W09823750 Chemokines are a family of Chemokine activities can be Abnormal proliferation, C-C chemokine Accession related small, secreted proteins determined using assays known in regeneration, degeneration, W60649 involved in biological processes the art: Methods in Molecular and atrophy disorders, ranging from hematopoiesis, BiOlogy, 2000, vol. 138: Chemokine including cancer angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human C-C GeneSeq W09823750 Chemokines are a family of Chemokine activities can be Immune disorders, cell chemokine Accession related small, secreted proteins determined using assays known in proliferation disorders, cancer DGWCC W60650 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

=
Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X , Identifier Human STCP-1 GeneSeq W09824907 Chemokines are a family of Chemokine activities can be Immune disorders, particularly Accession related small, secreted proteins determined using assays known in T cell related disorders, viral W62783 involved in biological processes the art: Methods in Molecular infection, and inflammation, ranging from hetnatopoiesis, Biology, 2000, vol. 138: Chemokine especially joint angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Exodus protein GeneSeq W09821330 Chemokines are a family of Chemokine activities can be Immune and inflammatory Accession related small, secreted proteins determined using assays known in disorders, angiogenesis, W61279 involved in biological processes the art: Methods in Molecular cancer, and proliferation ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, particularly angiogenesis, and leukocyte Protocols. Edited by: A.E.I. myeloproliferative diseases trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane 0-protein-coupledreceptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09814581 Chemokines are a family of Chemokine activities can be Cancer and degenerative Chrl9Kine Accession related small, secreted proteins determined using assays known in disorders protein W50887 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. CD Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human T cell GeneSeq US5780268 Chemokines are a family of Chemoldne activities can be Immune, inflammatory, and mixed Accession related small, secreted proteins determined using assays known in infectious disorders, cancer lymphocyte W58703 involved in biological processes the art: Methods in Molecular reaction ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine expressed angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
chemokine trafficking. Members of this Proudfoot, T.N.C. Wells, and CA.
(TMEC) family are involved in a similarly Power. CD
Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 (.71 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human 6CKine GeneSeq W09814581 Chemokines are a family of Chemokine activities can be Cancer and degenerative protein Accession related small, secreted proteins determined using assays known in disorders W50885 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G.-protein-coupled receptors. Over 40 Ul human chemokines have been described, which bind to ¨17 receptors thus far identified.

0 =

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier human liver and GeneSeq W09817800 Chemokines are a family of Chemokine activities can be Immune, inflammatory, and activation Accession related small, secreted proteins determined using assays known in infectious disorders, cancer regulated W57475 involved in biological processes the art: Methods in Molecular chemokine ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (LARC) angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier RANTES GeneSeq W097(1/1462 Chemokines are a family of Chemokine activities can be Infectious diseases, peptide Accession related small, secreted proteins determined using assays known in particularly HIV
W29538 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨1'7 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier RANTES 8-68 GeneSeq W09741462 Chemokines are a family of Chemokine activities can be Infectious diseases, Accession related small, secreted proteins determined using assays known in particularly HIV
W29529 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier RANTES 9-68 GeneSeq W09744462 Chemokines are a family of Chemokine activities can be Infectious diseases, Accession related small, secreted proteins determined using assays known in particularly HIV
W29528 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane 0-protein-coupled receptors. Over 40 to-J-1.4 human chemokines have been C11 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09811226 Chemokines are a family of Chemokine activities can be Abnormal proliferation, chemokine Accession related small, secreted proteins determined using assays known in regeneration, degeneration or protein 331D5 W59433 involved in biological processes the art: Methods in Molecular atrophy, including cancer ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. C Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, yiral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨47 =
receptors thus far identified.

CO
.10 Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09811226 Chemokines are a family of Chemokine activities can be Abnormal proliferation, chemokine Accession related small, secreted proteins determined using assays known in regeneration, degeneration or protein 61164 W59430 involved in biological processes the art: Methods in Molecular atrophy, including cancer ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been 00 described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09809171 Chemokines are a family of Chemokine activities can be Immune, inflammatory, and MCP-4 Accession related small, secreted proteins determined using assays known in infectious diseases W56690 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis; Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ui human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human stromal GeneSeq FR2751658 Chemokines are a family of Chemokine activities can be HIV infections cell-derived Accession related small, secreted proteins determined using assays known in chemokine, W50766 involved in biological processes the art: Methods in Molecular =
SDF-1 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Thymus GeneSeq W09801557 Chemokines are a family of Chemoldne activities can be Immune and inflammatory expressed Accession related small, secreted proteins determined using assays known in disorders chemokine W44397 involved in biological processes the art: Methods in Molecular (TECK) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been crµ
described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09801557 Chemokines are a family of Chemokine activities can be Immune and inflammatory chemokine Accession related small, secreted proteins determined using assays known in disorders MIP-3alpha W44398 involved in biological processes the art:
Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09801557 Chemokines are a family of Chemokine activities can be Immune and inflammatory chemokine Accession related small, secreted proteins determined using assays known in disorders MIP-3beta W44399 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proucifoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09802459 Chemokines are a family of Chemokine activities can be Immune disorders, respiratory monocyte Accession related small, secreted proteins determined using assays known in disorders, cancer chemotactic W42072 involved in biological processes the art:
Methods in Molecular proprotein ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (MCPP) angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
sequence trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Macrophage- GeneSeq US5688927 / Chemokines are a family of Chemokine activities can be Immune, and inflammatory derived Accessions US5932703 related small, secreted proteins determined using assays known in disorders, cancer chemokine W40811 and involved in biological processes the art:
Methods in Molecular (MDC) Y24414 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NI
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Macrophage GeneSeq US5932703 Chemokines are a family of Chemokine activities can be Immune and inflammatory derived Accession related small, secreted proteins determined using assays known in disorders chemokine Y244I6 involved in biological processes the art: Methods in Molecular analogue MDC- ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine eYfY angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Prouclfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, . and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ui human chemokines have been csN described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Macrophage GeneSeq US5932703 Chemokines are a family of Chemokine activities can be Immune and inflammatory derived Accession related small, secreted proteins determined using assays known in disorders chemokine Y24413 involved in biological processes the art: Methods in Molecular analogue MDC ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (n+1) angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
=
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been described, which bind to ¨17 receptors thus far identified.

= 0 CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Macrophage GeneSeq US5932703 Chemokines are a family of Chemokine activities can be Immune and inflammatory derived Accession related small, secreted proteins determined using assays known in disorders chemokine Y24415 involved in biological processes the art: Methods in Molecular analogue MDC- ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine Y1 angiOgenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by =
acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human type CC GeneSeq JP11243960 Chemokines are a family of Chemokine activities can be Allergic diseases and HIV
chemokine Accession related small, secreted proteins determined using assays known in infection eotaxin 3 Y43178 involved in biological processes the art: Methods in Molecular protein ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine sequence angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human MCP-3 GeneSeq W09946392 Chemokines are a family of Chemokine activities can be Cancer and immune disorders, and human Accession related small, secreted proteins determined using assays known in particularly HIV infection Muc-1 core Y29893 involved in biological processes the art: Methods in Molecular epitope (VNT) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine fusion protein angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to -17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IP-10 GeneSeq W09946392 Chemokines are a family of Chemokine activities can be Cancer and immune disorders, and human Accession related small, secreted proteins determined using assays known in particularly IIIV infection Muc-1 core Y29894 - involved in biological processes the art: Methods in Molecular epitope (VNT) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine fusion protein angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Ul human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human IP-10 GeneSeq W09946392 Chemokines are a family of Chemokine activities can be Cancer and immune disorders, and HIV-1 Accession related small, secreted proteins determined using assays known in particularly HIV infection gp120 Y29897 involved in biological processes the art: Methods in Molecular hypervariable ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine region fusion angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
protein trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been t=.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09936540 Chemokines are a family of Chemokine activities can be Breast disease, including mammary Accessions related small, secreted proteins determined using assays known in cancer associated Y29092 and involved in biological processes the art: Methods in Molecular chemokine Y29093 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (MACK) angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
protein Full- trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
Length and family are involved in a similarly Power.
Humana Press Inc., Mature diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been L44 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Tim-1 protein GeneSeci W09933990 Chemokines are a family of Chemokine activities can be Inflammation due to stimuli Accession related small, secreted proteins determined using assays known in such as heart attacks and Y28290 involved in biological processes the art: Methods in Molecular stroke, infection, physical ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine trauma, UV or ionizing angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. radiation, burns, frostbite or trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. corrosive chemicals family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 )¨µ human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human Lkn-1 GeneSeq W09928473 and Chemokines are a family of Chemoldne activities can be HIV infection and cancer, Full-Length and Accessions W09928472 related small, secreted proteins determined using assays known in particularly leukemia Mature protein Y17280, Y17274, involved in biological processes the art: Methods in Molecular Y17281, and ranging from hematopoiesis, Biology, 2000, vol. 138:
Chemokine Y17275 angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 . receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier N-terminal GeneSeq W09920759 Chemokines are a family of Chemokine activities can be Inhibit or stimulate modified Accession related small, secreted proteins determined using assays known in angiogenesis, inhibit the chemokine met- Y05818 involved in biological processes the art: Methods in Molecular bindinc, of HIV
hSDF-1 alpha ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ' including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been ON described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier N-terminal GeneSeq W09920759 Chemokines are a family of Chemokine activities can be Inhibit or stimulate modified Accession related small, secreted proteins determined using assays known in angiogenesis, inhibit the chemokine met- Y05819 involved in biological processes the art: Methods in Molecular binding of HIV, hSDF-1 beta ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine antiinflammatory;
angiogenesis, and leukocyte Protocols. Edited by: A.E.I. immunosuppressant trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier N-terminal GeneSeq W09920759 Chemokines are a family of Chemokine activities can be Inhibit or stimulate modified Accession related small, secreted proteins determined using assays known in angiogenesis, inhibit the chemokine Y05820 involved in biological processes the art: Methods in Molecular binding of HIV, GroHEK/hSDF- ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine antiinflammatory;
lalpha angiogenesis, and leukocyte Protocols. Edited by: A.E.I. immunosuppressant trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been Co described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier N-terminal GeneSeq W09920759 Chemokines are a family of Chemokine activities can be Inhibit or stimulate modified Accession related small, secreted proteins determined using assays known in angiogenesis, inhibit the chemokine Y05821 involved in biological processes the art: Methods in Molecular binding of HIV, GroHEK/hSDF- ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine antiinflammatory;
1beta. angiogenesis, and leukocyte Protocols. Edited by: A.E.I. immunosuppressant trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been v) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Increase or enhance an Eotaxin. Accession related small, secreted proteins determined using assays known in inflammatory response, an Y14230 involved in biological processes the art: Methods in Molecular immune response or ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine haematopoietic cell-associated angiogenesis, and leukocyte Protocols. Edited by: A.E.I. activity; treat a vascular trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. indication; Cancer; enhance family are involved in a similarly Power. Humana Press Inc., wound healing, to prevent or diverse range of pathologies Totowa, NJ
treat asthma, organ transplant including inflammation, allergy, rejection, rheumatoid arthritis tissue rejection, viral infection, or allergy and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular hMCP1 a Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14225 involved in biological processes the art:
Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols. Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. response, family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular hMCP1 b Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14226 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. response, family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo t.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular hSDFlb Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14228 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. response family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 p¨ human chemokines have been La described, which bind to 47 receptors thus far identified.

CO
.10 Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine hIL- GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular 8 Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14229 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. response family are involved in a similarly Power. CD Humana Press Inc., diverse range of pathologies Totowa, NJ;
and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemolcines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular hMCP1 Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14222 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking,- Members of this Proudfoot, T.N.C. Wells, and C.A. response family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by cc acting on a family of seven transmembrane G-protein-cc coupled receptors. Over 40 human chemokines have been t..rc described, which bind to ¨17 cc receptors thus far identified.
cc CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular hMCP2 Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14223 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. response family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein--coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Chemokine GeneSeq W09912968 Chemokines are a family of Chemokine activities can be Immune disorders, Vascular 1iMCP3 Accession related small, secreted proteins determined using assays known in disorders, Wound healing, Y14224 involved in biological processes the art: Methods in Molecular cancer, prevent organ ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine transplant rejection, Increase angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. or enhance an inflammatory trafficking. Members of this Prouclfoot, T.N.C. Wells, and C.A. response family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been c:30 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier C-C chemokine, GeneSeq EP905240 Chemokines are a family of Chemokine activities can be Inflammatory, immune and MCP2 Accession related small, secreted proteins determined using assays known in infectious diseases; pulmonary Y05300 involved in biological processes the art: Methods in Molecular diseases and skin disorders;
ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by co acting on a family of seven transmembrane G-protein-co coupled receptors. Over 40 human ehemokines have been oo Co described, which bind to ¨17 co receptors thus far identified.
co CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Wild type GeneSeq EP906954 Chemokines are a family of Chemokine activities can be Inflammatory, immune and monocyte Accession related small, secreted proteins determined using assays known in infectious diseases; pulmonary chemotactic Y07233 involved in biological processes the art: Methods in Molecular diseases and skin disorders;
protein 2 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Truncated GeneSeq EP906954 Chemokines are a family of Chemokine activities can be Inflammatory, immune and monocyte Accession related small, secreted proteins determined using assays known in infectious diseases; pulmonary chemotactic Y07234 involved in biological processes the art: Methods in Molecular diseases and skin disorders;
protein 2 (6-76) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been kr) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Truncated GeneSeq EP905241; EP906954 Chemokines are a family of Chemokine activities can be Inflammatory, immune and RANTES Accessions related small, secreted proteins determined using assays known in infectious diseases; pulmonary =
protein (3-68) Y07236 and involved in biological processes the art: Methods in Molecular diseases and skin disorders;
Y07232 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols. Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. diseases family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Wild type GeneSeq EP905241 Chemokines are a family of Chemokine activities can be Inflammatory, immune and monocyte Accession related small, secreted proteins determined using assays known in infectious diseases; pulmonary chemotactic Y07237 involved in biological processes the art:
Methods in Molecular diseases and skin disorders;
protein 2 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols. Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. diseases family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

_ Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Truncated GeneSeq EP905241 Chemokines are a family of Chemokine activities can be Inflammatory, immune and monocyte Accession related small, secreted proteins determined using assays known in infectious diseases; pulmonary chemotactic Y07238 involved in biological processes the art: Methods in Molecular diseases and skin disorders;
protein 2 (6-76) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine tumours, and angiogenesis-angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. and haematopoiesis-related trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been cfrs described, which bind to ¨17 receptors thus far identified.

Aft CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A partial GeneSeq EP897980 Chemokines are a family of Chemokine activities can be Soluble CXCR4B receptor CXCR4B Accession related small, secreted proteins determined using assays known in polypeptides may be useful for protein W97363 involved in biological processes the art:
Methods in Molecular inhibiting chemokine activities ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine and viral infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The ehemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Interferon GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, gamma- Accession related small, secreted proteins determined using assays known in Inflammatory and Immune inducible W96709 involved in biological processes the art: Methods in Molecular disorders, CardiO-Vascular protein (IP-10) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been LA described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A monokine GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, induced by Accession related small, secreted proteins determined using assays known in Inflammatory and Immune gamma- W96710 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular interferon ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal (MIG) angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been \ described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Interleukin-8 GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, (IL-8) protein. Accession related small, secreted proteins determined using assays known in Inflammatory and Immune W96711 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoof, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ; and Holmes et al including inflammation, allergy, (1991)Science 253, 1278-80.
tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to -47 = receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Epithelial GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, neutrophil Accession related small, secreted proteins determined using assays known in Inflammatory and Immune activating W96712 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular protein-78 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal (ENA-78) angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Growth related GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, oncogene-alpha Accession related small, secreted proteins determined using assays known in Inflammatory and Immune (GRO-alpha). ' W96713 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. t Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Growth related GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, oncogene-beta Accession related small, secreted proteins determined using assays known in Inflammatory and Immune (GRO-beta). W96714 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 t\-4 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Growth related GeneSeq US5871723 Chemoldnes are a family of Chemokine activities can be Angiogenesis, Cancer, oncogene- Accession related small, secreted proteins determined using assays known in Inflammatory and Immune gamma (GRO- W96715 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular gamma) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 tN.) human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A platelet basic GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, protein (PBP) Accession related small, secreted proteins determined using assays known in Inflammatory and Immune W96716 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 tµ. human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Connective GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, tissue activating Accession related small, secreted proteins determined using assays known in Inflammatory and Immune protein-III W96717 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular (CTAP-III) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols. Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified, CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Beta- GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, thromboglobuli Accession related small, secreted proteins determined using assays known in Inflammatory and Immune n protein (beta- W96718 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular TG) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. (D Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 N.) human chemokines have been 41. described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Neutrophil GeneSeq US5871723 Chemokines are a family of Chemokine activities can be Angiogenesis, Cancer, activating Accession related small, secreted proteins determined using assays known in Inflammatory and Immune peptide-2 W96719 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular (NAP-2) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. CI Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been Ui described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Granulocyte GeneSeq US5871723 Chemokines are a family of Chemoldne activities can be Angiogenesis, Cancer, chemotactic Accession related small, secreted proteins determined using assays known in Inflammatory and Immune protein-2 (GCP- W96720 involved in biological processes the art: Methods in Molecular disorders, Cardio-Vascular 2) ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine disorders, Musco-skeletal angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. disorders trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts..) human chemokines have been (73 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq EP887409 Chemokines are a family of Chemokine activities can be Immune disorders, viral, chemokine Accession related small, secreted proteins determined using assays known in parasitic, fungal or bacterial MIG-beta W90124 involved in biological processes the art: Methods in Molecular infections, Cancer;
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven = transmembrane G-protein- 0 coupled receptors. Over 40 t\..) human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W09854326 Chemokiiies are a family of Chemokine activities can be Immune disorders, cancer, ZCHEM0-8 Accession related small, secreted proteins determined using assays known in myelopoietic disorders, protein W82716 involved in biological processes the art: Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. 0 Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemokines have been CD
00 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human Act-2 GeneSeq W09854326 Chemokines are a family of Chemokine activities can be Immune disorders, cancer, protein Accession related small, secreted proteins determined using assays known in myelopoietic disorders, W82717 involved in biological processes the art: Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
= including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven 1.) transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been %.0 described, which bind to ¨17 1.) receptors thus far identified.

1.) CO

=
Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human SISD GeneSeq W09854326 Chemokines are a family of Chemokine activities can be Immune disorders, cancer, protein Accession related small, secreted proteins determined using assays known in myelopoietic disorders, W82720 involved in biological processes the art:
Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols. Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human MI10 GeneSeq W09854326 Chemokines are a family of Chemokine activities can be Immune disorders, cancer, protein Accession related small, secreted proteins determined using assays known in myelopoietic disorders, W82721 involved in biological processes the art:
Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols. Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human MHA GeneSul W09854326 Chemokines are a family of Chemokine activities can be Immune disorders, cancer, protein Accession related small, secreted proteins determined using assays known in myelopoietic disorders, W82722 involved in biological processes the art: Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols.
Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 IN) human chemokines have been ts.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CCC3 GeneSeq W09854326 Chemokines are a family of Chemokine activities can be Immune disorders, cancer, protein Accession related small, secreted proteins determined using assays known in myelopoietic disorders, W82723 involved in biological processes the art: Methods in Molecular autoimmune disorders and ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine immunodeficiencies, angiogenesis, and leukocyte Protocols. Edited by: A.E.I. Inflammatory and infectious trafficking. Members of this Prouclfoot, T.N.C.
Wells, and C.A. diseases, Vascular disorders, family are involved in a similarly Power. Humana Press Inc., wound healing diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A human L105 GeneSeq W09856818 Chemokines are a family of Chemokine activities can be Cancer, wound healing, chemokine Accession related small, secreted proteins determined using assays known in designated W87588 involved in biological processes the art: Methods in Molecular huL105_3. ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A human L105 GeneSeq W09856818 Chemokines are a family of Chemolcine activities can be Cancer, wound healing, chemokine Accession related small, secreted proteins determined using assays known in designated W87589 involved in biological processes the art: Methods in Molecular huL105_7. ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨47 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human mature GeneSeq W09848828 Chemokines are a family of Chemokine activities can be Infectious diseases, sepsis gro-alpha Accession related small, secreted proteins determined using assays known in polypeptide W81498 involved in biological processes the art: Methods in Molecular used to treat ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine sepsis angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human mature GeneSeq W09848828 Chemokines are a family of Chemokine activities can be Infectious diseases, sepsis gro-gamma Accession related small, secreted proteins determined using assays known in polypeptide W81500 involved in biological processes the art: Methods in Molecular used to treat ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine sepsis angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human thymus GeneSeq W00053635 Chemokines are a family of Chemoldne activities can be Inflammatory disorders, expressed Accessions related small, secreted proteins determined using assays known in cancer, Immune and vascular chemokine B19607 and involved in biological processes the art: Methods in Molecular disorders TECK and B19608 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine TECK variant angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15791 related small, secreted proteins determined using assays known in Immune, Vascular and SDFlalpha involved in biological processes the art:
Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSet' W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, .tD
chemokine Accession B15793 related small, secreted proteins determined using assays known in Immune, Vascular and GROalpha involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been t.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15794 related small, secreted proteins determined using assays known in Immune, Vascular and eotaxin involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been 1,) described, which bind to ¨17 receptors thus far identified:

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine MIG Accession B15803 related small, secreted proteins determined using assays known in Immune, Vascular and involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemokines have been Ls.) described, which bind to 47 receptors thus far identified.

CO
_ Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine PF4 Accession B15804 related small, secreted proteins determined using assays known in Immune, Vascular and involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 6.) human chemokines have been C.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine I- Accession B15805 related small, secreted proteins determined using assays known in Immune, Vascular and 309 involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte ProtocOls.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been t\.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemoldne Accession B15806 related small, secreted proteins determined using assays known in Immune, Vascular and HCC-1 involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been ts.) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine C10 Accession B15807 related small, secreted proteins determined using assays known in Immune, Vascular and involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeg W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15808 related small, secreted proteins determined using assays known in Immune, Vascular and CCR-2 involved in biological processes the art:
Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

co Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemoldne activities can be Autoimmune disorders, chemokine Accession B15809 related small, secreted proteins determined using assays known in Immune, Vascular and ENA-78 involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Promlfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been C.) 00 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSet' W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15810 related small, secreted proteins determined using assays known in Immune, Vascular and GRObeta involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., =
diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemoldnes exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 Iµ) human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine IP- Accession B15811 related small, secreted proteins determined using assays known in Immune, Vascular and involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. CD Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts..) human chemokines have been 0 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemoldne activities can be Autoimmune disorders, chemokine Accession B15812 related small, secreted proteins determined using assays known in Immune, Vascular and SDFlbeta involved in biological processes the art:
Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15813 related small, secreted proteins determined using assays known in Immune, Vascular and GRO alpha involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by:
trafficking. Members of this Prouclfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been La ts..) described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00042071 Chemokines are a family of Chemokine activities can be Autoimmune disorders, chemokine Accession B15831 related small, secreted proteins determined using assays known in Immune, Vascular and MIPlbeta involved in biological processes the art: Methods in Molecular Inflammatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemoldne angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. ID Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemokines have been Lk) LA.) described, which bind to 47 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier A human C-C GeneSeq US6096300 Chemokines are a family of Chemokine activities can be Cancer chemokine Accession B07939 related small, secreted proteins determined using assays known in designated involved in biological processes the art: Methods in Molecular exodus ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq US6084071 Chemokines are a family of Chemokine activities can be Chemotaxis, Gene Therapy, chemokine Accession related small, secreted proteins determined using assays known in Wound healing L105_7 Y96922 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemoldnes have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSec] US6084071 Chemokines are a family of Chemokine activities can be Chemotaxis, Gene Therapy, chemokine Accession related small, secreted proteins determined using assays known in Wound healing L105_3 Y96923 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 ts.) human chemokines have been C71 described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00038706 Chemokines are a family of Chemokine activities can be Cancer, Vascular and Immune secondary Accession B01434 related small, secreted proteins determined using assays known in disorders lymphoid involved in biological processes the art:
Methods in Molecular chemokine ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine (SLC) angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and CA.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been described, which bind to ¨17 receptors thus far identified.

CO
=

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human non- GeneSeq W00029439 Chemokines are a family of Chemokine activities can be Immune and Inflammatory ELIZ CXC Accession related small, secreted proteins determined using assays known in disorders, Cancer, haemostatic chemokine Y96310 involved in biological processes the art: Methods in Molecular and thrombolytic activity H174. ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane 0-protein-coupled receptors. Over 40 human chemokines have been oo described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human non- GeneSeq W00029439 Chemokines are a family of Chemoldne activities can be Immune and Inflammatory ELR CXC Accession related small, secreted proteins determined using assays known in disorders, Cancer, haemostatic chemokine IP10 Y96311 involved in biological processes the art: Methods in Molecular and thrombolytic activity ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
= including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human non- GeneSeq W00029439 Chemokines are a family of Chemokine activities can be Immune and Inflammatory ELR CXC Accession related small, secreted proteins determined using assays known in disorders, Cancer, haemostatic chemokine Mig Y963 13 involved in biological processes the art: Methods in Molecular and thrombolytic activity ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., =
diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00028035 Chemokines are a family of Chemokine activities can be Cancer, wound healing, chemokine Accession related small, secreted proteins determined using assays known in inflammatory and Ckbeta-7 Y96280 involved in biological processes the art: Methods in Molecular immmunoregulatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 irs.) human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier =
Human GeneSeq W00028035 Chemokines are a family of Chemokine activities can be Cancer, wound healing, chemokine Accession related small, secreted proteins determined using assays known in inflammatory and MIP-I alpha Y96281. involved in biological processes the art: Methods in Molecular immmunoregulatory disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. 0 Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 t\) human chemokines have been tNa described, which bind to -,17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human mature GeneSeq W00028035 Chemokines are a family of Chemokine activities can be Cancer, wound healing, chemokine Accession related small, secreted proteins determined using assays known in inflammatory and Ckbeta-7 Y96282 involved in biological processes the art: Methods in Molecular immmunoregulatory disorders (optionally ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine truncated) angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.-family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq W00018431 Chemokines are a family of Chemokine activities can be Soluble CXCR3 polypeptides chemolcine Accession related small, secreted proteins determined using assays known in may be useful for inhibiting receptor Y79372 involved in biological processes the art:
Methods in Molecular chemokine activities and viral CXCR3 ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine infection.
angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human GeneSeq US6043086 Chemokines are a family of Chemokine activities can be Neurological disorders, neurotactin Accession related small, secreted proteins determined using assays known in Immune and respiratory chemokine like Y53259 involved in biological processes the art: Methods in Molecular disorders domain ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols. Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C.
Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The o chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemokines have been described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Human CC type GeneSeq JP11302298 Chemoldnes are a family of Chemokine activities can be Cancer and infectious diseases chemokine Accession related small, secreted proteins determined using assays known in interleukin C Y57771 involved in biological processes the art: Methods in Molecular ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Prom1foot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The chemokines exert their effects by acting on a family of seven transmembrane G-protein-coupled receptors. Over 40 human chemoldnes have been cr, described, which bind to ¨17 receptors thus far identified.

CO

Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y o Protein X , Identifier ----I
Human CKbeta- GeneSeq US6153441 Chemokines are a family of Chemokine activities can be Cancer, Auto-immune and o .6.
9 Accession B50860 related small, secreted proteins determined using assays known in inflammatory disorders, .6.
.6.
involved in biological processes the art: Methods in Molecular Cardiovasular disorders ranging from hematopoiesis, Biology, 2000, vol. 138: Chemokine angiogenesis, and leukocyte Protocols.
Edited by: A.E.I.
trafficking. Members of this Proudfoot, T.N.C. Wells, and C.A.
family are involved in a similarly Power. Humana Press Inc., , diverse range of pathologies Totowa, NJ
including inflammation, allergy, tissue rejection, viral infection, and tumor biology. The n chemokines exert their effects by acting on a family of seven iv transmembrane 0-protein-coupled receptors. Over 40 co co IN) human chemokines have been co -.3 41, --.1 described, which bind to ¨17 iv receptors thus far identified.

iv Preproapolipopr GeneSeq W09637608 apoa-1 participates in the reverse Lipid binding activity can be Useful for cardiovascular H
otein "paris" Accession transport of cholesterol from determined usilig assays known in disorders, cholesterol 0 variant W08602 tissues to the liver for excretion the art, such as, for example, the disorders, and 0 co by promoting cholesterol efflux Cholesterol Efflux Assays of Hyperlipidaemia from tissues and by acting as a Takahashi et al., P.N.A.S., Vol. 96, cofactor for the lecithin Issue 20, 11358-11363, September cholesterol acyltransferase 28, 1999.
(kat).
Preproapolipopr 5,721,114 apoa-1 participates in the reverse Lipid binding activity can be ' Useful for cardiovascular otein "milano" transport of cholesterol from determined using assays known in disorders, cholesterol variant tissues to the liver for excretion the art, such as, for example, the disorders, and IV
by promoting cholesterol efflux Cholesterol Efflux Assays of Hyperlipidaemia n from tissues and by acting as a Takahashi et al., P.N.A.S., Vol. 96, cofactor for the lecithin Issue 20, 11358-11363, September cp o cholesterol acyltransferase 28, 1999.
¨...
1¨, (lcat).
n.) o 1¨, c,.) Therapeutic Exemplary PCT/Patent Number Biological Activity Exemplary Activity Assay Preferred Indication Y
Protein X Identifier Glycodelin-A; GeneSeq W09628169 Naturally produced female Glycodelin-A activity can be Naturally derived Progesterone- Accession contraceptive that is removed determined using the hemizona contraceptive useful for the associated W00289 rapidly from the body following assay as described in Oehninger, S., prevention of pregnancy.
endometrial 2-3 days production. Uses Coddington, C. C., Hodgen, G. D., protein include contraception and Seppala, M. (1995) Fertil. Steril.
63, 377-383.
NOGO-A Genbank NOGO polypeptides are potent Inhibition of Neurite outgrowth. NOGO-A polypeptide Accession inhibitors of neurite growth.
Antagonists to NOGO polypeptides antagonists are useful for the CAB99248 may promote the outgrowth of promotion of neural growth, neurites, thus inducing regeneration which could be useful in the of neurons, treatment of neural disorders and dysfunction due to degenerative diseases or trauma; useful in the treatment 0 of neoplastic diseases of the ts.) CNS; induce regeneration of oo neurons or to promote the structural plasticity of the 0 CNS.
NOGO-B Genbank NOGO polypeptides are potent Inhibition of Neurite outgrowth. NOGO-B polypeptide 0 Accession inhibitors of neurite growth.
Antagonists to NOGO polypeptides antagonists are useful for the 0 co CAB99249 may promote the outgrowth of promotion of neural growth, neurites, thus inducing regeneration which could be useful in the of neurons. treatment of neural disorders and dysfunction due to degenerative diseases or trauma; useful in the treatment = of neoplastic diseases of the CNS; induce regeneration of neurons or to promote the 1-3 structural plasticity of the CNS.
o.) DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (22)

THE EMBODIMENTS OF THE INVENTION FOR WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An albumin fusion protein having follicle stimulating hormone (FSH) activity, said albumin fusion protein comprising a FSH alpha subunit and a FSH
beta subunit fused to an albumin polypeptide, and wherein said albumin polypeptide comprises an amino acid sequence selected from the group consisting of:
(a) amino acids 1 to 585 of SEQ ID NO: 18;
(b) amino acids 1 to 387 of SEQ ID NO:18;
(c) amino acids 54 to 61 of SEQ ID NO: 18;
(d) amino acids 76 to 89 of SEQ ID NO: 18;
(e) amino acids 92 to 100 of SEQ ID NO: 18;
(f) amino acids 170 to 176 of SEQ ID NO: 18;
(g) amino acids 247 to 252 of SEQ ID NO: 18;
(h) amino acids 266 to 277 of SEQ ID NO: 18;
(i) amino acids 280 to 288 of SEQ ID NO: 18;
(j) amino acids 362 to 368 of SEQ ID NO: 18;
(k) amino acids 439 to 447 of SEQ ID NO: 18;
(l) amino acids 462 to 475 of SEQ ID NO: 18;
(m) amino acids 478 to 486 of SEQ ID NO: 18;
(n) amino acids 560 to 566 of SEQ ID NO: 18; and (o) amino acid sequence at least 95% identical to the sequence of SEQ ID
NO:18;
and wherein said albumin polypeptide has the ability to prolong the serum plasma half-life of FSH compared to the serum plasma half-life of FSH in an unfused state.
2. The albumin fusion protein of claim 1, wherein the albumin polypeptide comprises the amino acid sequence of amino acids 1-387 of SEQ ID NO: 18.
3. The albumin fusion protein of claim 1 or 2, wherein the albumin polypeptide is separated by a linker from the FSH alpha subunit polypeptide;
from the FSH beta subunit polypeptide; or both the FSH alpha subunit and the FSH beta subunit polypeptide.
4. The albumin fusion protein of any one of claims 1 to 3, wherein shelf-life of the albumin fusion protein is greater than the shelf-life of the FSH
in an unfused state.
5. The albumin fusion protein of any one of claims 1 to 4, wherein the in vitro biological activity of the albumin fusion protein is prolonged compared to the in vitro biological activity of the FSH in an unfused state.
6. The albumin fusion protein of any one of claims 1 to 5, wherein the in vivo biological activity of the albumin fusion protein is prolonged compared to the in vivo biological activity of the FSH in an unfused state.
7. The albumin fusion protein of any one of claims 1 to 6, which is non-gl ycosylated.
8. The albumin fusion protein of any one of claims 1 to 7, which is expressed from an isolated host cell.
9. The albumin fusion protein of any one of claims 1 to 7, which is expressed in yeast.
10. The albumin fusion protein of claim 9, wherein the yeast is glycosylation deficient.
11. The albumin fusion protein of claim 9, wherein the yeast is glycosylation and protease deficient.
12. The albumin fusion protein of any one of claims 1 to 6, which is expressed by a mammalian cell.
13. The albumin fusion protein of any one of claims 1 to 6, wherein the albumin fusion protein is expressed by a mammalian cell in culture.
14. The albumin fusion protein of any one of claims 1 to 6, wherein the albumin fusion protein further comprises a secretion leader sequence.
15. A composition comprising the albumin fusion protein of any one of claims 1 to 14 and a pharmaceutically acceptable carrier.
16. A kit comprising (a) the albumin fusion protein of any one of claims 1 to 14 or the composition of claim 15 and (b) instructions for use.
17. Use of the albumin fusion protein of any one of claims 1 to 14 in the manufacture of a medicament to treat reproductive system disorders.
18. Use of a therapeutically effective amount of the albumin fusion protein of any one of claims 1 to 14 to treat reproductive system disorders.
19. A method of extending the shelf life of follicle stimulating hormone (FSH) comprising the step of fusing a FSH alpha subunit, and a FSH beta subunit to an albumin polypeptide; and wherein said albumin polypeptide comprises an amino acid sequence selected from the group consisting of:
(a) amino acids 1 to 585 of SEQ LID NO: 18;
(b) amino acids 1 to 387 of SEQ ID NO:18;
(c) amino acids 54 to 61 of SEQ ID NO: 18;
(d) amino acids 76 to 89 of SEQ ID NO: 18;
(e) amino acids 92 to 100 of SEQ ID NO: 18;
(1) amino acids 170 to 176 of SEQ ID NO: 18;

(g) amino acids 247 to 252 of SEQ ID NO: 18;
(h) amino acids 266 to 277 of SEQ ID NO: 18;
(i) amino acids 280 to 288 of SEQ ID NO: 18;
(j) amino acids 362 to 368 of SEQ ID NO: 18;
(k) amino acids 439 to 447 of SEQ ID NO: 18;
(l) amino acids 462 to 475 of SEQ ID NO: 18;
(m) amino acids 478 to 486 of SEQ ID NO: 18;
(n) amino acids 560 to 566 of SEQ ID NO: 18; and (o) amino acid sequence at least 95% identical to the sequence of SEQ ID
NO:18;
wherein said albumin has the ability to prolong the shelf life of the FSH
compared to the shelf-life of the FSH in an unfused state.
20. A nucleic acid molecule comprising a polynucleotide sequence encoding the albumin fusion protein of any one of claims 1 to 14.
21. A vector comprising the nucleic acid molecule of claim 20.
22. A host cell comprising the nucleic acid molecule of claim 20 or the vector of claim 21.
CA2405557A 2000-04-12 2001-04-12 Albumin fusion proteins Expired - Lifetime CA2405557C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22935800P 2000-04-12 2000-04-12
US19938400P 2000-04-25 2000-04-25
US25693100P 2000-12-21 2000-12-21
PCT/US2001/012013 WO2001079444A2 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Publications (2)

Publication Number Publication Date
CA2405557A1 CA2405557A1 (en) 2001-10-25
CA2405557C true CA2405557C (en) 2013-09-24

Family

ID=27394014

Family Applications (8)

Application Number Title Priority Date Filing Date
CA002405912A Abandoned CA2405912A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405563A Abandoned CA2405563A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405525A Abandoned CA2405525A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2405557A Expired - Lifetime CA2405557C (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405701A Withdrawn CA2405701A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2747325A Abandoned CA2747325A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405550A Abandoned CA2405550A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405709A Abandoned CA2405709A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA002405912A Abandoned CA2405912A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405563A Abandoned CA2405563A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405525A Abandoned CA2405525A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA002405701A Withdrawn CA2405701A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2747325A Abandoned CA2747325A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405550A Abandoned CA2405550A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405709A Abandoned CA2405709A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Country Status (10)

Country Link
US (23) US20040010134A1 (en)
EP (21) EP2216409B1 (en)
JP (9) JP2003531590A (en)
AU (7) AU2001262942A1 (en)
BE (1) BE2016C059I2 (en)
CA (8) CA2405912A1 (en)
DK (2) DK2216409T3 (en)
ES (2) ES2484966T3 (en)
FR (1) FR16C0043I2 (en)
WO (7) WO2001079480A1 (en)

Families Citing this family (638)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2002024719A1 (en) * 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
WO2002068638A1 (en) * 2001-02-23 2002-09-06 Human Genome Sciences, Inc. 83 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (en) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Human and murine semaphorin L
US20030082767A1 (en) * 1997-09-18 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1088084T3 (en) * 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-human serum albumin fusion protein
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (en) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド Stabilized bioactive peptides and methods of identification, synthesis and use
ES2260009T3 (en) * 1999-05-05 2006-11-01 Phylogica Limited INSULATION OF BIOLOGICAL MODULATORS FROM BANKS OF BIODIVERSE GENETIC FRAGMENTS.
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU1438001A (en) * 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 27 human secreted proteins
CA2388019A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
AU1449001A (en) * 1999-11-05 2001-06-06 Human Genome Sciences, Inc. 28 human secreted proteins
JP2003520031A (en) * 1999-11-12 2003-07-02 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 28 human secreted proteins
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
WO2001079480A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
CA2408664A1 (en) * 2000-05-12 2001-11-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung F-box containing protein
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
AU2001274923A1 (en) * 2000-05-23 2001-12-03 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
IL152886A0 (en) 2000-06-06 2003-06-24 Bristol Myers Squibb Co B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
JP2004500862A (en) * 2000-06-08 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド Intracellular signaling protein
MXPA02012717A (en) * 2000-06-21 2003-09-22 Amgen Inc Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof.
CA2418680A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 11 human secreted proteins
AU2001232810A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. 23 human secreted proteins
EP1317471A4 (en) * 2000-08-18 2004-07-21 Human Genome Sciences Inc 21 human secreted proteins
EP1313761A4 (en) * 2000-08-28 2005-01-26 Human Genome Sciences Inc 18 human secreted proteins
CA2421147A1 (en) * 2000-09-29 2002-04-11 Human Genome Sciences, Inc. 24 human secreted proteins
CA2425827A1 (en) * 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
US6949371B2 (en) 2000-10-20 2005-09-27 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (en) * 2000-10-30 2002-05-03 Inst Nat Sante Rech Med RENIN AND / OR PRORENIN RECEPTOR PROTEIN, NUCLEIC ACID ENCODING THE RECEPTOR AND THEIR APPLICATIONS
DE60128008T2 (en) * 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison RECEPTOR FOR A TOXIN FROM BACILLUS ANTHRACIS
ES2328510T3 (en) 2000-12-07 2009-11-13 ELI LILLY & COMPANY GLP-1 FUSION PROTEINS.
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
JP4344519B2 (en) * 2000-12-28 2009-10-14 旭化成ファーマ株式会社 NF-κB activating gene
CA2441006A1 (en) * 2001-03-08 2002-09-19 Hyseq, Inc. Methods and materials relating to fibulin-like polypeptides and polynucleotides
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
WO2003005033A2 (en) * 2001-07-06 2003-01-16 Geneprot, Inc. Carcinoma-related peptides
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
DE10251673A1 (en) 2001-11-09 2003-07-10 Hoffmann La Roche Alström syndrome gene, gene variants, encoded protein and method for diagnosing Alström syndrome
KR100406760B1 (en) * 2001-11-16 2003-11-21 신코엠 주식회사 Semiconductor memory device
US7553483B2 (en) 2001-12-17 2009-06-30 Merck Serono Sa Chemokine mutants acting as chemokine antagonists
US20040082761A1 (en) * 2001-12-18 2004-04-29 Duggan Brendan M. Cell adhesion proteins
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
DE10205520A1 (en) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitory, monoclonal antibody against the clotting factor VII activating protease
BR0307871A (en) * 2002-02-21 2005-04-12 Wyeth Corp Folistatin Domain-Containing Proteins
WO2003075742A2 (en) * 2002-03-05 2003-09-18 Merck & Co., Inc. Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CN100525829C (en) * 2002-04-15 2009-08-12 美国国家红十字会 Method for detecting ligands and targets in a mixture
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
AU2003234136A1 (en) 2002-04-18 2003-11-03 The General Hospital Corporation Drg11-responsive (dragon) gene family
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2381265T3 (en) * 2002-06-07 2012-05-24 Zymogenetics, Inc. Use of IL-21 and monoclonal antibody to treat solid cancers
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN1241946C (en) * 2002-07-01 2006-02-15 美国福源集团 Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
CN101172091B (en) * 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same
AU2003245089A1 (en) * 2002-07-03 2004-01-23 Nexgen Biotechnologies, Inc. Fusion polypeptide comprising epidermal growth factor and human serum albumin
EP2332956A1 (en) * 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
JPWO2004009626A1 (en) * 2002-07-22 2005-11-17 アステラス製薬株式会社 Rheumatoid arthritis-related novel gene
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
JP2005534330A (en) * 2002-08-07 2005-11-17 デルタ バイオテクノロジー リミテッド Albumin fusion ciliary neurotrophic factor
US20060129082A1 (en) * 2002-08-13 2006-06-15 Jacek Rozga Selective plasma exchange therapy
AU2003243413B2 (en) 2002-08-28 2009-07-09 Takeda Pharmaceutical Company Limited Methods for preserving organs and tissues
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (en) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Asthma treatment procedure using antibodies against complement component C5
RU2005111253A (en) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) GHRH ANALOGUES
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
US20080182236A1 (en) * 2002-12-20 2008-07-31 Geneos Oy Asthma Susceptibility Locus
AU2003292774A1 (en) * 2002-12-26 2004-07-22 Takeda Pharmaceutical Company Limited Novel proteins and use thereof
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
NZ570201A (en) * 2003-02-11 2011-03-31 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
CA2518898A1 (en) * 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070041987A1 (en) * 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
KR20060017585A (en) * 2003-04-04 2006-02-24 유니베르시떼 드 로잔느 Peptabody for cancer treatment
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
WO2004094589A2 (en) * 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US7517655B2 (en) * 2003-06-30 2009-04-14 Nihon University Protein capable of deposition onto extracellular matrix
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
JP4765039B2 (en) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド A method for treating cancer expressing CD40 antigen.
ATE539086T1 (en) * 2003-12-03 2012-01-15 Monika Kroez INTERLEUKIN-11 FUSION PROTEINS
CN100379762C (en) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 Interfusion protein between human serum albumin and interleukin, and encoding genes
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
JPWO2005061704A1 (en) * 2003-12-24 2007-07-12 武田薬品工業株式会社 Cancer preventive / therapeutic agent
KR101184391B1 (en) * 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
SE0400489D0 (en) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
EP1721008B1 (en) * 2004-03-03 2010-02-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
AU2005227192A1 (en) * 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
ATE492564T1 (en) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc EPHB4-BINDING ANTIBODIES FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
WO2005115444A2 (en) * 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7307148B2 (en) * 2004-04-23 2007-12-11 Conjuchem Biotechnologies Inc. Method for purification of albumin conjugates
KR100599454B1 (en) * 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 3 Novel use of AIM3 acting as a tumor suppressor
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
US8008020B2 (en) * 2004-06-03 2011-08-30 Vermillion, Inc. Biomarkers for peripheral artery disease
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
JP2008506703A (en) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション Netrin-related compounds and uses
CN102680686A (en) * 2004-08-13 2012-09-19 千年药品公司 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060078541A1 (en) * 2004-10-01 2006-04-13 Giles Brian C Method and formula for stem cells' stimulation, targeting release, trafficking and homing
JP5303146B2 (en) * 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ B7-H1 and methods for diagnosis, prognosis and treatment of cancer
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
DK1809660T3 (en) * 2004-10-25 2014-10-20 Immune System Key Ltd THYMUS-SPECIFIC PROTEIN
KR100583350B1 (en) * 2004-11-03 2006-06-05 (주)넥스젠 -1 Method for Producing Epidermal Growth Factor Using Fusion Proteins Comprising Fas-1 Domain
PT1809663E (en) * 2004-11-09 2008-10-02 Ares Trading Sa Method for purifying fsh
AU2005317828A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
ES2732623T3 (en) 2005-01-06 2019-11-25 Innate Pharma Sa Anti-KIR combination treatments and methods
US20060178301A1 (en) * 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
CA2601667A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
MX2007011405A (en) * 2005-03-23 2007-10-11 Wyeth Corp Detection of an immune response to gdf-8 modulating agents.
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PL1874821T3 (en) 2005-04-26 2013-09-30 Trion Pharma Gmbh Combination of antibodies and glucocorticoids for treating cancer
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8653028B2 (en) * 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
CA2606334A1 (en) * 2005-05-12 2006-11-12 Zymogenetics, Inc. Methods of using phhla2 to co-stimulate t-cells
EP2397156B1 (en) 2005-06-08 2016-11-02 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EA015901B1 (en) * 2005-08-26 2011-12-30 Арес Трейдинг С.А. Process for the preparation of glycosylated interferon beta
US7713715B2 (en) * 2005-09-06 2010-05-11 University Of Tennessee Research Foundation Method for diagnosing infections
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20080274096A1 (en) * 2005-10-03 2008-11-06 Astrazeneca Ab Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
EP1968636A4 (en) * 2005-12-09 2010-06-02 Seattle Genetics Inc Methods of using cd40 binding agents
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex tracking assay
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2009532474A (en) 2006-04-05 2009-09-10 アボツト・バイオテクノロジー・リミテツド Antibody purification
KR101492422B1 (en) * 2006-04-11 2015-02-12 체에스엘 베링 게엠베하 Method of increasing the in vivo recovery of therapeutic polypeptides
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
CA2654055A1 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2013202566C1 (en) * 2006-06-14 2018-07-12 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
AU2007274035A1 (en) * 2006-07-13 2008-01-17 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
MX2009001066A (en) 2006-07-24 2009-02-05 Biorexis Pharmaceutical Corp Exendin fusion proteins.
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
JP5395664B2 (en) * 2006-09-06 2014-01-22 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド Fusion peptide therapeutic composition
KR20090060294A (en) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 Modified human plasma polypeptide or fc scaffolds and their uses
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7910102B2 (en) 2006-10-25 2011-03-22 Amgen Inc. Methods of using conjugated toxin peptide therapeutic agents
WO2008049920A2 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
JP5492563B2 (en) 2006-12-12 2014-05-14 バイオレクシス ファーマシューティカル コーポレーション Transferrin fusion protein library
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
JP5448839B2 (en) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Modified clotting factor with long half-life in vivo
ATE525392T1 (en) 2007-01-30 2011-10-15 Epivax Inc REGULATORY T-CELL EPITOPES AND COMPOSITIONS THEREOF AND APPLICATIONS THEREOF
KR101629702B1 (en) * 2007-02-12 2016-06-13 체에스엘 베링 게엠베하 Therapeutic application of Kazal-type serine protease inhibitors
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
KR20100017514A (en) 2007-05-07 2010-02-16 메디뮨 엘엘씨 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008143878A1 (en) 2007-05-14 2008-11-27 Medimmune, Llc Methods of reducing eosinophil levels
US8420779B2 (en) * 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2170946A2 (en) 2007-07-13 2010-04-07 The Johns Hopkins University B7-dc variants
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
MX346172B (en) 2007-08-29 2017-03-10 Sanofi - Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
JP2009055838A (en) * 2007-08-31 2009-03-19 Nipro Corp Fusion protein, gene related to the fusion protein, vector, transformant and anti-inflammatory medicinal composition
BRPI0817108B8 (en) * 2007-09-21 2021-05-25 Univ California composition comprising a fusion protein, kit comprising said composition and use thereof.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP2011500756A (en) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Method for purifying Fc fusion protein
JP2011500757A (en) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Method for purifying Fc-containing protein
JP5490714B2 (en) 2007-11-28 2014-05-14 メディミューン,エルエルシー Protein preparation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
WO2009097318A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company A fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
JP5020135B2 (en) * 2008-03-19 2012-09-05 ソニーモバイルコミュニケーションズ, エービー Portable terminal device and computer program
CN102065903B (en) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 Insulin albumin conjugates
CA2720763A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
MX2010011957A (en) 2008-05-02 2011-03-04 Novartis Ag Star Improved fibronectin-based binding molecules and uses thereof.
EP2291523B1 (en) 2008-06-24 2014-12-17 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
AU2013202564B2 (en) * 2008-06-24 2015-09-17 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CN102131516B (en) 2008-06-27 2016-03-16 杜克大学 Comprise the therapeutic agent of elastin-like peptides
WO2010005580A2 (en) 2008-07-10 2010-01-14 Angion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EP2837388A1 (en) 2008-08-05 2015-02-18 Novartis AG Compositions and methods for antibodies targeting complement protein C5
US8114845B2 (en) 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2010027827A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
CN102282168A (en) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 Human serum albumin linkers and conjugates thereof
DK2370593T3 (en) 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
LT4209510T (en) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
JP2013516389A (en) 2009-01-06 2013-05-13 ダイアックス コーポレーション Treatment of mucositis with kallikrein inhibitors
US20100227818A1 (en) 2009-01-16 2010-09-09 Teva Biopharmaceuticals Usa, Inc. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor For The Prevention Of Neutropenia
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BR122021021381B1 (en) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc METHOD FOR IMPROVING A PROPERTY OF A BIOLOGICALLY ACTIVE PROTEIN
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
US9403898B2 (en) 2009-05-07 2016-08-02 Novozymes Biopharma Dk A/S Method for purifying albumin
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
WO2010138555A2 (en) * 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
AU2010258898B8 (en) * 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN101628346B (en) * 2009-07-25 2012-05-16 大连理工大学 Method for slowing down outlet speed of carbon fiber composite material hand-made hole and buffer device thereof
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
AU2010290131C1 (en) * 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120322075A1 (en) * 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
CN102596249A (en) 2009-10-30 2012-07-18 默沙东公司 AX1 and AX189 PCSK9 antagonists and variants
ES2700230T3 (en) 2009-10-30 2019-02-14 Albumedix Ltd Albumin variants
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2501714A4 (en) * 2009-11-17 2015-10-07 Univ Montreal Heteropeptides useful for reducing nonspecific adsorption
JP5903048B2 (en) 2009-12-06 2016-04-13 バイオジェン ヘモフィリア インコーポレイテッド Factor VIII-Fc chimeric and hybrid polypeptides and methods of use thereof
CN102711795A (en) 2009-12-08 2012-10-03 泰华制药工业有限公司 BChE albumin fusions for the treatment of cocaine abuse
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
JP2013526840A (en) 2009-12-21 2013-06-27 ファーマシーネ,インコーポレイテッド Recombinant butyrylcholinesterase and its truncated form
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
AR079944A1 (en) 2010-01-20 2012-02-29 Boehringer Ingelheim Int NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8592364B2 (en) * 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy
JP5826194B2 (en) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ Biparatopic A-beta binding polypeptide
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
KR20130066631A (en) 2010-05-06 2013-06-20 노파르티스 아게 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
PE20130207A1 (en) 2010-05-06 2013-02-28 Novartis Ag ANTIBODIES ANTAGONISTS TO LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103282380B (en) 2010-08-10 2018-02-16 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6057896B2 (en) 2010-08-20 2017-01-11 ノバルティス アーゲー Antibody to epidermal growth factor receptor 3 (HER3)
KR20140018837A (en) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 Notum protein modulators and methods of use
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
ES2641869T3 (en) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Leptin-ABD fusion polypeptides with increased duration of action
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) * 2010-10-26 2014-10-07 Pioneer Hi Bred International Inc Antifungal proteins and methods of use
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
NZ705008A (en) 2010-12-08 2017-05-26 Abbvie Stemcentrx Llc Novel modulators and methods of use
KR101883515B1 (en) 2010-12-28 2018-07-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Diagnostic drug and diagnostic method for alzheimer's disease
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
IL269565B1 (en) 2011-01-06 2024-02-01 Dyax Corp Plasma kallikrein binding proteins
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
WO2012117336A2 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
CN103732628B (en) 2011-03-03 2017-06-23 酵活有限公司 Multivalence heteropolymer frame design and construct
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
WO2012120128A1 (en) 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
AU2012228990B2 (en) 2011-03-16 2017-04-06 Amgen Inc. Potent and selective inhibitors of Nav1.3 and Nav1.7
US9340584B2 (en) 2011-03-29 2016-05-17 The General Hospital Corporation Engineered thioredoxin-like fold proteins
MA34978B1 (en) 2011-03-30 2014-03-01 Boehringer Ingelheim Int ANTIDOTES FOR ANTICOAGULANTS
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) * 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
RU2650784C2 (en) * 2011-05-05 2018-04-17 Альбумедикс А/С Versions of albumin
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
JP2014523900A (en) * 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー Serpin fusion polypeptide and method of use thereof
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
US10844349B2 (en) 2011-07-05 2020-11-24 Albumedix Ltd. Albumin formulation and use
PT2729160T (en) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Engineered polypeptides having enhanced duration of action and reduced immunogenicity
KR20140039257A (en) 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 Fusion proteins releasing relaxin and uses thereof
EP2734239A2 (en) * 2011-07-18 2014-05-28 Arts Biologics A/S Long acting luteinizing hormone (lh) compound
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Inhibitory anti-factor xii/xiia monoclonal antibodies, methods of producing the same, pharmaceutical compositions containing the same and medical uses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (en) 2011-10-03 2019-08-30 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
JP2014533247A (en) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド Antibodies and methods of treating cancer
US8993831B2 (en) * 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
JP6326371B2 (en) 2011-11-04 2018-05-16 ザイムワークス,インコーポレイテッド Stable heterodimeric antibody design with mutations in the Fc domain
BR112014010409A2 (en) 2011-11-04 2017-04-25 Novartis Ag constructs that prolong the half-life of low density lipoprotein-related protein 6 (lrp6)
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP2788380B1 (en) 2011-12-05 2019-08-28 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
MX2014007233A (en) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions.
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
DK2793935T3 (en) 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
CA2863328A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
SG10201609500QA (en) 2012-02-15 2016-12-29 Ecole Polytech Erythrocyte-binding therapeutics
PL2814502T3 (en) * 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
KR102008190B1 (en) 2012-02-15 2019-08-07 바이오버라티브 테라퓨틱스 인크. Recombinant factor viii proteins
JP6256882B2 (en) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド Factor VIII composition, and method of making and use of the composition
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
US9035029B2 (en) 2012-02-27 2015-05-19 Boehringer Ingelheim International Gmbh CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015513912A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified polynucleotides for the production of proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
KR102138743B1 (en) 2012-04-27 2020-07-29 싸이톰스 테라퓨틱스, 인크. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
EP3360418A1 (en) 2012-05-30 2018-08-15 Bayer CropScience Aktiengesellschaft Composition comprising a biological control agent and a fungicide
ES2672500T3 (en) 2012-05-30 2018-06-14 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
KR20150021502A (en) 2012-05-30 2015-03-02 바이엘 크롭사이언스 아게 Compositions comprising a biological control agent and an insecticide
IN2014DN09381A (en) 2012-05-30 2015-07-17 Bayer Cropscience Ag
AR091196A1 (en) 2012-05-30 2015-01-21 Bayer Cropscience Ag COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND A FUNGICIDE
MX355328B (en) 2012-05-30 2018-04-16 Bayer Cropscience Ag Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis.
DK2854547T3 (en) 2012-05-30 2018-11-26 Bayer Cropscience Ag COMPOSITION CONTAINING A BIOLOGICAL PESTICID AND TRIFLOXY STROBIN
CN104507319B (en) 2012-05-30 2018-08-03 拜尔农作物科学股份公司 Include the composition of biocontrol agent and the fungicide selected from lipid film synthetic inhibitor, melanocyte biosynthesis inhibitor, nucleic acid synthetic inhibitor or signal transduction inhibitor
JP6130909B2 (en) 2012-05-30 2017-05-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Composition comprising a biopesticide and an insecticide
HUE040336T2 (en) 2012-05-30 2019-03-28 Bayer Cropscience Ag Composition comprising a biological control agent and fluopicolide
TR201816272T4 (en) 2012-05-30 2018-11-21 Bayer Cropscience Ag The composition comprising a biological control agent and flopicolide.
EP2854542B1 (en) 2012-05-30 2018-08-01 Bayer Cropscience AG Compositions comprising a biological control agent and an insecticide
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
SI2882450T1 (en) 2012-07-11 2020-02-28 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
JP6498601B2 (en) 2012-07-13 2019-04-10 ザイムワークス,インコーポレイテッド Multivalent heteromultimeric scaffold designs and constructs
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
JP6487328B2 (en) 2012-11-08 2019-03-20 アルブミディクス リミティド Albumin variant
KR102643443B1 (en) 2012-11-13 2024-03-06 비온테크 에스이 Agents for treatment of claudin expressing cancer diseases
ES2921623T3 (en) 2012-11-26 2022-08-30 Modernatx Inc terminally modified RNA
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CA2893767C (en) 2012-12-05 2022-11-08 Novartis Ag Compositions and methods for antibodies targeting epo
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
CA2896793A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (en) * 2013-01-17 2015-03-20 서울대학교산학협력단 Recombinant protein vaccine for preventing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae infection diseases
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2014214630A1 (en) 2013-02-11 2015-08-06 Bayer Cropscience Lp Compositions comprising gougerotin and a biological control agent
PT3889173T (en) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Optimized factor viii gene
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
DK2961422T3 (en) 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
CN105188750A (en) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 Treatment and prevention of remote ischemia-reperfusion injury
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
TW201446792A (en) 2013-03-12 2014-12-16 Amgen Inc Potent and selective inhibitors of Nav1.7
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI745671B (en) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP2981282B1 (en) * 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
DK2796145T3 (en) 2013-04-22 2018-01-29 Csl Ltd A covalent complex of von Willebrand factor and factor VIII linked by a disulfide bridge
UY35620A (en) 2013-06-21 2015-01-30 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
CN105339010A (en) 2013-06-28 2016-02-17 德国杰特贝林生物制品有限公司 Combination therapy using a factor XII inhibitor and a C1-inhibitor
CN104342420B (en) * 2013-07-30 2017-09-15 惠觅宙 A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
CA2922547C (en) 2013-08-28 2020-03-10 Stemcentrx, Inc. Site-specific antibody conjugation methods and compositions
MX2016002574A (en) 2013-08-28 2016-06-14 Stemcentrx Inc Novel sez6 modulators and methods of use.
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
CN103468662A (en) * 2013-09-29 2013-12-25 惠觅宙 Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) * 2013-10-17 2015-04-23 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of inflammatory bowel disease
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3063275B1 (en) 2013-10-31 2019-09-25 Resolve Therapeutics, LLC Therapeutic nuclease-albumin fusions and methods
EP3063171B1 (en) * 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
WO2015106052A1 (en) 2014-01-10 2015-07-16 Biogen Ma Inc. Factor viii chimeric proteins and uses thereof
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR20160135214A (en) 2014-02-21 2016-11-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3116898B1 (en) 2014-03-11 2022-01-26 University of Florida Research Foundation, Inc. Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en) 2014-04-16 2015-10-22 Bayer Cropscience Lp Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
AU2015276089B2 (en) 2014-06-18 2021-03-18 Csl Behring Gmbh Therapy using a Factor XII inhibitor in a neurotraumatic disorder
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
RU2017101436A (en) 2014-06-24 2018-07-24 Ново Нордиск А/С MIC-1 FUSION PROTEINS AND THEIR APPLICATION
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PE20170287A1 (en) 2014-08-07 2017-04-05 Novartis Ag ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4 AND METHODS OF USE
RU2685869C1 (en) * 2014-08-22 2019-04-23 Нэшенл Ченг Кунг Юниверсити Versions of disintegrin and their pharmaceutical application
US10667522B2 (en) 2014-09-17 2020-06-02 Basf Se Compositions comprising recombinant Bacillus cells and another biological control agent
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN107001440A (en) 2014-09-26 2017-08-01 拜耳制药股份公司 Stabilized adrenomedulin derivative and application thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
JP6625627B2 (en) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR20170074852A (en) 2014-10-31 2017-06-30 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
WO2016102068A1 (en) * 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
CA2981312C (en) * 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP2016204292A (en) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Bmp7 mutant-albumin cointegrate, and renal disease therapeutic agent containing the same
SI3288965T1 (en) * 2015-04-29 2019-10-30 Mediolanum Farm S P A A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
US10047155B2 (en) 2015-06-05 2018-08-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
CA2989110A1 (en) 2015-06-11 2016-12-15 Attwill Medical Solutions Inc. Medical devices, systems, and methods utilizing antithrombin-heparin compositions
JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
US11020455B2 (en) * 2015-07-30 2021-06-01 Endor Technologies, S.L Colony stimulating factor for use in pancreatic or colon cancer treatment
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
CN115043944A (en) 2015-08-03 2022-09-13 诺华股份有限公司 Methods of treating FGF 21-associated disorders
JP6978407B2 (en) * 2015-08-06 2021-12-08 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Its use in compositions for treating GLP-1 and metabolic disorders
MX2018001825A (en) 2015-08-20 2018-05-07 Albumedix As Albumin variants and conjugates.
KR102360744B1 (en) 2015-09-08 2022-02-08 제이씨알 파마 가부시키가이샤 Novel human serum albumin variants
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
PE20181368A1 (en) 2015-09-09 2018-08-27 Novartis Ag STROMAL THYMIC LYMPHOPOYETIN (TSLP) BINDING MOLECULES AND METHODS OF USE OF THE MOLECULES
CN117659160A (en) 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 Orthogonal cytokine/receptor pairs of biological relevance
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
UA122079C2 (en) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Biparatopic polypeptides antagonizing wnt signaling in tumor cells
CN116077648A (en) 2015-12-11 2023-05-09 武田药品工业株式会社 Plasma kallikrein inhibitors and their use for the treatment of hereditary angioedema attacks
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
CN108367053A (en) 2015-12-22 2018-08-03 诺华股份有限公司 The method that metabolic disease is treated or improved using growth and differentiation factor 15 (GDF-15)
EP3402819A1 (en) 2016-01-11 2018-11-21 Novartis AG Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
LT3411478T (en) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2017159540A1 (en) 2016-03-14 2017-09-21 Jcrファーマ株式会社 Serum albumin-20 k growth hormone fusion protein
KR20220004226A (en) 2016-03-22 2022-01-11 바이오노믹스 리미티드 Administration of an anti-lgr5 monoclonal antibody
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
AU2017247004B2 (en) 2016-04-06 2022-07-07 Csl Limited Method of treating atherosclerosis
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
EP3458478B1 (en) 2016-05-18 2021-01-06 Boehringer Ingelheim International GmbH Anti pd-1 and anti-lag3 antibodies for cancer treatment
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
ES2832648T3 (en) * 2016-07-08 2021-06-10 CSL Behring Lengnau AG Subcutaneous Administration of Long-Acting Factor IX in Humans
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110337590A (en) 2016-11-04 2019-10-15 奥胡斯大学 The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed
US11324804B2 (en) * 2016-11-18 2022-05-10 Sepsia Therapeutics, S.L. Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
KR20190090827A (en) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. How Chimeric Coagulation Factors Can Be Used to Treat Hemophilic Arthrosis
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
KR20230125856A (en) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Gene editing of pcsk9
JP7139332B2 (en) 2016-12-23 2022-09-20 ノバルティス アーゲー Factor XI Antibodies and Methods of Use
US20200231701A1 (en) 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020517657A (en) 2017-04-20 2020-06-18 ノヴォ ノルディスク アー/エス Purification method of albumin fusion protein
TWI710377B (en) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1 compounds and uses thereof
JP7216024B2 (en) 2017-05-31 2023-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Polypeptides that antagonize Wnt signaling in tumor cells
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CA3068360A1 (en) 2017-06-29 2019-01-03 CSL Behring Lengnau AG 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
AU2018309090B2 (en) 2017-08-04 2023-03-30 Amgen Inc. Method of conjugation of cys-mAbs
AU2018313921A1 (en) 2017-08-09 2020-03-12 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
AU2018334213A1 (en) 2017-09-15 2020-03-26 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200100116A (en) 2017-12-15 2020-08-25 시에스엘 리미티드 Use of FXIIa-inhibitors in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Triabody, preparation method and use thereof
CN117050184A (en) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 Single domain antibodies to TIGIT and variants thereof
US11246908B2 (en) * 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
SG11202004233UA (en) 2018-01-15 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against pd-1
KR20200118089A (en) 2018-02-01 2020-10-14 바이오버라티브 테라퓨틱스 인크. Use of lentiviral vectors expressing factor VIII
SG11202008770QA (en) 2018-03-13 2020-10-29 Zymeworks Inc Anti-her2 biparatopic antibody-drug conjugates and methods of use
HRP20230984T1 (en) * 2018-03-13 2023-12-08 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
KR20200136453A (en) 2018-03-28 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 Interleukin-2/interleukin-2 receptor alpha fusion protein and method of use
KR102119197B1 (en) * 2018-04-23 2020-06-05 주식회사 엘베이스 Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same
EP3794022A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113840832A (en) 2018-05-14 2021-12-24 狼人治疗公司 Activatable interleukin-2 polypeptides and methods of use thereof
TW202015723A (en) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 Methods of treating hemophilia a
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
KR20210042128A (en) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and their use for nonviral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
WO2020058759A1 (en) * 2018-09-17 2020-03-26 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
EP4321530A2 (en) 2018-09-27 2024-02-14 Xilio Development, Inc. Masked cytokine polypeptides
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
US20210388059A1 (en) * 2018-10-29 2021-12-16 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CN114989298A (en) 2019-03-22 2022-09-02 反射制药有限公司 D-peptide compounds against VEGF
WO2020198075A2 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
AU2020272036A1 (en) 2019-04-11 2021-11-04 Angion Biomedica Corp. Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
WO2020232305A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
CU20210096A7 (en) 2019-05-21 2022-06-06 Novartis Ag CD19 BINDING MOLECULES
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
TW202110881A (en) 2019-05-24 2021-03-16 法商賽諾菲公司 Methods for treating systemic sclerosis
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
TW202122414A (en) 2019-09-06 2021-06-16 瑞士商諾華公司 Therapeutic Fusion Proteins
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202126284A (en) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 Lentiviral vector formulations
JP2021066730A (en) 2019-10-17 2021-04-30 Jcrファーマ株式会社 Method for producing fusion protein of serum albumin and growth hormone
CN114728043A (en) 2019-10-30 2022-07-08 Jcr制药股份有限公司 Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
EP4072576A4 (en) 2019-12-13 2024-01-03 Synthekine Inc Il-2 orthologs and methods of use
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
TW202233668A (en) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
MX2023005353A (en) 2020-11-06 2023-05-22 Novartis Ag Cd19 binding molecules and uses thereof.
WO2022166720A1 (en) * 2021-02-05 2022-08-11 华南理工大学 Serum albumin-based fusion protein, and nano-assembly, preparation method therefor and application thereof
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
CN114133458B (en) * 2021-12-08 2023-11-14 福州大学 Method for fusing polypeptide in human serum albumin
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer

Family Cites Families (517)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2449885C3 (en) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4283489A (en) 1977-09-23 1981-08-11 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en) 1977-09-23 1983-10-04 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) * 1978-04-19 1984-05-08 Regents Of The University Of California Microorganism containing gene for human chorionic somatomammotropin
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US5514567A (en) * 1979-01-30 1996-05-07 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
CY1346A (en) 1980-01-08 1987-01-16 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides
JP2687995B2 (en) 1980-04-03 1997-12-08 バイオゲン インコーポレイテッド DNA sequence, recombinant DNA molecule and method for producing human fibroblast interferon-like polypeptide
DE3023787A1 (en) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
IL63916A0 (en) 1980-09-25 1981-12-31 Genentech Inc Microbial production of human fibroblast interferon
EP0052322B1 (en) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (en) 1981-02-04 1982-08-19 Sugano Haruo Human interferon-beta gene
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en) 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4792602A (en) 1981-06-19 1988-12-20 Cornell Research Foundation, Inc. Adaptors, and synthesis and cloning of proinsulin genes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en) 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079739A3 (en) 1981-11-12 1984-08-08 The Upjohn Company Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en) 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
IT1167610B (en) 1982-01-19 1987-05-13 Cetus Corp MULTICLASS HYBRID INTERFRERON, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PRODUCTION PROCESS
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
FI82266C (en) 1982-10-19 1991-02-11 Cetus Corp Process for Preparation of IL-2 Mutein
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
US4840934A (en) * 1983-01-25 1989-06-20 Eleanor Roosevelt Institute For Cancer Research, Inc. Therapeutic method using T cell growth factor
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4914026A (en) * 1983-04-07 1990-04-03 Chiron Corporation Alpha factor leader sequence directed secretion of insulin
US5015575A (en) * 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60501140A (en) 1983-04-22 1985-07-25 アムジエン Secretion of exogenous polypeptides by yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4576813A (en) 1983-07-05 1986-03-18 Monsanto Company Heat recovery from concentrated sulfuric acid
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (en) 1983-09-23 1985-05-17 ジェネックス・コーポレイション Variant control region
EP0142641B1 (en) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system
US4518564A (en) * 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en) 1983-12-22 1984-02-01 Bass Plc Fermentation processes
JPS60136596A (en) 1983-12-26 1985-07-20 Suntory Ltd Peptide and diuretic comprising it as active ingredient
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
FR2564106B1 (en) * 1984-05-09 1988-04-22 Transgene Sa FACTOR IX EXPRESSION VECTORS, CELLS TRANSFORMED BY THESE VECTORS, AND PROCESS FOR THE PREPARATION OF FACTOR IX.
DK58285D0 (en) * 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
EP0172619A1 (en) 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Novel transformant and use thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4734491A (en) 1984-08-31 1988-03-29 University Patents, Inc. DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GB8504099D0 (en) * 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
FR2579224B1 (en) * 1985-03-25 1987-05-22 Genetica PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
JPS6229985A (en) 1985-06-17 1987-02-07 ジエネツクス・コ−ポレ−シヨン Cloned prepro-human serum alubmin, human serum alubmin gene,plasmid containing said genes, bacteria receiving form conversion by plasmid and production of prepro-human serum alubmin using said bacteria
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS6296086A (en) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol Composite plasmid
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
CA1295566C (en) 1987-07-21 1992-02-11 Robert T. Garvin Characterization and structure of genes for protease a and protease b from streptomyces griseus
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2594846B1 (en) * 1986-02-21 1989-10-20 Genetica PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IT1203758B (en) 1986-03-27 1989-02-23 Univ Roma CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
DK179286D0 (en) 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IT1204400B (en) * 1986-06-20 1989-03-01 Sclavo Spa PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
IT1196484B (en) 1986-07-11 1988-11-16 Sclavo Spa YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
JPH01502669A (en) 1987-03-13 1989-09-14 アムジエン・インコーポレーテツド Purified platelet-derived growth factor and its purification method
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
BR8806573A (en) * 1987-04-09 1989-10-31 Delta Biotechnology Ltd LIGHT VECTOR
JPH0198489A (en) 1987-04-22 1989-04-17 Chiron Corp Recombinant production of platelet-derived growth factor a chain polypeptide
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ZA885536B (en) 1987-07-28 1989-04-26 Gist Brocades Nv Kluyveromyces as a host strain
JP2627899B2 (en) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 Production method of gene-encapsulated liposome
SE459586B (en) 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JPH0811074B2 (en) 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP2791418B2 (en) * 1987-12-02 1998-08-27 株式会社ミドリ十字 Method for producing heterologous protein, recombinant DNA, transformant
ZA89430B (en) 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (en) * 1988-02-16 1989-09-25 Green Cross Corp:The Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) * 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096707A (en) * 1988-04-15 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
PT90959B (en) 1988-06-24 1995-05-04 Dow Chemical Co PROCESS FOR THE PREPARATION OF BIFUNCTIONAL MACROCYCLIC CHELANTES, OF THEIR COMPLEXES AND THEIR CONJUGATES WITH ANTIBODIES
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
IL90730A0 (en) 1988-06-24 1990-01-18 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
AU633020B2 (en) 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
FR2635115B1 (en) 1988-08-05 1992-04-03 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5260202A (en) 1988-09-07 1993-11-09 Delta Biotechnology Limited Fermentation method
JPH02227079A (en) 1988-10-06 1990-09-10 Tonen Corp Human serum albumin fragment
US5298243A (en) 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (en) 1988-10-26 1990-05-01 Tonen Corp Production of human serum albumin a by yeast host
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
DK105489D0 (en) * 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (en) 1989-03-21 2003-05-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2034790T3 (en) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh USE OF AT LEAST ONE CITROQUINE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE SYSTEMATIC TREATMENT OF PRENEOPLASTIC INJURIES.
EP0395918A3 (en) 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (en) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (en) 1989-05-24 1995-12-20 Merck & Co. Inc. Purification and characterization of a glioma-derived growth factor
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
JPH0327320A (en) 1989-06-26 1991-02-05 Ajinomoto Co Inc Human b cell differentiation factor pharmaceutical composition
DK0479909T3 (en) 1989-06-29 1997-04-07 Medarex Inc Bispecific reagents for AIDS treatment
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (en) * 1989-07-26 1991-01-31 Behringwerke Ag ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
CU22222A1 (en) 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) * 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (en) 1989-10-17 1993-03-26 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5173408A (en) 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
JPH03201987A (en) 1989-12-29 1991-09-03 Tonen Corp Human serum albumin fragment
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2086521T3 (en) * 1990-01-25 1996-07-01 Univ Washington LACI-FACTOR X HYBRID PROTEIN.
JPH04211375A (en) 1990-02-05 1992-08-03 Ajinomoto Co Inc Synthetic gene and production of human serum albumin using the synthetic gene
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2660863B1 (en) * 1990-04-17 1994-01-21 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2063515T3 (en) 1990-07-10 1995-01-01 Boehringer Ingelheim Int IFN-ALPHA O-GLYCOSYLATED.
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5071872A (en) 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) * 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
IT1242149B (en) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
JPH07108232B2 (en) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 Method for producing peptide or protein
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
FR2668368B1 (en) 1990-10-30 1995-03-10 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
JPH0638771A (en) 1990-10-31 1994-02-15 Tonen Corp Expression of human protein disulfide isomerase gene and production of polypeptide by co-expression with the gene
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
AU656353B2 (en) 1990-11-29 1995-02-02 Institut National De La Recherche Agronomique (Inra) New variants derived from interferons of type I, production process thereof and their applications
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5272080A (en) * 1991-02-19 1993-12-21 Pharmavene, Inc. Production of butyrylcholinesterase
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
EP0503583A1 (en) 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
US5817471A (en) 1991-03-14 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
EP0509841A3 (en) 1991-04-18 1993-08-18 Tonen Corporation Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
AU665758B2 (en) 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
US5330901A (en) 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
FR2676070B1 (en) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa YEAST PROMOTER AND ITS USE.
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
FR2677996B1 (en) 1991-06-21 1993-08-27 Rhone Poulenc Rorer Sa CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH05292972A (en) 1991-07-29 1993-11-09 Tonen Corp Improved yeast expression system
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (en) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgenic rats that contain at least one human gene in their genome that is involved in blood pressure regulation
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT101031B (en) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
US5786883A (en) * 1991-11-12 1998-07-28 Pilkington Barnes Hind, Inc. Annular mask contact lenses
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
US5540923A (en) * 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ES2204899T3 (en) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. MODELS OF TRANSGENIC ANIMALS FOR ALZHEIMER'S DISEASE.
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (en) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5230886A (en) 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
CZ281108B6 (en) 1992-06-09 1996-06-12 Hoppe Ag Lock system with a latch and process of assembling thereof
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (en) 1992-07-08 2002-03-25 三菱ウェルファーマ株式会社 Method for producing human serum albumin
FR2694294B1 (en) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Yeast promoter and its user.
NZ255158A (en) 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
DE4226971C2 (en) 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modified fungal cells and processes for the production of recombinant products
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2701953B1 (en) 1993-02-22 1995-05-24 Centre Nat Rech Scient Multi-VIP fusion protein and method for preparing recombinant VIP.
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
PT699075E (en) * 1993-05-21 2002-05-31 Novo Nordisk As MODIFIED FACTOR VII FOR INHIBITION OF VASCULAR RESTENOSE AND PLATELET DEPOSITION
EP0702722B1 (en) 1993-06-07 2005-08-03 Vical Incorporated Plasmids suitable for gene therapy
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DK82893D0 (en) * 1993-07-08 1993-07-08 Novo Nordisk As PEPTIDE
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5459031A (en) 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (en) 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
GB9411356D0 (en) 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
JPH0851982A (en) 1994-08-11 1996-02-27 Asahi Glass Co Ltd Modified gene coding human serum albumen
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726576B1 (en) 1994-11-07 1997-01-31 Pf Medicament PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
ATE364614T1 (en) 1994-11-07 2007-07-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR GAMMA
FR2726471B1 (en) * 1994-11-07 1997-01-31 Pf Medicament PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
AT403167B (en) 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
US5695750A (en) 1994-11-25 1997-12-09 The United States Of America As Represented By The Secretary Of The Army Compositions for use to deactivate organophosphates
JPH11501506A (en) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター Chimeric cytokines and their use
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) * 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
JP2758154B2 (en) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
JP4312259B2 (en) 1995-04-27 2009-08-12 アムジェン フレモント インク. Human antibodies derived from immunized XenoMouse
EP2017337A1 (en) 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
EP0871672A4 (en) 1995-05-05 1999-05-12 Human Genome Sciences Inc Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
DE69632062T2 (en) 1995-11-02 2004-11-18 Schering Corp. CONTINUOUS, LOW-DOSE CYTOKINE INFUSION THERAPY
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (en) 1996-02-28 1997-09-04 Bayer Ag Parapox viruses that contain foreign DNA, their production and their use in vaccines
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (en) * 1996-03-04 2006-07-12 第一アスビオファーマ株式会社 Method for culturing microorganisms with methanol metabolism
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248538A1 (en) 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1997034997A1 (en) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc Apoptosis inducing molecule ii
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
EP1854481B1 (en) * 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1997047737A1 (en) * 1996-06-11 1997-12-18 Boehringer Mannheim Gmbh Recombinant blood-coagulation proteases
WO1998002543A1 (en) 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Novel vegf-like factors
ATE397660T1 (en) 1996-08-16 2008-06-15 Schering Corp MAMMAL CELL SURFACE ANTIGEN AND RELATED REAGENTS
JP2000516474A (en) 1996-08-16 2000-12-12 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Human endokine alpha
DE69739469D1 (en) 1996-08-23 2009-07-30 Vegenics Ltd Recombinant vascular endothelial growth factor D (VEGF-D)
EP0961832A4 (en) * 1996-09-18 2003-02-26 Human Genome Sciences Inc Human tumor necrosis factor receptor-like genes
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5994112A (en) 1996-10-09 1999-11-30 Incyte Pharmaceuticals, Inc. Human protein tyrosine kinase
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955508A (en) * 1996-10-15 1999-09-21 Loyola University Of Chicago Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
WO1998018921A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
JPH10134761A (en) 1996-10-30 1998-05-22 Ebara Corp Ion implantation device and method
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
DE69834027D1 (en) 1997-01-14 2006-05-18 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTOR 5
EP0954589A1 (en) * 1997-01-24 1999-11-10 Novo Nordisk A/S Synthetic leader peptide sequences
PT1012274E (en) 1997-01-28 2007-08-14 Craig A Rosen Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
GB2324529A (en) 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
JP3876002B2 (en) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト Novel methods for producing anti-human antigen receptors and their use
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2292790A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
US5858719A (en) 1997-07-17 1999-01-12 Incyte Pharmaceuticals, Inc. Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
DE69801970T2 (en) 1997-09-21 2002-06-13 Schering Corp Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2305690A1 (en) * 1997-10-09 1999-04-22 Human Genome Sciences, Inc. 53 human secreted proteins
JP4441112B2 (en) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド VEGI is an inhibitor of angiogenesis and tumor growth
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
PT1037927E (en) * 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp USEFUL HYPERODODYMMIC PROTEINS FOR SELECTIVE APPROACH IMMUNOTHERAPY AND GENERAL IMMUNOLOGICAL STIMULATION
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
DE19813802A1 (en) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-viral effects of propolis through inhibition of viral nucleic acid polymerases
GB9806631D0 (en) 1998-03-28 1998-05-27 Safeglass Europ Limited Safetyglass
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
ES2172288T3 (en) 1998-05-15 2002-09-16 Schering Corp COMBINATION THERAPY THAT UNDERSTANDS RIBAVIRINA AND INTERFERED ALPHA IN PATIENTS WHO HAVE NOT BEEN SUBJECTED TO ANTIVIRAL TREATMENT AND HAVE CHRONIC HEPATITIS C INFECTION.
CN1119352C (en) 1998-05-15 2003-08-27 中国科学院上海生物化学研究所 Express and purification of human serum albumin in pichia
US5970300A (en) * 1998-06-01 1999-10-19 Xerox Corporation Apparatus for applying scents to paper in a printer/copier
DK1088084T3 (en) * 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-human serum albumin fusion protein
CN1105727C (en) 1998-06-17 2003-04-16 上海海济医药生物工程有限公司 Process for preparing recombined human serum albumin
US6194391B1 (en) 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
GB9817084D0 (en) 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US7232889B2 (en) * 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
US6348192B1 (en) * 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PL352332A1 (en) 1999-05-19 2003-08-11 Lexigen Pharm Corp Expression and export of interferon-alpha proteins as fc fusion proteins
PE20010288A1 (en) * 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
AU1573601A (en) 1999-10-21 2001-04-30 Monsanto Company Post-translational modification of recombinant proteins produced in plants
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001079480A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
KR100758044B1 (en) * 2000-05-15 2007-09-11 에프. 호프만-라 로슈 아게 New pharmaceutical composition
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ES2328510T3 (en) * 2000-12-07 2009-11-13 ELI LILLY & COMPANY GLP-1 FUSION PROTEINS.
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002097038A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
ES2556338T3 (en) * 2001-10-10 2016-01-15 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
EP1458860A2 (en) 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
MXPA04012496A (en) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms.
CN1241946C (en) * 2002-07-01 2006-02-15 美国福源集团 Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
US6913890B2 (en) * 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
DK1596888T3 (en) * 2003-02-27 2012-03-26 Baxter Int Method for the validable inactivation of pathogens in a biological fluid by irradiation
KR101184391B1 (en) * 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
US7436410B2 (en) * 2005-04-01 2008-10-14 Seiko Epson Corporation System and method for programming a controller
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
CA2562249A1 (en) 2005-10-20 2007-04-20 University Of Ottawa Heart Institute Anf analogue
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2654055A1 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
EP2717898B1 (en) * 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof

Also Published As

Publication number Publication date
JP2003530852A (en) 2003-10-21
EP2295456A1 (en) 2011-03-16
EP1274719A4 (en) 2004-05-19
EP1276756A4 (en) 2004-06-09
US20080269127A1 (en) 2008-10-30
ES2484966T3 (en) 2014-08-12
US20180200346A1 (en) 2018-07-19
CA2405550A1 (en) 2001-10-25
US20130266553A1 (en) 2013-10-10
WO2001079271A1 (en) 2001-10-25
ES2529300T3 (en) 2015-02-18
EP1832599A3 (en) 2007-11-21
CA2405557A1 (en) 2001-10-25
US6994857B2 (en) 2006-02-07
EP2213743A1 (en) 2010-08-04
US20120252732A1 (en) 2012-10-04
US9849162B2 (en) 2017-12-26
WO2001079444A3 (en) 2002-05-23
US20080269126A1 (en) 2008-10-30
EP1276756A1 (en) 2003-01-22
AU2001274809A1 (en) 2001-10-30
WO2001079442A3 (en) 2002-06-06
EP2357008A1 (en) 2011-08-17
CA2405563A1 (en) 2001-10-25
EP1803730A1 (en) 2007-07-04
EP1278767A1 (en) 2003-01-29
EP2298355A3 (en) 2011-06-29
US20030125247A1 (en) 2003-07-03
EP2311872A1 (en) 2011-04-20
US9821039B2 (en) 2017-11-21
CA2405525A1 (en) 2001-10-25
JP2011217750A (en) 2011-11-04
WO2001079271A9 (en) 2002-02-28
AU2001259066A1 (en) 2001-10-30
EP1278767A4 (en) 2003-11-12
US10080785B2 (en) 2018-09-25
US9775888B2 (en) 2017-10-03
EP1274720A1 (en) 2003-01-15
US20030219875A1 (en) 2003-11-27
WO2001079480A1 (en) 2001-10-25
JP2003531590A (en) 2003-10-28
EP2298355A2 (en) 2011-03-23
EP2206720A1 (en) 2010-07-14
EP2216409B1 (en) 2014-12-03
CA2747325A1 (en) 2001-10-25
CA2405709A1 (en) 2001-10-25
US20080131399A1 (en) 2008-06-05
FR16C0043I2 (en) 2020-04-10
AU2001266557A1 (en) 2001-10-23
US20110280830A9 (en) 2011-11-17
JP2003530838A (en) 2003-10-21
AU2001264563A1 (en) 2001-10-30
BE2016C059I2 (en) 2020-08-20
US7507414B2 (en) 2009-03-24
DK2236152T3 (en) 2014-07-07
US20080267962A1 (en) 2008-10-30
DK2216409T3 (en) 2015-01-05
US20090285816A9 (en) 2009-11-19
US7482013B2 (en) 2009-01-27
US20120141449A1 (en) 2012-06-07
US20040010134A1 (en) 2004-01-15
US20030171267A1 (en) 2003-09-11
US20050266533A1 (en) 2005-12-01
WO2001079258A1 (en) 2001-10-25
JP2004506407A (en) 2004-03-04
WO2001079443A2 (en) 2001-10-25
WO2001079443A3 (en) 2002-02-21
US20050266532A1 (en) 2005-12-01
US20080261877A1 (en) 2008-10-23
EP2216409A1 (en) 2010-08-11
JP2014057589A (en) 2014-04-03
US20080269125A1 (en) 2008-10-30
EP1276849A2 (en) 2003-01-22
US20030199043A1 (en) 2003-10-23
EP1276856A4 (en) 2004-06-09
US20100189686A1 (en) 2010-07-29
CA2405701A1 (en) 2001-10-25
FR16C0043I1 (en) 2016-12-09
WO2001079258A9 (en) 2002-02-28
WO2001077137A9 (en) 2002-05-02
EP2067488A1 (en) 2009-06-10
AU2001262942A1 (en) 2001-10-30
WO2001079480A9 (en) 2003-09-18
EP1276849A4 (en) 2004-06-09
EP2236152A1 (en) 2010-10-06
US20070287173A9 (en) 2007-12-13
US20080269128A1 (en) 2008-10-30
US7785599B2 (en) 2010-08-31
US6926898B2 (en) 2005-08-09
EP1274720A4 (en) 2004-08-18
EP2267026A1 (en) 2010-12-29
WO2001077137A1 (en) 2001-10-18
WO2001079444A2 (en) 2001-10-25
US20140004095A1 (en) 2014-01-02
US6905688B2 (en) 2005-06-14
AU2001259063A1 (en) 2001-10-30
JP2003530839A (en) 2003-10-21
JP2003530847A (en) 2003-10-21
WO2001079442A2 (en) 2001-10-25
EP2275557A1 (en) 2011-01-19
US20120141415A1 (en) 2012-06-07
EP1276856A1 (en) 2003-01-22
EP2236152B1 (en) 2014-06-04
JP2003530846A (en) 2003-10-21
EP1278544A2 (en) 2003-01-29
US20140010798A1 (en) 2014-01-09
CA2405912A1 (en) 2001-10-18
AU2001261024A1 (en) 2001-10-30
EP1274719A2 (en) 2003-01-15
EP1278544A4 (en) 2004-08-18
EP1832599A2 (en) 2007-09-12
US20040171123A1 (en) 2004-09-02
US8946156B2 (en) 2015-02-03
EP1983055A1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
CA2405557C (en) Albumin fusion proteins
US11103558B2 (en) Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
JP6657284B2 (en) Albumin variant
RU2670063C2 (en) Albumin variants
RU2650784C2 (en) Versions of albumin
US8729018B2 (en) Therapeutic agents comprising elastic peptides
JP5969458B2 (en) Albumin derivatives and variants
AU2002323501B2 (en) Modified transferrin fusion proteins
US20060130158A1 (en) Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
AU2821699A (en) Therapeutic chemokine receptor antagonists
US8129504B2 (en) Oral delivery of modified transferrin fusion proteins

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210412